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Abstract 
 
Uropathogenic Escherichia coli (UPEC) are the primary cause for all urinary tract infections. 
Autotransporter (AT) proteins are virulence factors secreted by the type V secretion pathway. This 
project examined the prevalence, regulation and expression of the vacuolating AT toxin (Vat), and 
the role of periplasmic chaperone proteins in AT translocation. 
 
The vacuolating autotransporter (AT) toxin (Vat) contributes to Uropathogenic Escherichia 
coli (UPEC) fitness during systemic infection. Vat is a serine protease AT of Enterobacteriaceae 
(SPATE) with cytotoxic activity. Here we characterised Vat and investigated its regulation in UPEC. 
We assessed the prevalence of vat in a collection of 45 UPEC urosepsis strains and showed it that 
was present in 31 (68%) of the isolates. The isolates containing the vat gene corresponded to 
three major E. coli sequence types (ST12, 73 and 95) and these strains secreted the Vat protein. 
Further analysis of the vat genetic locus identified a conserved gene located directly downstream 
of vat that encodes a putative MarR-like transcriptional regulator, which we termed vatX. The vat-
vatX genes were present in the UPEC reference strain CFT073 and RT-PCR revealed both genes are 
co-transcribed. Over-expression of vatX in CFT073 led to a 3-fold increase in vat gene 
transcription. The vat promoter region contained three putative nucleation sites for the global 
transcriptional regulator H-NS; thus the hns gene was mutated in CFT073 (to generate CFT073hns). 
Western blot analysis using a Vat-specific antibody revealed a significant increase in Vat 
expression in CFT073hns compared to wild-type CFT073. Direct H-NS binding to the vat promoter 
region was demonstrated using purified H-NS in combination with electrophoresis mobility shift 
assays. Finally, Vat-specific antibodies were detected in plasma samples from urosepsis patients 
infected by vat-containing UPEC strains, demonstrating Vat is expressed during infection. Overall, 
this study has demonstrated that Vat is a highly prevalent and tightly regulated cytotoxin secreted 
by UPEC during infection. 
 
This project also investigated the role of periplasmic chaperones in the translocation of 
UPEC-associated type Va and type Vc AT proteins. In the absence of the periplasmic chaperone 
Skp, expression of the AT proteins Vat, antigen 43 (Ag43) and the trimeric AT E. coli 
immunoglobulin binding protein D (EibD) was reduced. Ag43 and EibD-mediated biofilm formation 
iii 
 
in the K-12 strain MG1655 (harbouring plasmids encoding Ag43 or EibD, respectively) was 
significantly reduced in a skp mutant. Impaired Ag43-mediated auto-aggregation and decreased 
intracellular concentrations of monomeric EibD were also observed in an MG1655skp mutant. 
Finally, secretion of Vat in a CFT073skp mutant was also reduced. Overall, this work demonstrated 
an important role for Skp in the translocation and secretion of AT proteins. 
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1.0 Chapter 1: Introduction and Literature Review  
1.1 Pathogenic Escherichia coli 
The Gram-negative bacterium Escherichia coli reside in the human large intestine as part 
of the normal flora. However, some strains of E. coli acquire genetic material that encode for 
virulence factors that enable them to cause disease. Based on the PCR method detecting the 
presence/absence of the genes chuA, yjaA, TSPE4.C2 (putative lipase esterase gene) and 
arpA, E. coli strains can be readily classified into eight distinct phylogroups (Clermont et al., 
2013, Clermont et al., 2000). The eight phylogroups are termed A, B1, B2, C, D, E, F and the 
E. coli cryptic clade I. The majority of pathogenic E. coli belong to group B2 or to a lesser 
extent group D (Bert et al., 2010, Ewers et al., 2007).  
 
Depending on the prevalence of certain virulence factors and location of infection, 
pathogenic E. coli are classified as either extraintestinal or intestinal pathogenic E. coli 
(ExPEC or IPEC, respectively). IPEC can be further classified into the following pathotypes: 
i) enteropathogenic E. coli (EPEC), ii) diffusely adhering E. coli (DAEC) iii) enterotoxigenic 
E. coli (ETEC), iv) Shiga toxin-producing E. coli (STEC), v) adherent-invasive E. coli 
(AIEC), vi) enterohaemorrhagic E. coli (EHEC) or vii) enteroaggregative E. coli (EAEC) 
(Robins-Browne and Hartland, 2002, Nataro and Kaper, 1998, Jafari et al., 2012). 
Enteroaggregative haemorrhagic E. coli (EAHEC) is the most recently described E. coli 
pathotype, which shares virulence factors typical of EAEC and EHEC. Notably, a Shiga 
toxin-producing prophage region was also identified within this pathotype (Brzuszkiewicz et 
al., 2011, Wu et al., 2011a, Scheutz et al., 2011). Although phylogenetically distinct from 
IPEC, ExPEC pathotypes are less defined due to overlapping molecular epidemiological 
traits. Instead, ExPEC strains are categorised based on corresponding clinical syndromes 
(Russo and Johnson, 2000, Johnson and Russo, 2002, Kaper et al., 2004, Johnson and Russo, 
2005, Kohler and Dobrindt, 2011). Common non-intestinal diseases caused by ExPEC 
include urinary tract infections (UTI), septicaemia and neonatal meningitis.  
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1.2 Urinary Tract Infections (UTI) 
1.2.1 Causes, Symptoms and Disease  
Strains of E. coli that cause UTI are referred to as uropathogenic E. coli (UPEC) and 
are responsible for >80% of all UTIs (Foxman, 2003, Laupland et al., 2007). Other microbial 
pathogens that cause UTIs include Klebsiella pneumoniae, Staphylococcus saprophyticus, 
Pseudomonas aeruginosa, Proteus mirabilis, Enterobacter cloacae, Acinetobacter baumannii 
and Enterococcous species (Morrissey et al., 2013, Laupland et al., 2007, Lu et al., 2012). 
UTIs typically occur as an ascending infection, initiated by colonisation of the urethra 
(urethritis), followed by infection of the bladder (cystitis), the kidneys (pyelonephritis) and if 
left untreated, infection can progress into the bloodstream to cause septicaemia (urosepsis 
[Figure 1.1]). In men, the prostate gland can also be afflicted by infection resulting in 
prostatitis. Adult patients suffering from an acute uncomplicated UTI often experience 
polyuria, dysuria, cramping and nausea. Patients suffering from pyelonephritis typically 
experience more severe symptoms such as intense lower back pain, nausea, vomiting, fever 
or chills, delirium (especially with the elderly), haematuria or foul smelling urine. Extreme 
cases of pyelonephritis can lead to acute kidney failure, irreversible kidney damage or even 
death. Under rare circumstances patients may also develop UTI-related haemolytic uremic 
syndrome (HUS), also clinically referred to as atypical HUS (Scheutz et al., 2000, Hogan et 
al., 2001, Starr et al., 1998, Chiurchiu et al., 2003, Tarr et al., 1996).  
 
Approximately 25% of women will suffer from chronic, recurrent UTI (Foxman et al., 
2000). Risk factors such as physical/functional genitourinary tract abnormalities, 
catheterization, diabetes, neurological disorders, pregnancy or supressed immunity can 
predispose patients to chronic UTI (Haider et al., 2010, Turner et al., 2015, Storm et al., 
2012, Buonaiuto et al., 2014, De Ruz et al., 2000, Nicolle et al., 1996, Carton, 1992, Kunin et 
al., 1992). In the nosocomial environemt, catheter-associated UTI (CAUTI) is very common 
(Al-Hazmi, 2015, Apisarnthanarak et al., 2007). CAUTI is often associated with mixed 
infection and biofilm formation. The catheter surface is easily colonised, promoting infection 
of the bladder (reviewed in Trautner and Darouiche, 2004b, Trautner and Darouiche, 2004a, 
Saint and Chenoweth, 2003). However, not all cases of CAUTIs result in symptomatic 
disease (Tambyah and Maki, 2000). Another condition associated with infection of the 
urinary tract is asymptomatic bacteriuria (ABU), a condition where an individual may be 
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colonised by large numbers of bacteria in the bladder in the absence of symptoms. 
Community acquired ABUs often go undiagnosed and as such impede on surveillance 
statistical analyses. 
 
Figure 1.1: Diagram depicting the female human 
urinary tract with associated diseases (labelled in 
brackets) caused by UPEC infection. Urinary tract 
infections typically occur as an ascending infection, 
initiated by colonisation of the urethra. Modified 
illustration originally created by Carlyn Iverson 
(2010). 
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1.2.2 Epidemiology  
In the US alone there were 40.9 million recorded ambulatory visits regarding UTIs 
between 2006 and 2010 (May et al., 2014). UTI-related expenses are estimated to cost an 
annual sum of approximately 1.6 to 3.5 billion dollars on the US economy (Griebling, 2005, 
Foxman, 2002, Litwin et al., 2005). UTIs are also one of the most common infections 
acquired within hospital intensive care units (Pradhan et al., 2014, Richards et al., 1999, 
Rosenthal et al., 2006). UTIs represent one of the leading infections in long-term aged care 
facilities (Zingg et al., 2014, Chami et al., 2011, Dwyer et al., 2013). Data collected from 
more than 14, 500 healthcare facilities in the USA via the National Healthcare Safety 
Network was analysed by the Centre for Disease Control and Prevention (CDC), revealing a 
6% increase in CAUTI incidence over a four year period (Lacey Avery et al., 2015).  
 
Due to innate anatomical differences, women are more at risk than men for 
developing acute and uncomplicated UTIs (Rocha et al., 2012, Scholes et al., 2005, Foxman, 
2003). It has previously been estimated one third of all women will experience at least one 
UTI by the age of 26 (Foxman et al., 2000). Sexual activity, including use of contraceptive 
diaphragms and spermicides, is a major contributing factor for UTI in younger women 
(Foxman et al., 1995, Fihn et al., 1996, Foxman and Chi, 1990, Hooton et al., 1996). UTIs are 
often associated with increased sexual activity, and identical UPEC strains have been isolated 
from sexual partners (Foxman et al., 2002, Foxman et al., 1997, Johnson and Delavari, 2002, 
Alwali et al., 1989). It is presumed the mechanical act of intercourse drives gastrointestinal 
strains of pathogenic E. coli into close proximity to the periurethral area, thereby promoting 
initial colonisation of the urinary tract. UPEC can also be transmitted from person to person 
via direct contact or the faecal-oral route, usually due to consumption of contaminated food 
or water (Manges et al., 2007, Foxman, 2002). Since 2008, the most recent UTI-related 
outbreak causing concern on a global scale comprises a clonal group of UPEC strains 
characterised by the O26 serotype and the multi-locus sequence type ST131 (reviewed in 
Rogers et al., 2011, Peirano and Pitout, 2010, Pitout, 2010, Nicolas-Chanoine et al., 2014). 
ST131 strains are associated with an enhanced virulence profile and possession of the CTX-
M-15 extended-spectrum β-lactamase (ESBL) gene. The largest subgroup of the ST131 
lineage exhibits resistance to fluoroquinolones, a broad-spectrum class of antimicrobials 
frequently used to treat UTI (Johnson et al., 2013, Price et al., 2013, Colpan et al., 2013). 
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1.2.3 Diagnosis and Treatment 
Suspected cases of uncomplicated UTIs are initially diagnosed using the rapid urine 
Dipstick test, detecting nitrite levels and the presence of leukocyte esterase (Little et al., 
2006, Mambatta et al., 2015). Clean-catch urine specimens (collected mid-stream) are 
subsequently analysed, with the presence of >10
5
 bacterial colony forming units (CFU)/ mL 
indicative of infection (Stamm et al., 1980). Microscopy is also used to check for the 
presence of white blood cells (>10 cell count/ high power field [40x]) within the patient’s 
urine, indicative of pyuria (Hoberman et al., 1994, Hiraoka et al., 1993). Examination of a 
blood sample is required in suspected cases of septicaemia. Due to the increase in 
antimicrobial drug resistance in the past decade, cultures isolated from patients also undergo 
antimicrobial susceptibility testing to ensure efficient administration of treatment. Ultrasound 
or cystoscopy can be used to examine the urinary tract for urinary stones, residual urine 
within the bladder post-voiding, internal bleeding or other abnormalities.  
 
According to the Royal Australian College of General Practitioners 
(http://www.racgp.org.au), an acute and uncomplicated UTI is initially treated with an oral 
course of one of the following antibiotics: i) trimethoprim, ii) cephalexin (a first-generation 
cephalosporin) or iii) amoxicillin in combination with the β-lactamase inhibitor clavulanate. 
Short courses of antibiotic treatments are recommended for women (3-7 days) with slightly 
longer treatment time periods for men. Short doses are used in order to lessen the amount of 
selective pressure produced during treatment, thereby decreasing the chance of developing 
bacterial resistance. Upon culture-proven resistance, use of fluoroquinolones such as 
ciprofloxacin and norfloxacin are considered for alternative treatment. Due to the low tissue-
penetration rate, nitrofurantoin may also be used to treat acute uncomplicated cystitis but not 
pyelonephritis or prostatitis.  
 
Contrastingly, relatively healthy individuals diagnosed with ABU do not receive 
pharmaceutical intervention. Research over the past two decades has shown treatment of 
ABU patients to be non-beneficial (especially in elderly women), leading to bacterial 
persistence, increased risk of resistance and antibiotic-associated side effects (Boscia et al., 
1987, Nicolle et al., 1987, Nicolle et al., 1988, Zalmanovici Trestioreanu et al., 2015). 
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Unfortunately, resistance towards fluoroquinolones, trimethoprim and penicillins has 
increased dramatically (10-20% increase) over the past ten years (Cullen et al., 2012, Cullen 
et al., 2013, Kurutepe et al., 2005, Junquera et al., 2005). Increasingly, nitrofurantoin has 
been used in the treatment of UTI. Nitrofurantoin inhibits bacterial growth and is considered 
low-risk in regards to bacterial resistance (Karlowsky et al., 2002, Zhanel et al., 2000, 
Sanchez et al., 2012, Rock et al., 2007). Spontaneous mutations correlating to nitrofurantoin 
resistance typically occur within nitro-reducing genes (nfsA and nfsB) and result in reduced 
bacterial fitness (Sandegren et al., 2008).  
 
1.3 UPEC Pathogenesis and Virulence Factors 
UPEC express a wide range of virulence factors including (i) iron acquisition 
siderophores such as enterobactin, aerobactin, and yersiniabactin; (ii) protectins such as O-
antigen and the capsule that confer anti-phagocytic and serum resistant properties on the cell; 
(iii) afimbrial adhesins such as the Ag43 autotransporter (AT) protein; (iv) fimbriae such as 
type 1 and P fimbrie; and (v) toxins such as the vacuolating autotransporter toxin (Vat), 
secreted autotransporter toxin (Sat) and α-hemolysin (Figure 1.2). Genes encoding for UPEC 
virulence factors are often horizontally acquired via i) transformation of free DNA, ii) as a 
plasmid-encoded gene through the process of conjugation or iii) via phage-mediated 
chromosomal insertion of DNA through the process of transduction. Pathogenicity islands 
(PAIs) are large clusters of virulence-associated genes found on the chromosome (Hacker et 
al., 1990). PAIs are distinct regions of horizontally acquired DNA that are often >10Kbp in 
size, possess a low G+C content, and contain multiple virulence genes (reviewed in Hacker et 
al., 1997, Oelschlaeger et al., 2002, Blum-Oehler et al., 2000). Additional PAI-associated 
characteristics include the presence of insertion sequences and flanking tRNA or direct repeat 
sequences. Genes encoding for tRNA are considered as ‘hot spots’ for PAI insertion due to 
the strong similarity often observed between the 3’ end of the tRNA gene and bacteriophage 
attachment sites (Ritter et al., 1995, Blum et al., 1994). PAIs may also possess functional or 
cryptic mobility genes such as phage-like integrases or transposases. Functional integrases/ 
transposases, in combination with the presence of repeat sequences, can drive spontaneous 
recombination events, often resulting in modified genetic content or PAI location. The 
plasticity exhibited by PAIs contributes to the evolution of UPEC.  
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Figure 1.2: Schematic overview of UPEC virulence factors. Many UPEC virulence 
factors aid in adhesion, including various types of fimbriae/ pili (e.g. type 1 fimbriae, P 
fimbriae, curli pili and S fimbriae) as well as afimbrial adhesins (e.g. Ag43). Other 
virulence factors include iron acquisition systems (e.g. enterobactin, aerobactin, 
yersiniabactin), flagella for motility, O-antigen (for serum resistance), capsule (for 
immune evasion) and toxins (e.g. vacuolating autotransporter toxin, secreted 
autotransporter toxin and α-hemolysin) (Image modified from Behrens-Kneip, 2010). 
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1.3.1 Fimbrial Adhesins  
In order to colonise the bladder, UPEC must combat natural hydrodynamic forces of 
urine flow. The expression of fimbriae contributes to UPEC virulence by aiding in initial 
attachment to urothelial cells. UPEC possess multiple types of fimbriae, including type 1 
fimbriae (cystitis associated), P fimbriae (pyelonephritis associated) and S/ F1C fimbriae 
(Rahdar et al., 2014, Blanco et al., 1997, Toval et al., 2014, Norinder et al., 2012). Type 1 and 
P fimbriae represent the two best studied fimbriae present in UPEC. Some of the more 
recently characterised UPEC fimbriae include F9, type 3-like, Ygi and Yad (Spurbeck et al., 
2011, Ulett et al., 2007a, Ong et al., 2008). The genes encoding for fimbriae are always 
contained within a single operon (Wurpel et al., 2013), and are often phase variable (e.g. type 
1 and P fimbriae) (Abraham et al., 1985, Baga et al., 1985). Fimbrial synthesis is coordinated 
via a chaperone-usher pathway whereby the chaperone targets subunit proteins to a ß-barrel 
structured usher platform integrated into the outer membrane (OM). The subunits then filter 
through the platform structure to build upon each other, forming a helical multimer of the 
major subunit. Based on usher protein sequences, E. coli fimbriae can be phylogenetically 
classified into six distinct clades (α, β, γ, κ, π and σ), with five γ-related subclades (γ1, γ2, γ3, 
γ4 and γ*) (Nuccio and Baumler, 2007, Wurpel et al., 2013). The type 1 and P fimbriae 
belong to the γ1 subclade and π clade, respectively.  
 
E. coli fimbriae confer different target specificity. This “lectin–like” fimbrial affinity 
is attributed to the protein located at the fimbrial tip. The FimH protein constitutes the 
adhesin tip for type 1 fimbriae and binds to N-linked mannose-containing glycoproteins 
present within the urinary tract (Krogfelt et al., 1990, Klemm and Christiansen, 1987, Hanson 
and Brinton, 1988). P fimbriae bind to α-D-galactopyranosyl-(1-4)-β-D-galactopyranoside 
moieties present within host glycolipids (Korhonen et al., 1982, Svenson et al., 1983). Three 
different PapG adhesins have been described for P fimbriae (papGJ96[Class I], 
papGAD/IA2[Class II] and prsGJ96[Class III]), each of which possess different binding 
specificity (Stromberg et al., 1990, Johanson et al., 1992, Arthur et al., 1989). Type-1 
fimbriae also contribute to biofilm formation on abiotic surfaces (Pratt and Kolter, 1998, 
Schembri and Klemm, 2001, Otto et al., 1999) and  invasion of bladder epithelial cells (Wu et 
al., 1996, Martinez et al., 2000, Mulvey et al., 1998, Duncan et al., 2004).  
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1.3.2 Afimbrial Adhesins (AFA) and Autotransporter Proteins 
Afimbrial adhesins (AFA) were initially designated as such due to the lack of a 
defined fimbrial structure visible by electron microscopy, in combination with their capacity 
to mediate Mannose-Resistant Haemoagglutination (MRHA) of human erythrocytes 
(Labigneroussel et al., 1984). AFA adhesins are encoded within an operon typically 
consisting of five genes. Similar to fimbriae, AFA biosynthesis occurs via the chaperone-
usher pathway. The adhesin of AFA (AfaE) exhibits heterogeneity, resulting in antigenically 
distinct AfaE subtypes (Labigne-Roussel and Falkow, 1988). AFAs belong to the Dr adhesin 
family as the AfaE subtypes bind to the Cromer blood group antigen Dr(a) present on the 
human decay-accelerating factor (DAF or CD55), facilitating erythrocyte hemagglutination 
(Nowicki et al., 2001). Several AFA operons have been described from pathogenic E. coli, 
including afa-I, afa-II, afa-III, afa-V and afa-VIII, in addition to other related operons such as 
f1845, daa, rifa, nfa and dra (Servin, 2005, Servin, 2014, Le Bouguenec and Servin, 2006). 
The Dr hemagglutinin is encoded by the dra operon and was originally characterised distinct 
from the AFA protein family due the topology of the adhesin (Nowicki et al., 1988, Nowicki 
et al., 1987). In 2001, however, the Dr adhesin was proposed to be included within the AFA 
protein family due to its similar gene organisation and substrate specificity (Nowicki et al.). 
In contrast, an afa-III operon was discovered to form fragile fimbrial organelles on the 
bacterial surface, which collapse during preparation of samples for electron microscopy 
(Anderson et al., 2004). 
 
In addition to AFA/Dr adhesins, another class of UPEC afimbrial adhesins is 
represented by the autotransporter (AT) proteins. Several AT proteins have been 
characterized from UPEC including Ag43, UpaB, UpaC, UpaG and UpaH. Ag43 is a self-
associating adhesin that contributes to biofilm formation and long-term UPEC colonisation of 
the mouse urinary tract (Ulett et al., 2007b). Ag43 is phase variable due to Dam/OxyR 
regulation and causes visible auto-aggregation of bacterial cells (Wallecha et al., 2002). 
UpaB, UpaC, UpaG and UpaH are more recently characterised UPEC AT adhesins (Allsopp 
et al., 2010, Allsopp et al., 2012b, Totsika et al., 2012b). Expression of UpaG and UpaC 
promotes biofilm formation and cell aggregation by the prototype UPEC strain CFT073 
(Totsika et al., 2012b, Allsopp et al., 2012b). UpaH, on the other hand, promotes biofilm 
formation but not cell aggregation (Allsopp et al., 2010). UpaB possesses an affinity for 
fibrinogen while both UpaG and UpaB bind to two additional extracellular matrix (ECM) 
29 
 
proteins, laminin and fibronectin (Allsopp et al., 2012b, Valle et al., 2008a). UpaG is 
expressed on the UPEC cell surface as a trimer and also binds to T24 bladder epithelial cells 
(Valle et al., 2008a).  
 
1.3.3 Motility 
Flagellar-mediated bacterial motility has been extensively studied. Flagella contribute 
to UPEC pathogenesis by mediating dissemination in the urinary tract (Wright et al., 2005, 
Lane et al., 2005, Lane et al., 2007, Schwan, 2008). Flagella also contribute to UPEC biofilm 
formation and invasion of host renal epithelial cells (Hadjifrangiskou et al., 2012, Pichon et 
al., 2009). In P. mirabilis, mutation of flagella genes leads to attenuation of virulence 
(Allison et al., 1992, Mobley et al., 1996). More than 50 genes are involved in flagellar 
expression (McCarter, 2006, Aldridge and Hughes, 2002, Jones and Aizawa, 1991, Smith and 
Hoover, 2009, Guttenplan and Kearns, 2013), including 24 core structural genes (Liu and 
Ochman, 2007); these genes are clustered at several different locations  on the chromosome. 
Flagellar gene expression occurs in a hierarchal manner involving three different gene 
classes. The master regulatory operon flhDC is considered the sole class I operon and 
encodes for two regulatory proteins, FlhD and FlhC (Stafford et al., 2005, Claret and Hughes, 
2002, Liu and Matsumura, 1994). An in vivo study analysing flhDC transcription within the 
UPEC strain UTI89 showed strong flhDC expression during early intracellular bacterial 
community (IBC) formation (Wright et al., 2005). In a similar study conducted by Lane et al. 
(2007), expression of the gene encoding for the major flegellin subunit fliC was significantly 
increased during ascension of infection towards the kidneys. Indeed, the UPEC strain 
CFT073 outcompeted an isogenic fliC mutant for kidney colonisation in a mouse UTI model.  
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1.3.4 Biofilm Formation  
Biofilm formation is strongly associated with UPEC-mediated UTI. Biofilms are a 
primary problem associated with CAUTI, and the biofilm blocks urine flow through the 
catheter. Biofilm formation also contributes to UPEC pathogenesis and aids in persistence of 
infection (Blango and Mulvey, 2010, Hadjifrangiskou et al., 2012). Biofilms protect bacteria 
from external chemical and physical stresses, thereby diminishing the effectiveness of 
antibiotic treatment. UPEC biofilm formation occurs in a series of five steps (Figure 1.3). The 
first two steps involve reversible attachment of planktonic bacteria to an abiotic or living 
surface, followed by irreversible attachment, mediated by bacterial adhesins such as Ag43, 
type 1 fimbriae or curli filaments. Once firmly adhered, bacteria secrete various proteins to 
form the complex and protective ECM. UPEC also produce a polysaccharide-rich ECM that 
includes cellulose and functional curli fibres as major components (McCrate et al., 2013, 
Anderson et al., 2003). As bacteria continue to grow and replicate, the biofilm matures to 
become a dynamic macrocolony-like structure with spatially distinct subpopulations. The 
final stage of biofilm formation involves detachment and dispersal of bacterial cells.  
 
In mice, UPEC invasion into bladder superficial epithelial cells leads to the formation 
of IBCs, which exhibit biofilm-like properties (Anderson et al., 2003, Justice et al., 2004). 
UPEC invasion of bladder cells contributes to persistance (Mulvey et al., 1998, Schilling et 
al., 2002, Mysorekar and Hultgren, 2006) and recurrent infection (Mysorekar and Hultgren, 
2006, Mulvey et al., 2001). Invasion and IBC formation also triggers exfoliation of 
superficial bladder epithelial cells (Mulvey, 1999, Rosen et al., 2007, Mysorekar and 
Hultgren, 2006). At this stage, UPEC can disseminate into the lumen of the bladder or even 
invade the underlying basal epithelium to form non-replicating quiescent intracellular 
reservoirs (Mulvey et al., 2001). UPEC cells released from shedding superficial urothelial 
cells can possess a filamentous morphology (Justice et al., 2004, Mulvey et al., 1998). The 
sheer size of these elongated cells may prevent phagocytosis by host leukocytes (Justice et 
al., 2006). 
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Figure 1.3 Developmental stages of UPEC (A) extracellular and (B) intracellular 
biofilm formation. A) Extracellular biofilm formation occurs in five stages: 1) 
reversible attachment, 2) irreversible attachment, 3) early cell replication and 
extracellular matrix production, 4) biofilm maturation and 5) UPEC detachment/ 
dispersal. B) Upon adherence to host urothelial cells, bacteria can invade and 
replicate to form intracellular bacterial communities (IBC). Continual replication 
of bacterial cells can trigger exfoliation of the superficial epithelium. Dispersing 
UPEC can further invade underlying tissues to form quiescent intracellular 
reservoirs or take on a protective filamentous morphology. A) was taken from 
(Van Houdt and Michiels, 2005) and B) was modified from (Justice et al., 2004). 
  
A 
B 
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1.3.5 Iron Acquisition 
 Iron is essential for bacterial growth and is limited in the urinary tract. UPEC 
sequester iron through surface bound ligands and/or secretion of molecules with high affinity 
for Fe(III) (ferric iron). Iron can also be derived from host haemoglobulin (heme iron). In the 
human host, Fe(III) is tightly bound to various proteins and thus free iron is present in very 
low concentrations (approximately 10
-24
M) (Aisen et al., 1978, Martin et al., 1987, Kretchmar 
et al., 1988). UPEC strains can contain up to four different siderophore systems: i) 
enterobactin, ii) enterobactin’s glycosylated derivative salmochelin, and the mixed ligand 
siderophores iii) yersiniabactin and iv) aerobactin (Henderson et al., 2009). The importance 
of iron acquisition systems in UPEC pathogenesis was demonstrated in a series of mouse 
model infection assays involving the UPEC strains CFT073, 536, 83972 and UCB34, where 
strains deficient in iron receptor molecules (IutA, FyuA, FepA, IroN and Iha) were 
outcompeted by corresponding WT strains (Garcia et al., 2011a, Watts et al., 2012b, Torres et 
al., 2001, Johnson et al., 2005, Leveille et al., 2006). Additionally, independent mouse UTI 
assays comparing CFT073 and an isogenic strain lacking both the siderophore receptor gene 
entF and the aerobactin biosynthesis gene iucB, exhibited a reduced ability to colonise the 
urinary tract (Torres et al., 2001). In addition to siderophore receptors, UPEC also produce 
two heme receptors, ChuA and Hma, both of which contribute to UPEC virulence in mouse 
models (Hagan and Mobley, 2009, Torres et al., 2001).  
  
33 
 
1.3.6 Polysaccharide Capsules and Lipopolysaccharides 
Lipopolysaccharide (LPS) provides structural integrity for the outer membrane and 
consists of the O polysaccharide, the core oligosaccharide and lipid A. The O polysaccharide 
varies between strains and its composition determines the serotype for E. coli. LPS is also 
highly toxic and elicits a potent immune response mediated by the TLR4 pathway (Anderson 
et al., 2003, da Silva Correia and Ulevitch, 2002, Park et al., 2004, Hyakushima et al., 2004). 
UPEC (and many other pathogenic bacteria) also produce a thick polysaccharide layer 
outside of the outer membrane known as the capsule. The linear homopolymer of α-2,8-
linked N-acetylneuraminic composes the K1 subtype and is the most common UPEC capsular 
antigen. The K1, K4 and K5 antigens produced by certain ExPEC strains (Neonatal 
meningitis E. coli strain O18:K1:H7; UPEC strains O5:K4:H4 and 010:K5:H4) mimic 
mammalian sialic acid, chondroitin and heparin, respectively (Rodriguez et al., 1988, Vann et 
al., 1981, Devi et al., 1991). Capsule molecular mimicry contributes to the evasion of host 
immunity by UPEC. Indeed, the capsule protects UPEC (and many other bacterial pathogens) 
from complement-mediated phagocytosis (Van Dijk et al., 1979, Stevens et al., 1983, Glynn 
and Howard, 1970, Howard and Glynn, 1971) and contributes to the survival of UPEC within 
the urinary tract, the bloodstream (Agüero and Cabello, 1983) and the cerebrum of mice 
(Howard and Glynn, 1971). Other studies have shown a role for the capsule in IBC formation 
(Anderson et al., 2010, Goller and Seed, 2010).  
 
1.3.7 Toxins  
Toxins associated with UPEC include the repeat-in-toxins α-hemolysin (HlyA) and 
TosA, cytotoxic necrotizing factor 1 (CNF1), the protease involved in colonisation (Pic), the 
secreted AT toxin (Sat) and the vacuolating AT toxin (Vat). CNF1 causes cytoskeletal 
rearrangements of host cells, enabling internalisation of UPEC, and has also been shown to 
exhibit immunomodulatory properties (Garcia et al., 2013a, Falzano et al., 2003, Davis et al., 
2006, Davis et al., 2005). HlyA is a calcium-binding protein that causes host cell lysis, 
resulting in cytokine production and the subsequent inflammatory responses characteristic of 
cystitis and pyelonephritis (Sanchez-Magraner et al., 2007, Sanchez-Magraner et al., 2006). 
TosA is the most recently characterised toxin of UPEC (Vigil et al., 2012). Pic, Sat and Vat 
are ~110KDa secreted proteins and belong to the serine protease autotransporters of 
Enterobacteriaceae (SPATE) protein family. Pic is homologous (97% amino acid sequence 
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identity) to the ShET1 toxin produced by Shigella flexneri 2a and degrades a range of 
substrates including human spectrin, pepsin, coagulation factor V, bovine submaxillary gland 
mucus and leukocyte glycoproteins (Parham et al., 2004, Dutta et al., 2002). Sat has been 
characterized from UPEC strain CFT073 and possesses cytotoxic activity on HEp-2 cells 
(Guyer et al., 2002). Vat was originally thought to be temperature-sensitive hemagglutinin 
(Tsh), but only shares 78% amino acid identity to Tsh. Expression of Vat from the avian 
pathogenic E. coli strain EC222 mediates a vacuolating cytopathic effect on chicken embryo 
fibroblasts (Parreira and Gyles, 2003).  
 
1.4 Type V Secretion Pathway 
Six different secretion systems (Types I-VI) have been defined in Gram-negative 
bacteria (PMID: 25978706). Many of the bacterial virulence factors mentioned above utilise 
these secretion pathways for exportation to the cell surface, secretion into the extracellular 
environment, transfer of genetic material to other bacteria, injection of proteins into host cells 
or for host cell invasion. A seventh secretion system has also been discovered in 
mycobacterium, while the E. coli secretory mechanisms involved in biogenesis of curli 
filaments have been proposed as an eighth type of secretion system (Abdallah et al., 2007, 
Desvaux et al., 2009). Additionally, the Por secretion system found within Bacteroidetes 
species has recently been suggested to represent a ninth type of secretion system (McBride 
and Zhu, 2013). The majority of these secretion pathways (excluding type V) involve the 
formation of different protein complexes that span both the inner and outer membranes. The 
Type V secretion pathway was originally thought to occur autonomously, as all the 
machinery required was presumed to be encoded by the translocated protein (Figure 1.4). As 
a result, proteins exported by the Type V secretion pathway are commonly referred to as 
autotransporter (AT) proteins.  
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1.4.1 Translocation across the Inner Membrane (IM) 
AT proteins of the type V secretion system possess three conserved domains: i) a 
signal peptide, ii) a passenger domain and iii) a β-barrel (or translocator) domain. Based on 
the organisation of conserved domains within the protein and the consequent manner of OM 
translocation, proteins exported via the type V pathway can be further classified into five 
additional subgroups (Type Va-e [Figure 1.4]). Protein translocation across the IM within E. 
coli can occur via the SecYEG (Sec tranlosocon) pathway or the twin arginine (TAT) 
pathway. Translocation of AT proteins across the IM utilises the Sec translocon for all 
subtype V secretion pathways. AT signal peptides target the protein to the Sec translocon via 
SecB-dependent post-translational translocation across the IM. However, the AT proteins 
Hbp and to a lesser extent EspP have been shown to be co-translationally translocated across 
the IM via the signal recognition particle (SRP)-pathway (Peterson et al., 2006, Sijbrandi et 
al., 2003, Peterson et al., 2003). AT signal peptides are cleaved post-IM translocation, leaving 
the passenger domain and the beta-barrel domain to be exported to the cell surface via one of 
the subtype V (a-e) secretion pathways.  
 
1.4.2 Type Va: Classical Autotransporter (AT) Proteins 
AT proteins of the Type Va pathway represent the largest subclass of proteins 
belonging to the Type V secretion system. Immunoglobulin A protease (IgA1) from 
Neisseria gonorrhoeae was the first AT protein to be described and represents the structural 
model for the Type Va subclass, also referred to as “classical” AT proteins (Pohlner et al., 
1987). Domain organisation for classical ATs consists of the three conserved domains (the 
signal sequence, the passenger domain and the β-barrel domain) in sequential order, with a 
small intergenic linker region connecting the passenger and the β-barrel domains. The β-
barrel domain integrates into the OM as a β-barrel structure, while the passenger translocates 
across the OM to be expressed on the cell surface. The C-terminal domain of AT proteins is 
highly conserved and is thought to form a hairpin like structure within the OM, triggering 
protein folding in a C to N terminal direction (Ieva and Bernstein, 2009b, Peterson et al., 
2010, Junker et al., 2006, Soprova et al., 2010). The direction of AT folding is thought 
prevent reversible folding back into the periplasm, as the interactions formed during this 
process are thermodynamically favoured. Once translocation across the OM is complete, the 
passenger domain can remain anchored to the β-barrel domain or may be proteolytically 
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cleaved. The cleaved AT passenger domain can remain attached to the β-barrel domain via 
non-covalent interactions or be released into the extracellular milieu.  
 
The crystal structure of the translocator domain has been solved for several bacterial 
AT proteins, all of which consist of 12 amphipatic β-strands in anti-parallel orientation (van 
den Berg, 2010, Gawarzewski et al., 2014, Fairman et al., 2012, Oomen et al., 2004, Kuhnel 
and Diezmann, 2011, Meng et al., 2006a, Barnard et al., 2007, Tajima et al., 2010, Zhai et al., 
2011). The general structure typically contains a hydrophobic interface at the surface of the 
barrel and a hydrophilic central channel, enclosing an internal α-helix. Several crystal 
structures have been solved for the passenger domains of E. coli type Va AT proteins, 
including Hbp, EspP, Ag43 and Pet (Otto et al., 2005, Khan et al., 2011, Domingo Meza-
Aguilar et al., 2014, Heras et al., 2014). The passenger domain of these AT proteins share 
structural homology in the form of a triangular β-helical, right-handed spiralling stalk. In 
contrast to the β-barrel domain however, type Va AT passenger domains are less conserved 
in sequence and can be phylogenetically classified into two groups, the adhesin involved in 
diffuse adherence (AIDA-I) type AT proteins and the serine AT proteins of 
Enterobacteriaceae (SPATE) proteins. 
 
1.4.2.1 Adhesin Involved in Diffuse Adherence (AIDA)-type I AT Proteins 
AIDA-I was originally identified as a plasmid-encoded 100KDa protein produced by 
the DAEC strain 2787 (Benz and Schmidt, 1989, Benz and Schmidt, 1992). AIDA-I type AT 
proteins represent the largest and most diverse subgroup of the type V secretion pathway 
(Wells et al., 2010, Celik et al., 2012). The majority of the type Va AT proteins characterised 
within UPEC encode for surface localised adhesins such as the well-characterised UPEC AT 
protein Ag43. Ag43 mediates adherence to abiotic surfaces, auto-aggregation and biofilm 
formation (Hasman et al., 1999, Danese et al., 2000a, Sherlock et al., 2006). Ag43 auto-
aggregation is mediated through self-interaction with neighbouring cells, a property also 
observed for AIDA-I and TibA (Klemm et al., 2006). Self-associating adherence enables 
bacteria to aggregate and contributes to biofilm formation. The UPEC strain CFT073 
possesses two chromosomal copies of the agn43 (flu) gene (agn43a/fluA and agn43b/fluB 
[85% identical on an amino acid level]). Ag43a has been shown to be the principal AT 
contributing to CFT073 colonisation in the mouse bladder (Ulett et al., 2007b). Recent 
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crystallography data obtained from the purified Ag43 passenger domain revealed it to possess 
an L-shaped tertiary structure, which perpendicularly dimerises in a velcro-like manner with 
an Ag43 protein from another cell (Heras et al., 2014).  
 
1.4.2.2 Serine Protease ATs of Enterobacteriaceae (SPATEs) 
SPATE proteins constitute a second, smaller typeVa clade of proteins and are 
characterised by the presence of the conserved catalytic triad (GDSDS) motif. This catalytic 
triad motif functions in conjunction with conserved upstream aspartate and histidine residues. 
Upon translocation across the OM, SPATE proteins are autoproteolytically cleaved in 
between two conserved asparagine residues (FxxEVNNLNK motif) within the α-helix linker 
region (Dautin et al., 2007). Cleavage occurs inside of the β-barrel pore, releasing the SPATE 
protein in the extracellular milieu. SPATE proteins also possess an unusually long signal 
sequence, almost double in size, extending form the N-terminal region (Henderson et al., 
2004b, Desvaux et al., 2006). This extension exhibits hydrophobic properties and is thought 
to target the protein for SRP-mediated co-translational IM translocation. The extended signal 
peptide for the SPATE protein EspP has been shown to prevent accumulation of misfolded 
proteins (Desvaux et al., 2007). The EspP signal peptide has also been shown to slow the rate 
of IM translocation (Desvaux et al., 2007, Szabady et al., 2005). Hence, an extended signal 
peptide has been suggested to aid in AT translocation by providing enough time for the 
protein to properly fold within the periplasm.  
 
The molecular structure of the passenger domain of several SPATE proteins has been 
solved, including Hbp, EspP and Pet (Domingo Meza-Aguilar et al., 2014, Khan et al., 2011, 
Otto et al., 2005). In these structures, the catalytic triad resides within the chemotrypsin-like 
globular domain, adjacent to the β-helical stalk. Phylogenetic analysis of SPATE proteins 
reveals two distinct groups, referred to as class I and class II (Yen et al., 2008, Dutta et al., 
2002). Class I SPATE proteins exhibit cytotoxic effects on host cells, while class II SPATEs 
are primarily mucinases, with recent evidence indicating they also recognise and cleave host 
cell immunomodulating markers (Ruiz-Perez et al., 2011, Ayala-Lujan et al., 2014). An 
additional subdomain has also been described within class II SPATE passenger domains, 
known as domain 2 (Ruiz-Perez and Nataro, 2014b). Interestingly, domain 2 purified from 
the SPATE protein Hbp can bind calcium. 
38 
 
 
1.4.3 Type Vb: Two-Partner  AT Proteins 
Proteins belonging to the type Vb protein secretion pathway resemble the protein domain 
organisation of classical AT proteins lacking the linker region. The two-partner secretion 
system is largely modelled on the well-studied filamentous hemagglutinin (FHA) of 
Bordetella species, the ShlA haemolysin from Serratia marcescens and the two high 
molecular weight proteins (HMW1 and HMW1b) from Haemophilus influenzae (Jacob-
Dubuisson et al., 2001, Yeo et al., 2007, Jacob-Dubuisson et al., 2009). The β-barrel domain 
(TpsB) acts separately but in a coordinated fashion for the export of the passenger domain 
(TpsA). As such, the Type Vb secretion system is commonly referred to as the two-partner 
secretion system (Jacob-Dubuisson et al., 2001, Jacob-Dubuisson et al., 2013). The crystal 
structure solved for the TpsB protein FhaC, revealed a 16-stranded β-barrel structure, 
encompassing an N-terminal α-helix and an extracellular loop (L6) (Jacob-Dubuisson et al., 
2009, Maier et al., 2015). This extracellular loop extends into the β-barrel pore creating a 
“lid-like” topology and was found to play a key role in FHA secretion. TpsB proteins 
typically contain two polypeptide translocation-associated (POTRA) domains and are 
members of the Omp85 protein family (Moslavac et al., 2005, Heinz and Lithgow, 2014). 
The TpsA protein is recognised by the POTRA domains of the integral TpsB protein for 
consequent OM translocation (Hodak et al., 2006, Delattre et al., 2011). Based on 
experimental evidence analysing secretion of the FHA protein, the TpsA protein is thought to 
form a hairpin fold within the TpsB β-barrel pore, triggering consequent translocation in an 
N-C terminal direction (Jacob-Dubuisson et al., 2009, Mazar and Cotter, 2007). Examples of 
type Vb proteins characterised within E. coli include the contact-dependent growth inhibitors 
(CdiABI) of the E. coli strain EC93 (Aoki et al., 2005) and the HMW1 protein homologues 
(EtpBAC) identified within the ETEC strain H10407 (Fleckenstein et al., 2006) .  
 
1.4.4 Type Vc: Trimeric AT Proteins 
Trimeric AT proteins acquire a unique quaternary structure within the OM by linking 
together as a trimer. In comparison to type Va AT proteins, the β-barrel domains of trimeric 
proteins are shorter in length, while the passenger domains are on average much larger. The 
UPEC strain CFT073 expresses the trimeric AT UpaG (Valle et al., 2008a). A range of E. 
coli immunoglobulin binding proteins (EibACDEFG) have also been identified in other E. 
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coli strains (Lu et al., 2006, Merkel et al., 2010, Sandt and Hill, 2000, Sandt and Hill, 2001). 
In 2011, the crystal structure for the trimeric AT protein EibD was solved. Interestingly, the 
EibD head and stalk structure revealed the stalk to coil in a left-handed direction from the β-
barrel structure, and then switch to a right-handed-coil at approximately halfway (Leo et al., 
2011). Crystal structures have also been solved for partial domains of other Gram-negative 
trimeric AT proteins, including the Yersinia adhesion YadA (Nummelin et al., 2004, Alvarez 
et al., 2010), Hia (Meng et al., 2006b, Yeo et al., 2004), UspA1 (Conners et al., 2008), SadA 
(Hartmann et al., 2009), BadA (Szczesny et al., 2008) and BpA (Edwards et al., 2010). 
Overall, trimeric AT proteins constitute a ‘lollipop’ shape consisting of trimeric head domain 
connected to a single β-barrel domain via a coiled-coil stalk. The shorter β-barrel domains 
corresponding to each AT monomer contribute four β-strands within the overall 12- stranded 
β-barrel structure. Eib proteins, in addition to YadA, bind to the Fc region of mammalian IgA 
and IgG proteins (Leo and Goldman, 2009a, Sandt and Hill, 2000). Additionally, EibD and 
UpaG have also shown to promote cell-cell auto-aggregation, contribute to biofilm formation 
and mediate adherence to eukaryotic cells (Valle et al., 2008a, Leo et al., 2011). 
 
1.4.5 Type Vd: Fused Two-Partner AT Proteins 
The Type Vd AT group is a recently classified subclass of AT proteins based on the 
characterisation of the patatin-like protein D (PlpD) from Pseudomonas aeruginosa (Salacha 
et al., 2010). PlpD homologues were found within range of bacterial strains distributed 
among four phyla, Proteobacteria, Bacteroidetes, Fusobacteria and Chlorobi. The domain 
structure of the plpD gene resembles that for type Va classical AT proteins, a central 
passenger domain flanked by an N-terminal signal sequence and a C-terminal β-barrel 
domain. The 16-stranded β-barrel domain of PlpD displays similarity to TspB proteins 
associated with Type Vb AT proteins. In fact the PlpD passenger domain is connected to the 
β-barrel domain via a single POTRA domain. PlpD has been proposed as a model protein for 
a new subclass of type V AT proteins, consisting of “fused” type Vb AT proteins. However, 
the low sequence similarity observed between PlpD and other AT proteins suggests other 
putative type Vd proteins may possess similar sequence diversity.  
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1.4.6 Type Ve: Reverse AT Proteins  
The well-characterised Intimin and Invasin proteins have recently been suggested to 
exemplify a fifth subtype (Type Ve) of AT proteins (Oberhettinger et al., 2012). Intimin is 
produced by EPEC and EHEC strains and contributes to the formation of characteristic 
attachment and effacing lesions associated with these pathogens (Jerse et al., 1990, 
Donnenberg et al., 1993). Invasin is an important virulence factor found within Yersinia 
species and aids in host cell invasion by binding to β1-integrins present on the surface of 
intestinal M cells (Isberg et al., 1987, Pepe and Miller, 1990, Arencibia et al., 1997, Clark et 
al., 1998). EPEC and EHEC strains use the type III secretion pathway in order to inject the 
translocated Intimin receptor (Tir) protein into host cells (Kenny et al., 1997, DeVinney et al., 
2001). The integration of Tir into the host cell membrane triggers intimate intimin-mediated 
adherence of bacteria to the intestinal epithelium. Oligomerisation of Tir-Intimin protein 
complexes causes proximal actin filaments beneath the host cell surface to reshuffle, thereby 
creating a characteristic pedestal-like morphology (Liu et al., 1999, DeVinney et al., 2001, 
Gruenheid et al., 2001, Kenny, 1999). Invasin-mediated adherence of Yersinia bacterial 
species to host cells also causes cytoskeletal reorganisation to form pseudopods, triggering 
envelopment of bacterial cells through host cell mediated autophagy (Deuretzbacher et al., 
2009). Topological analysis was conducted for Intimin and Invasin by Fairman and 
colleagues (2012), utilising crystal structures previously resolved for partial Intimin/ Invasin 
domains. This analysis revealed an OM β-barrel structure similar to that of Type Va AT 
proteins, constituting a 12-stranded β-barrel structure (Pore diameter: ~6-10 Å) inclusive of 
an internal region, albeit extended form of the α-helical linker region. The extracellular 
portion of Intimin/ Invasin consists of repeated bacterial immunoglobulin-like (BIG) domains 
crowned with a C-type lectin-like domain. Intimin also contains two additional domains, a 
small N-terminal periplasmic LysM domain that is predicted to bind to peptidoglycan and a 
proteinase K resistant domain (100 amino acids in length) immediately following the 
extended linker region.  
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Figure 1.4 A) Domain organisation and B) topology of the five AT protein subtypes 
(Type Va-e), secreted by the type V secretion pathway. AT proteins consist of three 
domains: i) a signal sequence which is cleaved post-translocation across the inner 
membrane, ii) a passenger domain comprising the functional AT protein to be 
expressed and iii) a C-terminal domain which may be fused to the passenger via an α-
helical linker region. The C-terminal domain forms an integral 12-stranded β-barrel 
structure within the outer membrane. The C-terminal domain identified for the type 
Vb and the type Vd AT proteins also contains polypeptide transportation-associated 
domains characteristic of the Omp85 protein superfamily. Modified from (Leo et al., 
2012).  
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1.5 Maintenance of outer membrane structural integrity in Escherichia coli 
Maintenance of the bacterial OM is important for cell integrity. While phospholipids 
comprise the IM bilayer and the inner leaflet of the OM, the outer leaflet of the OM is 
primarily comprised of LPS. The OM also acts as an environmental interface through the 
presence of numerous and diverse integral OMPs. E. coli, like many other bacterial species, 
possess essential, highly conserved functional mechanisms for maintenance of the OM and 
for the translocation of OM proteins.  
 
1.5.1 Lipoprotein Biogenesis 
Transportation of negatively charged LPS molecules that comprise the LPS layer of 
the OM is a unique pathway involving multiple accessory proteins. LPS is first synthesised 
within the IM before final translocation and insertion into the OM. The lipid A core of LPS is 
flipped across the IM membrane via the ATP-binding cassette (ABC) transporter protein 
MsbA, a process driven by ATP hydrolysis (Karow and Georgopoulos, 1993, Polissi and 
Georgopoulos, 1996, Doerrler et al., 2004). The O-antigen of LPS is then ligated to the IM 
bound lipid A core to form LPS. Transport across the periplasmic space to the OM occurs by 
the formation of a multi-protein bridge termed the LPS transport (Lpt) bridge (Figure 1.5) 
(Chng et al., 2010a, Freinkman et al., 2012). The Lpt bridge consists of several Lpt proteins 
(LptA-G) that when bound together, extend from the cytoplasmic space to the OM. The LptB 
protein dimerises to form an integral ABC transporter protein complex in conjunction with 
the additional IM proteins LptC, LptF and LptG (LptB2CFG) (Narita and Tokuda, 2009, 
Chng et al., 2010a, Sherman et al., 2014). LptB2CFG is thought to extract LPS from the outer 
leaflet of the IM via ATP hydrolysis, leaving LPS transiently docked on LptC (Bowyer et al., 
2011). LptC connects to LptA within the periplasm, which connects to the integral OM 
LptDE sub-complex. The C-terminal domain of LptD is predicted to form a transmembrane 
22-stranded β-barrel structure while the N-terminal domain interacts with LptA within the 
periplasm (Sperandeo et al., 2011, Freinkman et al., 2012, Chng et al., 2010b). LptE forms an 
accessory lipoprotein within the LptD β-barrel core and is thought to guide LPS during 
translocation into the OM (Chng et al., 2010b, Freinkman et al., 2011). Overall, the Lpt 
bridge shuttles LPS towards the OM. 
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Additional lipoproteins embedded in the OM also require shielding of the N-terminal 
lipid moiety during translocation. While LPS traverses the Lpt bridge for biogenesis, other 
lipoproteins such as the abundant Lpp are translocated via the lipoprotein OM localisation 
(Lol) pathway (Figure 1.5). Following translocation across the IM (primarily via the Sec 
translocon), prolipoprotein diacylglyceryl transferase facilitates the addition of a 
diacylglyceride moiety to the first cysteine residue within the N-terminus of the lipoprotein 
(Sankaran and Wu, 1994). Similar to LPS synthesis, lipoproteins are synthesised and 
anchored within the IM via the N-terminal signal peptide. Upon cleavage of the signal 
peptide (Tokunaga et al., 1982), the exposed cysteine residue of the lipoprotein becomes 
tricacylated via the N-acyl transferase, Lnt (Jackowski and Rock, 1986, Gupta and Wu, 
1991). Lipoproteins destined for the OM (i.e. lack the Lol-avoidance specific residues) are 
released from the IM via the LolCD2E ABC transporter protein complex (Yakushi et al., 
2000). In contrast to the Lpt bridge used for LPS transport, lipoproteins are transported across 
the periplasm via a soluble chaperone LolA (Matsuyama et al., 1995). LolA delivers 
lipoproteins to the OMP LolB, which facilitates the insertion of lipoproteins into the outer 
leaflet of the OM (Matsuyama et al., 1997).  
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Figure 1.5 Overview of the two pathways 
involved in outer membrane biogenesis in E. coli. 
LPS is the major lipoprotein comprising the 
outer membrane and traverses the LPS 
transport (Lpt) trans-envelope protein bridge 
(LptA-G) for insertion into the OM. Other 
lipoproteins similarly traverse the lipoprotein 
outer membrane localisation (Lol) pathway for 
translocation to the cell membrane (LolA-E). 
Image was modified from (Ricci and Silhavy, 
2012). 
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1.5.2 The β-Barrel Assembly Machine (BAM) complex  
The β-barrel assembly machine (BAM) belongs to the Omp85 protein superfamily 
and is highly conserved within E. coli and other Gram-negative bacteria (Heinz and Lithgow, 
2014). The BAM complex is a heteropentameric protein complex essential for OM 
biogenesis. This complex consists of four accessory lipoproteins (BamB-D) that interact with 
the core transmembrane β-barrel protein BamA (Wu et al., 2005, Ruiz et al., 2005, Sklar et 
al., 2007a). Genes encoding two of the BAM proteins, BamA and BamD, are essential in E. 
coli (Malinverni et al., 2006, Gerdes et al., 2003, Wu et al., 2005, Werner and Misra, 2005). 
Deletion of the genes encoding the remaining three BAM complex proteins (BamBCE) can 
impact on OMP biogenesis, OM stability and cellular growth (Onufryk et al., 2005, Ruiz et 
al., 2005, Sklar et al., 2007a). BamA is the major protein that catalyses folding of OMPs and 
can act alone or in complex with either BamB or with BamC, BamD and BamE (Malinverni 
et al., 2006, Kim et al., 2007, Hagan et al., 2010, Plummer and Fleming, 2015). The C-
terminal domain of BamA forms a transmembrane 16-stranded β-barrel core, while the N-
terminal region of BamA forms five soluble periplasmic polypeptide-transport-associated 
domains (POTRA) (Jansen et al., 2015b, Kim et al., 2007, Gatzeva-Topalova et al., 2010, 
Gatzeva-Topalova et al., 2008). These POTRA domains contribute to BamA stability and 
directly interact with BamBD within the periplasm, nascent polypeptides and the periplasmic 
chaperone SurA (Bennion et al., 2010, Kim et al., 2007, Workman et al., 2012, Dong et al., 
2012a). The lipoproteins BamC and BamE interact directly with BamD (Kim et al., 2011a, 
Malinverni et al., 2006, Wu et al., 2005, Stenberg et al., 2005). The exact mechanism by 
which the BAM complex mediates insertion of OMPs into the OM has remained elusive for 
some time. Recent research over the past few years has called into question the mechanistic 
model for BAM-mediated OMP biogenesis, and the insertion of nascent peptides into the OM 
is now believed to occur laterally (Heuck et al., 2011, Noinaj et al., 2014, Noinaj et al., 
2013a, Ni et al., 2014). 
 
1.5.3 The Translocation and Assembly Module (TAM) 
The translocation and assembly module (TAM) constitutes another member of the 
Omp85 protein superfamily conserved within Proteobacteria (Stegmeier et al., 2007, Selkrig 
et al., 2012, Heinz and Lithgow, 2014). The TAM consists of two transmembrane proteins 
that interact within the periplasm, TamA and TamB. These two proteins are encoded by the 
tamAB (ytfMN) genes located on the chromosome. TamB is anchored within the IM while 
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TamA resides within the OM as a 16-stranded β-barrel domain with three periplasmic 
POTRA domains (Gruss et al., 2013b). The TamA β-barrel domain and the third POTRA 
domain (connecting to the β-barrel) share structural similarity with BamA (Selkrig et al., 
2015, Gruss et al., 2013b). However, the two remaining POTRA domains are different in 
sequence and in structure. These POTRA domains of the TAM are rigid and elongated in 
comparison to the five POTRA domains of BamA. The three TAM POTRA domains form a 
lever arm that interacts directly with the periplasmic portion of TamB and is thought to 
facilitate substrate binding and/or folding (Selkrig et al., 2015). The putative exit pore 
identified within the BAM complex was also identified within the TAM, suggesting TAM 
may function in parallel with BAM to facilitate the lateral insertion of OMPs into the OM 
(Gruss et al., 2013b, Selkrig et al., 2015). 
 
1.5.4 Periplasmic Chaperones 
Due to the heterogeneous nature of the OM phospholipid bi-layer, outer membrane 
proteins (OMPs) form various sized (8-24 antiparallel β-strands) β-helical structures for 
optimal integration. Such structures are thermodynamically stable as each β-strand laterally 
engages backbone hydrogen bonds with neighbouring strands, leaving the non-polar side 
chains exposed to the hydrophobic middle of the lipid bi-layer (reviewed in Vinothkumar and 
Henderson, 2010, Schulz, 2002, Haltia and Freire, 1995, Minetti and Remeta, 2006, Naveed 
and Liang, 2014). However, in order to maintain a folding competent state and/ or undergo 
partial folding, OMPs must traverse the hydrophilic periplasmic space often with the aid of 
conserved periplasmic chaperone proteins. Unlike the well-characterised DnaK and GroEL 
chaperones of the E. coli cytoplasm, the periplasm is devoid of nucleotide hydrolysis. 
Periplasmic chaperones provide A(G)TP independent mechanisms for protein folding and/ or 
stable transportation of peptide to the OM. Such processes may utilise the proton motive 
force as a primary energy source. There are three major classes of chaperones in the E. coli 
periplasm: i) chaperones that stabilise nascent proteins in their unfolded state, ii) catalysts of 
rate-limiting folding processes and iii) proteases.  
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Figure 1.6 Protein structures (cartoon representation) for selected E. coli 
periplasmic chaperones A) FkpA (Dimer: attached to the 
immunosuppressant FK506 in red (Saul et al., 2004)), B) SurA (Bitto and 
McKay, 2002), C) PpiA (Clubb et al., 1994) and D) Skp (Trimer (Walton 
and Sousa, 2004)). The 17-KDa Skp chaperone (monomers independently 
coloured) exists as a trimeric ‘jellyfish’ like structure within the periplasm 
and sequesters substrate proteins within the central cavity. SurA, FkpA 
and PpiA are peptidyl-prolyl cis-trans isomerases that catalyse the cis trans 
isomer conformational changes for substrate proline residues.  
SurA FkpA: Dimer 
PpiA 
Skp: Trimer 
A B
  A 
C D 
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1.5.4.1 Cavity Chaperones 
The 17KDa chaperone Skp is well-characterised in Gram-negative bacteria. Skp 
forms a ‘jellyfish’ like homotrimer (Figure 1.6) with a central β-barrel domain and three α-
helical ‘tentacles’ (Walton and Sousa, 2004, Korndorfer et al., 2004, Schlapschy et al., 2004). 
Skp is a cavity chaperone protein that facilitates partial protein folding or sequesters 
aggregative-prone substrates in order to maintain folding competency. The inner faces of the 
three α-helices form the hydrophobic cavity used to sequester OMPs. The end α-helical 
residues are basic and constitute negatively charged caps. Interestingly, putative LPS binding 
motifs were identified on the outer edge of the α-helical structures (Walton and Sousa, 2004). 
Research involving binding of Skp to the OMPs OmpA, OmpC and PhoE suggests that Skp 
binds to recently synthesised proteins during the early stages of translocation across the IM 
(Harms et al., 2001, Schafer et al., 1999, de Cock et al., 1999a, Wu et al., 2011b).  Substrates 
are thought to bind to Skp via a multitude of weak interactions rather than a specific binding 
motif, enabling flexibility for protein folding or easy protein-to-protein transfer to another 
chaperone pathway (Qu et al., 2007).    
 
1.5.4.2 Peptidyl-Prolyl cis-trans Isomerases (PPIase) 
Peptidyl-prolyl cis-trans isomerases are a class of chaperones that catalyse the rate-
limiting cis to trans conformational change of proline residues. Parvulin was identified in 
1994 and constitutes the smallest PPIase (~10KDa) in E. coli (Rahfeld et al., 1994). 
Subdomains belonging to larger isomerases that exhibit homology to Parvulin are termed 
Parvulin-like domains. SurA was originally identified in 1990 and was found to be essential 
for E. coli survival during stationary phase growth (Tormo et al., 1990). The N-terminal, the 
C-terminal and the first Parvulin-like PPIase (P1) domain of SurA constitutes the protein 
core, with the second Parvulin-like PPIase domain (P2) extending away (~30Å) from the core 
as a satellite domain (Figure 1.6) (Bitto and McKay, 2002). While the PPIase activity of SurA 
lies within the extended P2 domain, the SurA core is thought to primarily function as a 
chaperone. The core of SurA is also thought to aid in substrate recognition and proximal 
positioning towards the P2 domain (Behrens et al., 2001, Rouviere and Gross, 1996). Strains 
lacking SurA are known to exhibit decreased levels of various OMPs including OmpA, 
OmpC, OmpF, OmpX, FadL, LamB, FhuA, FecA and LptD (Vertommen et al., 2009). 
Depletion/ deletion of the surA gene is also known to trigger the σE stress response pathway 
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and can be lethal under some growth conditions or in conjunction with additional mutations 
(Rouviere and Gross, 1996, Missiakas et al., 1996). Overall, SurA plays a major role in OMP 
translocation, and recognises OMP proteins via an aromatic-random-aromatic substrate motif 
typically conserved within the C-terminal domain (Xu et al., 2007, Hennecke et al., 2005, 
Bitto and McKay, 2003). 
 
Additional PPIases identified in E. coli include the FK506-binding protein A (FkpA) 
(Horne and Young, 1995), PPIase protein A (PpiA) (Liu and Walsh, 1990) and PPIase 
protein D (PPIase D) (Dartigalongue and Raina, 1998). PpiA is homologous to cyclophilin 
found in human T cells and exhibits an almost identical structure (Clubb et al., 1994). PpiA 
possesses an 8-stranded anti-parallel β-barrel structure with two additional α-helices (Figure 
1.6) (Clubb et al., 1994). Although PpiA exhibits strong PPIase enzymatic activity in vitro 
(Compton et al., 1992), PpiA has not been linked to OMP biogenesis in E. coli. FkpA 
consists of an N-terminal single chaperone module attached to a C-terminal PPIase domain 
and is known to form a ‘V’ shaped dimer (Figure 1.6) (Saul et al., 2004). PpiD remains 
anchored to the IM via a short N-terminal region and is attached to three periplasmic 
domains, including one Parvulin-like domain (Weininger et al., 2010, Dartigalongue and 
Raina, 1998). Similar to FkpA, PpiD oligomerizes as homodimer and homotrimer protein 
complexes (Stenberg et al., 2005). The chaperone module of SurA is known to exhibit 
similarity to the N-terminal domain of PpiD (Stymest and Klappa, 2008). Overexpression of 
PpiD was reported to counteract the lethal phenotype caused by deletion of the surA gene in a 
ppiD mutant background (Dartigalongue and Raina, 1998), however this result was disputed 
in a recent study (Matern et al., 2010). Weininger and colleagues have also reported that the 
parvulin-like PPIase domain is devoid of PPIase activity (2010), suggesting further work is 
required to understand its function.  
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1.5.4.3 Serine Protease Chaperones 
DegP and DegQ are homologous E. coli endoproteases that possess dual chaperone 
properties. DegP was originally identified to enhance the survival of E. coli at elevated 
temperatures due to capacity to mediate proteolysis of toxic aggregates of misfolded proteins 
(Lipinska et al., 1989, Strauch et al., 1989, Seol et al., 1991). DegQ was later discovered due 
to its sequence conservation with DegP (57% at the amino acid level), and both proteins 
belong to a family of heat-required proteases (Waller and Sauer, 1996, Kolmar et al., 1996). 
DegP and DegQ contain a central protease domain flanked by two PDZ domains (PDZ1 and 
PDZ2) (Sassoon et al., 1999, Krojer et al., 2002). DegP exists as an inactive hexameric 
protein (Figure 1.7), consisting of two face-to-face trimer complexes (Krojer et al., 2002, 
Jomaa et al., 2007). DegQ, however, exists primarily as substrate-free catalytically active 
trimer (Bai et al., 2011). Both DegP and DegQ form higher oligomeric structures, including 
12-mer and 24-mer cage-like structures (Figure 1.7)  (Bai et al., 2011, Malet et al., 2012, 
Sawa et al., 2011, Krojer et al., 2008, Jiang et al., 2008). These cage-like structures are 
triggered by PDZ1 domain substrate recognition and are thought to dictate the chaperone/ 
protease functional mechanisms for both proteins.  
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Figure 1.7 Varying structures formed by the serine protease periplasmic chaperones 
DegP and DegQ. A) Both DegP and DegQ contain a central serine protease domain with 
the conserved catalytic triad motif (ball and stick), with two flanking PDZ domains 
(PDZ1 and PDZ2). B) DegP and DegQ exist as substrate free trimeric proteins. C) DegP 
can also exist as an inactive hexamer complex. Upon substrate recognition, both 
proteases (catalytically inactive: S→A) form higher oligomeric structures, including D) 
12-mer (DegP: OMP bound and DegQ: lysozyme bound) and E) 24-mer complexes 
(DegP: OMP bound and DegQ: β-casein bound) composed of trimeric “building block” 
subunits. A) and B) were modified from (Clausen et al., 2011). DegP [C), D) and E)] 
structures were taken from Ortega, et al., (2009), comprising modified surface 
structures based on the PDB files 1KY9, 2ZLE and 3SC0, respectively. DegQ cryo-EM 
modelled surface structures [D) and E): radially coloured] were taken from (Bai et al., 
2011). 
A) Monomer: DegP  C) Hexamer (side view): DegP
S210A
 
E) 24-mer 
B) Trimer: DegP  
D) 12-mer 
Protease 
PDZ2 PDZ1 
DegPS210A DegQ
S187A
 
DegPS210A DegQ
S187A
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1.6 Involvement of Periplasmic Proteins in Type V Secretion  
Translocation of the passenger domain through the β-barrel pore was originally 
suggested based upon characterisation of the IgA1 protease in Neisseria gonorrhoeae by 
Pohlner and co-workers (1987). The “autonomous” view of classical AT protein translocation 
was later challenged based on the narrow pore size of β-barrel structures and evidence 
suggesting AT proteins are secreted in a partially folded conformation (earlier reviews 
include Desvaux et al., 2004, Henderson et al., 2004b, Jacob-Dubuisson et al., 2004). 
However, in 2007, DegP was reported to contribute to IcsA biogenesis in Shigella flexneri 
(Purdy et al., 2007) and was shown to degrade misfolded Hbp proteins in E. coli (Jong et al.). 
In a series of reports published in 2009, the SPATE proteins EspP and Hbp were discovered 
to interact with BamA (Hbp, EspP), BamB (Hbp, EspP), SurA (Hbp, EspP), Skp (EspP) and 
DegP (EspP) using cross-linking, co-purification and yeast-two hybrid analyses (Sauri et al., 
Ruiz-Perez et al., Ieva and Bernstein). Impaired Hbp and EspP biogenesis was observed for 
E. coli bamA depletion strains (Hbp, EspP) or null mutant strains lacking functional SurA 
(Hbp) or DegP (EspP) periplasmic chaperones. Although Intimin has only recently classified 
as a Type Ve AT protein, an additional report published in 2009 (Bodelon et al.) found 
Intimin expression to be significantly reduced in EPEC strains lacking the periplasmic 
chaperones Skp and SurA. Subsequent reports similarly discovered the SPATE protein EspP 
to interact with the periplasmic chaperones SurA, Skp and FkpA (Ruiz-Perez et al., 2010), in 
addition to BamA and BamB of the BAM complex (Ieva et al., 2011).  
 
The TAM contributes to translocation of several AT proteins, including Ag43 and 
EhaA in E. coli, and a plasmid-encoded AT protein (p1112) in Citrobacter rodentium 
(Selkrig et al., 2012). In a recent study, Norell and colleagues (2014) were able to simulate 
BAM-mediated insertion of Ag43 into liposomes. However, the functional mechanism by 
which BAM (and TAM) mediates formation of the β-barrel and subsequent folding of the 
passenger domain remains to be fully elucidated. Recent structural analysis of both the TAM 
and the BAM complexes allude to lateral insertion of AT proteins into the OM (Noinaj et al., 
2013b, Gruss et al., 2013a, Noinaj et al., 2014). By comparing the crystal structure of BamA 
from Haemophilus ducreyi (lacks 3 POTRA domains) and N. gonorrhoeae, a conformational 
change between the first and last strand, which “opens” the β-barrel domain on one side (the 
shorter C-terminal side: ~9Å v.s. ~20Å), has been noted (Noinaj et al., 2013b). Additionally, 
the outer membrane layer in proximity to this lateral gate was found to be decreased in 
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phospholipid order and overall thickness, a result consistent with other studies (Gessmann et 
al., 2014, Sinnige et al., 2014, Burgess et al., 2008). This lateral gate is also structurally 
conserved within the crystal structure of the TamA protein (Gruss et al., 2013a). However, 
the C-terminal 16
th
 β-strand appeared to protrude inwards, thereby creating a small “kink” 
and weakening hydrogen bonding with the first strand. Another feature conserved between 
BamA and TamA comprises a spatial opening directly above the lateral gate and is referred to 
as the “exit pore” (Noinaj et al., 2014, Selkrig et al., 2015).  
 
An overall summary of AT translocation through the periplasm and the OM is 
depicted in Figure 1.8. Several periplasmic chaperones are thought to sequester AT proteins 
upon translocation across the IM. Depending on the chaperone, AT proteins are either 
degraded, kept in a translocating competent state and/ or undergo chaperone-assisted partial 
folding. SurA is thought to target certain AT chaperones to the POTRA domains of the 
Omp85 translocating BAM or TAM complexes. POTRA domain conformational changes 
either trigger or assist in AT hairpin formation. Initial folding of the C-terminal region is 
thought to transiently form an AT-BAM/TAM hybrid complex by integrating folded AT-β 
strands between the first and last BAM/TAM β-strands exposed upon opening of the lateral 
gate. The temporary increase in exit pore space and the overall diameter of the β-barrel 
structure enables subsequent AT folding into the weakened OM phospholipid bilayer. The 
AT protein is thought to gradually “bud” away from the BAM/ TAM complex during this 
folding process (Knowles et al., 2009, Kim et al., 2012, Gruss et al., 2013a, Noinaj et al., 
2014).  
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Figure 1.8 A) Role of external proteins in AT translocation across the periplasm and 
into the OM. Upon translocation across the IM via the SEC translocon (SecYEG), the 
signal peptide (N-terminus: orange) is cleaved leaving the passenger domain (pink) 
attached to the β-barrel domain (green). Nascent AT peptides may be sequestered via 
periplasmic chaperones such as Skp (trimer), FkpA (dimer), DegP (trimer, 12-mer, or 
24-mer oligomeric structures) or DegQ (trimer, 12-mer, or 24-mer oligomeric 
structures). Catalytically active DegP and DegQ serine proteases degrade misfolded 
ATs. While some AT proteins may directly insert into the OM, some AT proteins 
require the BAM or TAM complexes. SurA is thought to target unfolded AT proteins to 
the POTRA domains extending from β-barrel structures of BamA or TamA. B) Stages 
involved demonstrating the current model proposed for BAM/ TAM lateral insertion of 
AT proteins into the OM (Image (B) taken from Noinaj et al., 2014).   
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2.0 Chapter 2: General Materials and Methods  
 
This section includes general laboratory materials and methods used in this project that are 
not described in the Results chapters. 
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2.1 Bacterial strains and growth conditions 
Bacterial strains used in this study are specified within each chapter. Bacterial strains 
were routinely cultured on solid or in liquid Luria-Bertani (LB) medium at 37°C, unless 
otherwise specified. Liquid cultures were grown aerobically at 250rpm or under static 
conditions where specified. Strains were stored at -80°C in LB containing 25% glycerol and 
were cultured onto LB agar when required for laboratory use. Table 2.1 lists all types of 
media and corresponding compositions used in this project. Growth media were sterilised by 
autoclaving at 121°C for 20mins. The various chemicals and supplements added to growth 
media are listed in Table 2.2. 
 
Table 2.1: List of growth media frequently used in this study and the corresponding chemical 
composition. 
Media Composition 
Luria-
Bertani 
broth (LB) 
Dissolved 5g tryptone (Amresco®), 5g NaCl (Univar) and 2.5g yeast extract 
(Merck Millipore) in 500mL of H2O purified by reverse osmosis [RO]. 
Autoclaved for sterilisation. 
LB Agar 
LB stock with the addition of 7.5g agar (Merck Millipore), in 500mL of RO H2O. 
Autoclaved for sterilisation. Once cooled to ~55°C, agar was poured into sterile 
Petri dishes (20mL/ dish [90mm diameter]). Solidification occurred within the 
sterile environment of a Biosafety cabinet. 
M9 Minimal 
Media 
i) Made stock solution of 5x M9 salts (500mL of Milli-Q® H2O): 40.125g of 
Na2HPO4.2H2O (Univar), 7.5g of KH2PO4 (Sigma-Aldrich), 1.25g of NaCl 
(Univar) and 2.5g of NH4Cl (Univar). Autoclaved for sterilisation. 
ii) Added 100mL of 5x M9 salts to 389mL of Milli-Q® H2O (pre-sterilised), 
followed by filter sterilised (0.22μm) stock solutions: 10mL of 20% (w/v) D-
glucose (Sigma-Aldrich), 1mL of 1M MgSO4 (Univar) and 50μL of 1M CaCl2 
(Univar). 
SOC Media 
i) Dissolved 20g of tryptone (Amresco®), 5g of yeast extract (Merck Millipore), 
0.585g of NaCl (Univar) and 0.186g of KCl (Univar) in 970mL of Milli-Q® 
H2O. Autoclaved for sterilisation. 
ii) Once cooled, added 10mL of filter sterilised (0.22μm) 2M Mg2+ stock solution 
(1M of MgCl2 [Univar] and 1M MgSO4 [Univar]) and 10mL of filter sterilised 
(0.22μm) 1M D-glucose (Sigma-Aldrich). 
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Table 2.2 List of supplements frequently added to growth media (Table 2.1) used in this 
study. 
Supplement  Final Concentration Purpose 
Ampicillin (Amp [Amresco ®])  100μg/ mL 
Antibiotic selection 
Kanamycin  (Kan [Amresco ®]) 100μg/ mL 
Chloramphenicol (Cam [Sigma-Aldrich]) 30μg/ mL 
Gentamycin (Gent [Thermo Fisher 
Scientific]) 
20μg/ mL 
D-glucose (Sigma-Aldrich) 1% (w/v) Carbon source 
Anhydrotetracycline hydrochloride (AHT 
[Sigma-Aldrich]) 
≤ 0.2μg/ mL 
Induction and control 
of gene expression  
L-arabinose (Sigma-Aldrich) ≤ 0.2% (w/v) 
Isopropyl β-D-1-thiogalactopyranoside 
(IPTG [AG Scientific]) 
≤ 1mM 
 
2.2 General laboratory reagents  
The composition for buffers and reagents used in this project are listed in Table 2.3. 
Table 2.3 General laboratory reagents and buffers commonly used during experimental 
research. 
Reagent  Composition 
6x DNA loading dye 
6x stock solution: 30% (v/ v) glycerol, 0.25% (w/ v) Bromophenol 
blue (Bio-Rad) and 0.25% (w/ v) xylene cyanol. Stored at 4°C and 
DNA was added (1/6 dilution) immediately before loading.  
2x  Sodium Dodecyl 
Sulfate (SDS) loading 
buffer 
100mM Tris-Cl (pH6.8), 4% (w/ v) SDS, 0.2% (w/ v) Bromophenol 
blue (Bio-Rad), 20% glycerol (v/ v), 200mM dithiothreitol (DTT).  
Tris-Acetate-EDTA 
(TAE) buffer 
For 50x stock solution: dissolved 242g of Tris base (Sigma-Aldrich) 
in 600mL of Milli-Q
®
 H2O then added 57.1mL of glacial acetic acid 
(Merck Millipore) and 100mL of 0.5M EDTA (Sigma-Aldrich [pH 
8.0]) solution. Made up to a total volume of 1L and diluted (1/50) as 
required.  
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SDS-Polyacrylamide 
Gel Electrophoresis 
(PAGE) running buffer 
For 10x stock solution, dissolved 288g of glycine (Univar), 60.4g of 
Tris base (Sigma-Aldrich) and 20g SDS (Amresco ®) in 1.8L of 
Milli-Q® H2O. Made solution up 2L and diluted (1/10) as required 
(Final concentrations: 25mM Tris, 192mM glycine, 0.1% SDS). 
Stacking gel buffer 
Dissolved 30.25g of Tris-HCl (Sigma-Aldrich [0.5M final 
concentration]) in 350mL of Milli-Q
®
 H2O and adjusted pH to 6.8. 
Made solution up to 500mL in volume and stored at 4°C. 
Resolving gel buffer 
Dissolved 90.85g of Tris base (Sigma-Aldrich [1.5M final 
concentration]) in 350mL of Milli-Q
®
 H2O and adjusted pH to 8.8. 
Made solution up to 500mL in volume and stored at 4°C. 
Agarose gel 
Added 1.5g of agarose (Bridge) in 150mL of TAE buffer (1% w/ v) 
and heated to dissolve. Before solidification, added ethidium bromide 
(Bio-Rad) to molten agarose (0.5μg/ mL final concentration). 
Polyacrylamide gel 
Resolving gel: 6% or 12% (v/ v) Bis-Acrylamide, 0.375M Tris 
(Resolving gel buffer), 0.1% SDS (Amresco ®), 0.1% APS (Thermo 
Fisher Scientific) and 0.1% TEMED (Amresco ®). Stacking gel:  4% 
(v/ v) Bis-Acrylamide (Amresco ®), 0.125M Tris (Stacking gel 
buffer), 0.1% SDS, 0.1% APS and 0.1% TEMED. 
Saline solution 
0.9% NaCl (w/v [Univar]) in Milli-Q
®
 H2O, autoclaved for 
sterilisation. 
Western transfer 
buffer 
Dissolved 3.03g of Tris base (Sigma Aldrich) and 14.4g of glycine 
(Univar) in 1L of Milli-Q
®
 H2O. 
Phosphate Buffered 
Saline (PBS) solution 
Dissolved 8g of NaCl (Univar), 0.2g of KCl (Univar), 1.8g of 
Na2HPO4.2H2O (Sigma-Aldrich) and 0.24g of KH2PO4 (Univar) in 
800mL of Milli-Q
®
 H2O. Adjusted pH to 7.4 and autoclaved for 
sterilisation. 
Tris-Buffered Saline 
(TBS) solution 
Dissolved 8g of NaCl (Univar) and 1.21g of Tris base (Sigma-
Aldrich) in 1L of Milli-Q
®
 H2O. 
Blotto solution 5% (w/ v) skim milk powder dissolved in TBS solution. 
Tris-Buffered Saline 
Tween-20 (TBST) 
Made TBS solution with 1mL of Tween-20 (Univar), in a total 
volume of 1L. 
Crystal Violet solution 
(0.1% [w/ v]) 
For 10x stock solution, dissolved 5mg of Crystal Violet (C25H30ClN3)  
in 500mL of Milli-Q
®
 H2O (1% [w/ v]). Diluted 10x Crystal Violet 
stock solution in Milli-Q® H2O (50mL in 450mL H2O) to obtain 1x 
working solution (0.1%). 
Ethanol/ Acetone 
buffer 
Added 200mL of acetone to 800mL of ethanol (20%: 80% [v/ v]). 
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2.3 DNA manipulations and genetic techniques  
2.3.1 Genomic and plasmid DNA extractions 
Extraction of genomic DNA from bacterial strains was performed using the Wizard
®
 
genomic DNA extraction kit according to the manufacturer’s instructions. Plasmid DNA was 
extracted from bacterial strains using the QIAprep
®
 Spin Miniprep kit (Qiagen), as per 
instructions. Extracted DNA was rehydrated (gDNA) or eluted (Plasmid) in ddH2O and 
quantitated using the Nanodrop N1000 (Thermo Scientific).  
 
2.3.2 Primer design and polymerase chain reaction 
Primers were designed using the Primer3Plus program software. CLC workbench 
software was also used for sequence viewing and other in silico procedures.  Primers were 
generally designed as 18-23bp in length with ~50% GC content to ensure an annealing 
temperature of at least 55°C, with minimal difference (1-2°C) between primer pairs. Primers 
designed for molecular cloning included a flanking GC ‘clamp’ (GCGCG), an appropriate 
restriction endonuclease site and (where required) an optimized ribosome binding site 
(forward primer only). Custom oligonucleotides were synthesised by Integrated DNA 
Technologies
©
 (Singapore).  
 
Polymerase chain reactions (PCR) were routinely performed using the OneTaq
®
 DNA 
polymerase or Taq DNA polymerase as per the manufacturer’s instructions (New England 
Biolabs [NEB]). Screening PCRs were performed under the following conditions: initial 
denaturation at 94°C for 3mins, followed by 25 cycles of 15sec at 94°C, a primer-dependent 
annealing temperature of 50-60°C for 30 sec and an elongation step of 1min/ Kbp at 68°C 
(Taq) or 72°C (OneTaq®); finishing with a final 7min elongation period. More difficult or 
lengthy reactions requiring high fidelity were similarly performed using Phusion High-
Coomassie Blue 
staining solution 
Dissolved 0.5g (1% w/ v) of Coomassie Brilliant Blue G-250 
(Thermo Fisher Scientific) in 250mL of H2O (50% v/ v), gradually 
added 50mL of glacial acetic acid (10% v/ v [Merck Millipore]), 
followed by 200mL of methanol (40% v/ v).   
Coomassie Blue destain 
solution 
Staining solution without dye: i.e. 40% methanol, 50% water and 10 
% acetic acid (Merck Millipore). 
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Fidelity (NEB) of KAPA HiFi (KAPA Biosystems) DNA polymerase, as per the 
manufacturer’s instructions. Reactions were conducted using the GeneAmp® PCR 2700 
(Applied Biosystems) or Verirti
® 
(Applied Biosystems) thermal cyclers.  
 
2.3.3 Agarose gel electrophoresis  
Amplified PCR products (refer to section 2.3.2) were visualised by DNA agarose gel 
electrophoresis. Samples (5μL) were mixed with 6x loading dye (1μL) and loaded onto a 1% 
agarose gel containing ethidium bromide. The agarose gel was submersed in 1x TAE buffer 
within a Sub-cell
®
 apparatus (Bio Rad), and horizontal DNA electrophoresis was performed 
at 120V for 30 mins. Electrophoresis of PCR products was conducted alongside a 1Kbp plus 
DNA ladder (Invitrogen) for size comparison. Nucleotide bands were visualised via 
ultraviolet light using the Molecular Imager
®
 Gel Doc
TM
XR system (Bio Rad) in conjunction 
with Image Lab
TM
 software. PCR products required for further applications were purified 
using the QIAquick PCR Purification Kit (Qiagen) as per the guidelines provided by the 
manufacturer. The QIAquick Gel Extraction Kit was used to purify single DNA bands post-
electrophoresis as required.   
  
2.3.4 Molecular cloning  
Cloning reactions were performed using restriction enzymes ordered from NEB, as 
per manufacturer’s recommendations. Target genes were PCR amplified (refer to section 
2.3.2) with cloning PCR primers containing desired restriction sites. PCR reactions were 
performed using a high fidelity DNA polymerase. Purified PCR products and cloning vectors 
(refer to section 2.3.1) were digested, followed by ligation (1:3, plasmid to PCR product 
ratio) overnight at 16°C using T4 DNA ligase. Ligation reactions were transformed (refer to 
section 2.4) into the E. coli strain DH5α (Taylor et al., 1993) and incubated overnight at 
37°C. Transformed colonies were selected for and screened by colony PCR, using a 
combination of gene specific and plasmid specific primers. Successful clones were sequenced 
and stored at -80
o
C. 
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2.3.5 DNA Sequencing 
Sequencing reactions were performed using the Big Dye Terminator v3.1 Kit 
(Applied Biosystems) under the following conditions: 96°C for 1 min, followed by 30 cycles 
of 10 sec at 96°C, 5 sec at 50°C and 4 mins at 60°C. Samples were submitted to the 
Australian Equine Genetics Research Centre (Brisbane, Australia) for sequencing using the 
Applied Biosystems 3700 DNA Analyser.   
 
2.4 DNA transformation 
Purified plasmids (~40ng/ 50μL of cells) or PCR products (0.5-2μg /50μL of cells 
[refer to section 2.3.1]) were transformed into competent cells via heat shock or 
electroporation techniques. Heat shock was generally used to transform plasmids into 
chemically competent cells (42°C incubation for 90 sec). Electroporations were performed in 
2mm cuvettes using the ShockPod™ cuvette chamber, controlled by the Gene Pulser Xcell™ 
Electroporation System (Bio Rad). Competent cells (plus DNA) were electroporated under 
the following settings: 2500V, 400Ω and 25μF. Transformed cells were recovered in fresh 
LB or SOC media and grown aerobically at 37°C for at least 90 mins. Successful 
transformants were selected by growth on LB agar supplemented with appropriate antibiotics. 
 
2.4.1 Preparation of competent cells  
Competent cells were prepared from bacterial cultures (50mL) grown aerobically 
(refer to section 2.1) to an optical density at 600nm (OD600nm) of ~0.6 and harvested by 
centrifugation (6000 x g). Electrocompetent cells were washed three times using ice-cold 
10% glycerol solution (20mL). Chemically competent cells were resuspended in 50mM 
CaCl2 (25mL, ice cold), incubated on ice for 30 mins, washed and incubated a second time in 
500μL of 100mM CaCl2 (on ice for 1 hr). Competent cells were stored at -80°C. Prior to 
transformation, cells (50μL per transformation) were incubated on ice with purified DNA for 
10-15mins.  
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2.5  Protein detection and analysis  
2.5.1 Sample Preparation 
Whole cell lysate fractions were prepared from aerobic bacteria cultures (refer to 
section 2.1) standardised to OD600nm = 1.0. Cells were harvested via centrifugation (6000 x g) 
and resuspended in 50μL of dH2O. An equal amount of 2x SDS loading buffer was added to 
each sample and boiled for 10min. Samples were centrifuged (11,336 x g) for 2 mins prior to 
loading (10-15μL per well) onto a pre-cast polyacrylamide gel (6% or 12% acrylamide).  
 
Supernatant fractions were routinely prepared from bacterial cultures grown 
aerobically (refer to section 2.1) to a standardised OD600nm = 0.8-1.0. Cells were pelleted and 
the supernatant fractions (10mL) were filtered sterilised using 0.22μm PVDF membrane 
filters (low protein-binding [Millex
®
]). Proteins were precipitated overnight by the addition 
of trichloroacetic acid (TCA; 10% final concentration). Precipitated proteins were pelleted 
(14, 000 rcf; 30 min) and residual supernatant was removed. Protein pellets were washed 
twice with ice cold 80% acetone to remove residual TCA. Protein pellets were air dried and 
dissolved in 1x SDS loading buffer (100μL [100x concentrated]). Samples were boiled for 5 
mins prior to loading onto a polyacrylamide gel (6% or 12% acrylamide depending on the 
size of the proteins to be examined).     
 
2.5.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed at 150V for 90 mins using the Mini-PROTEAN
®
 Tetra Cell System (Bio Rad). 
Samples were run alongside Novex
®
 Sharp Pre-Stained Protein Standard, PageRuler™ 
Prestained Protein Ladder or HighMark™ Pre-Stained High Molecular Weight Protein 
Standard for size comparison.  Separated proteins were stained with Coomassie blue (30 
mins, followed by 1 hr in Destain). Proteins requiring detection using specific antibodies 
were transferred to a methanol-activated polyvinylidene difluoride (PVDF) membrane for 
immunoblotting. Western blot transfer was performed at 100V for 1hr using the Mini Trans-
Blot
®
 Cell system (Bio Rad).  
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2.5.3 Western Blotting 
Membranes blocked in blotto solution (overnight at 4°C) to avoid non-specific 
binding of antibodies. Membranes were incubated with primary a antibody for 90 mins 
(produced in rabbit), washed twice with TBST and incubated for a further 90 mins with an 
anti-rabbit IgG polyclonal antibody (produced in goat [1/10, 000 dilution]) conjugated to 
alkaline phosphatase (Sigma Aldrich). Bound secondary antibodies were detected using 
SigmaFast™ 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium (BCIP/NBT) 
using alkaline phosphatase substrate. Blots were developed in the dark for at least 5 mins 
before rinsing with H2O to stop the reaction.  
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3.0 Chapter 3: Molecular characterisation of the Vacuolating Autotransporter Toxin in 
Uropathogenic Escherichia coli 
 
This section includes work contributing to a manuscript published (May 2016 [copy: refer to 
appendix 5.1]) in the Journal of Bacteriology (vol. 198, issue 10).  
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3.1 Introduction 
Urinary tract infections (UTIs) are one of the most common human infections, and 
affect 40-50% of women and approximately 12% of men globally (Foxman, 2010). UTIs are 
ascending infections and can involve infection of the bladder (cystitis), kidneys 
(pyelonephritis) or dissemination into the bloodstream (urosepsis). Uropathogenic 
Escherichia coli (UPEC) are the primary etiological agent of UTI and cause 70-90% of all 
such infections (Hooton and Stamm, 1997). UPEC can survive in the urinary tract and cause 
disease due to a diverse range of virulence factors including fimbriae (Connell et al., 1996, 
Mulvey et al., 1998, Wu et al., 1996, Roberts et al., 1994), autotransporter (AT) proteins 
(Ulett et al., 2007b, Allsopp et al., 2012b, Allsopp et al., 2010, Totsika et al., 2012b), surface 
polysaccharides such as the O-antigen and capsule (Anderson et al., 2010, Sarkar et al., 2014, 
Phan et al., 2013), iron acquisition systems (Valdebenito et al., 2005, Garcia et al., 2011b, 
Watts et al., 2012a) and toxins (Guyer et al., 2002, Rippere-Lampe et al., 2001, Dhakal and 
Mulvey, 2012, Garcia et al., 2013b, Smith et al., 2008). 
 
AT proteins constitute a large family of proteins from Gram-negative bacteria that are 
translocated by a dedicated type V secretion system (reviewed in Leyton et al., 2012, Leo et 
al., 2012, Gawarzewski et al., 2013, Grijpstra et al., 2013, Benz and Schmidt, 2011). AT 
translocation also requires accessory proteins including the β-barrel assembly module (BAM) 
and the translocation and assembly module (TAM) (Ieva and Bernstein, 2009a, Sauri et al., 
2009, Selkrig et al., 2012, Jain and Goldberg, 2007). AT proteins consist of three major 
domains: i) a signal peptide that targets the protein to the secretory apparatus for inner 
membrane translocation; ii) a passenger domain that comprises the functional domain of the 
protein; and iii) a translocator domain that inserts into the outer membrane (reviewed in Leo 
et al., 2012, Henderson et al., 2004a, Desvaux et al., 2004, Leyton et al., 2012, Nishimura et 
al., 2010a, Grijpstra et al., 2013) . One major subgroup of AT proteins is the serine protease 
AT proteins of Enterobacteriae (SPATEs). SPATEs are characterised by the presence of an 
immunoglobulin A1-like protease domain (PF02395) within the passenger domain that 
contains the conserved serine protease motif GDSGS (Yen et al., 2008, Dautin, 2010). The 
first serine within this motif comprises the catalytic triad in conjunction with upstream 
conserved histidine and aspartate residues. SPATEs can be phylogenetically grouped into two 
classes (reviewed in Ruiz-Perez and Nataro, 2014a, Yen et al., 2008, Dutta et al., 2002). 
Class I SPATEs represent the major group of these proteins and exhibit cytotoxic activity 
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(Djafari et al., 1997, Dutta et al., 2002, Stein et al., 1996, Guyer et al., 2000, Al-Hasani et al., 
2000, Navarro-Garcia et al., 2004, Henderson et al., 1999). Class II SPATEs recognise a 
more diverse range of substrates including mucins (reviewed in Dutta et al., 2002, Yen et al., 
2008, Ruiz-Perez and Nataro, 2014a) and immunomodulatory host proteins (Ruiz-Perez et 
al., 2011).  
 
The vacuolating AT toxin (Vat) of E. coli is a class II SPATE (Parham et al., 2005, 
Yen et al., 2008, Ruiz-Perez and Nataro, 2014a) that exhibits cytotoxicity to chicken 
embryonic fibroblast cells and contributes to avian cellulitis infection (Parreira and Gyles, 
2003). The vat gene was originally identified within a pathogenicity island (Vat-PAI) from 
the avian pathogenic E. coli (APEC) strain Ec222 (Parreira and Gyles, 2003). The Vat-PAI is 
integrated into the Ec222 chromosome at the thrW-tRNA site between the proA and yagU 
genes (Parreira and Gyles, 2003, Parham et al., 2005). The Vat-PAI from Ec222 consists of 
33 open reading frames (ORFs), with the vat gene residing at ORF#27. Only five additional 
ORFs in this PAI were reported to share homology with other previously known protein 
sequences. This includes the ORF located downstream of vat (ORF#26), which shares 44% 
identity to the P pilus associated transcriptional regulatory protein PapX from UPEC strain 
CFT073 (Parreira and Gyles, 2003). PapX belongs to the family of multiple antibiotic 
resistance (MarR) regulators of Enterobacteriaceae and contributes to flagella regulation by 
binding to the promoter region of the flhDC master regulator genes (Simms and Mobley, 
2008b, Reiss and Mobley, 2011, Simms and Mobley, 2008a). In UPEC, the vat gene is 
associated with virulence and contributes to survival during murine systemic infection 
(Subashchandrabose et al., 2013). 
 
The full-length Vat protein is ~140 kDa and is processed during translocation to 
release a 111.8 kDa passenger domain into the extracellular milieu. Vat shares 78% identity 
to the APEC associated Temperature-sensitive hemagglutinin (Tsh), which is almost identical 
(99% amino acid identity) to the SPATE Haemoglobin binding protein (Hbp) (Otto et al., 
1998, Provence and Curtiss, 1994). Hbp has been analysed extensively in the E. coli intra-
abdominal clinical strain EB1, and its crystal structure has been solved (Otto et al., 2005, 
Tame et al., 2002). Tsh/Hbp possess dual proteolytic and adhesive properties (Nishimura et 
al., 2010b, van Dooren et al., 2001, Kobayashi et al., 2010). Unlike Tsh/Hbp, Vat is unable to 
digest casein at 37°C (Parham et al., 2005, Parreira and Gyles, 2003).   
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Despite these functional differences, the high protein sequence identity shared 
between Tsh/Hbp and Vat has led to confusion in the annotation of vat genes within E. coli 
genomes available on the NCBI database. For example, the CFT073 vat gene (c0393) has 
been annotated as hbp (Welch et al., 2002), and even referred to as tsh due to its temperature-
dependent regulation (Heimer et al., 2004). In addition, the vat gene from UPEC strain 536 is 
annotated as sepA, which encodes the Shigella extracellular protein A (Parham et al., 2005).  
 
In this study, we have examined the sequence conservation of vat genes from 
available E. coli genomes and compared its genomic location, with the aim to correct existing 
annotation errors and vat nomenclature. We also examined the role of the putative MarR 
regulator identified downstream of the vat gene as well as the histone-like nucleoid protein 
H-NS in regulation of the vat gene. Finally, we examined the prevalence, expression and 
secretion of Vat in a collection of UPEC urosepsis isolates, and investigated its 
immunogenicity by examining plasma from urosepsis patients.  
 
3.2 Materials and Methods  
3.2.1 Ethics statement 
 This study was performed in accordance with the ethical standards of The University 
of Queensland, Princess Alexandra Hospital, Gold Coast Hospital, Queensland Health, 
Griffith University and the Helsinki Declaration. The study was approved, and the need for 
informed consent was waived by the institutional review boards of the Princess Alexandra 
Hospital (2008/264), Queensland Health and Griffith University (MSC/18/10/HREC). 
Additionally, antibodies which were derived from rabbits were produced in accordance with 
the South Australian Animal Welfare Act (1985). 
 
3.2.2 Bacterial strains and growth conditions  
 E. coli strains CFT073 (Mobley et al., 1990), IHE3034 (Moriel et al., 2010), 536 
(LeClerc et al., 1996), MG1655 (Blattner et al., 1997) and BL21 (Jeong et al., 2009), as well 
as the E. coli reference (ECOR) collection (Ochman and Selander, 1984), have been 
described previously. The 45 urosepsis UPEC strains were isolated from the blood of patients 
presenting with urosepsis at the Princess Alexandra Hospital (Brisbane, Australia). A 
matching urine sample was also cultured from each patient; in all cases the blood and urine 
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isolates were identical as determined by virulence gene profiling. Unless otherwise stated, 
strains used in this study were routinely grown at 37°C on solid or in liquid Luria-Bertani 
broth (LB) supplemented with antibiotics: kanamycin (kan [100μg/mL]), ampicillin (amp 
[100μg/mL]) or chloramphenicol (cam [30μg/mL]). Supplementation of growth media with 
L-arabinose (0.2% [w/v]) or isopropyl β-D-1-thiogalactopyranoside (IPTG [1mM]) was used 
to induce plasmid-mediated gene expression. 
 
3.2.3 Bioinformatic analysis 
 The presence of the vat gene was determined in 77 complete E. coli genomes 
(Appendix 3.1) available from the National Centre for Biotechnology Information (NCBI) 
database by BLAST analysis using the vat gene (c0393) from the CFT073 genome (Genbank 
accession no.: AE014075.1 (Welch et al., 2002)) as a search tool. The genomic location 
surrounding the vat gene in each of the vat-positive strains was investigated in Artemis 
(Rutherford et al., 2000). All vat genes identified were located in a PAI defined by the proA 
and yagU genes. The nucleotide sequence of each vat-associated PAI was compared in 
EasyFig (Sullivan et al., 2011).  
 
 A comparative protein analysis of the family of MarR of transcriptional regulators 
(Appendix 3.2) was performed to determine the phylogenetic relationship between these 
regulators and the putative transcriptional regulator VatX. The MarR dataset was compiled 
using an iterative approach that involved BLAST analysis against the 77 complete E. coli 
genomes (Appendix 3.1) available from NCBI . Representative protein sequences were 
chosen for each MarR type regulator based on previous characterisation within the literature. 
Protein sequences chosen include MarR from MG1655 (b1530), MprA(EmrR) from MG1655 
(b2684), HosA from E2348/69 (E2348C_3010), HpcR/ HpaR from the E. coli strain W 
(WFL_22965), SlyA from MG1655 (b1642) and PapX from CFT073 (c3582). The 
evolutionary relationship between VatX and the resulting hits (E<0.001) was inferred using 
ClustalΩ and visualised through FigTree.  
 
3.2.4 DNA manipulation and genetic techniques 
  DNA techniques were performed as previously described (Sambrook, 2001). Isolation 
of plasmid DNA was performed using the QIAprep spin column miniprep kit (QIAGEN). 
69 
 
Polymerase chain reactions (PCR) were performed using the specified primers which were 
sourced from Integrated DNA Technologies (Singapore). PCR products were amplified using 
Taq DNA polymerase according to the manufacturer’s instructions (New England Biolabs). 
For sequencing, nucleic acid fragments were amplified using the BigDye Terminator v3.1 
cycle DNA sequencing kit as per the manufacturer's specifications (Applied Biosystems) and 
sequenced by the Australian Equine Genome Research Centre. Cloning reactions involving 
restriction endonucleases were performed as per the manufacturer’s instructions (New 
England Biolabs).  
 
3.2.5 Multi locus sequence typing (MLST) and PCR screening 
Prevalence of the vat gene was assessed by PCR using primers 2020 (5’-
GTATATGGGGGGCAACATAC-3’) and 2021 (5’-GTGTCAGAACGGAATTGTCG-3’), 
which were designed based on the sequence of the vat gene from CFT073 (c0393). The vat 
gene sequence from ten of the 31 vat-positive UPEC urosepsis strains was determined and 
deposited on the NCBI database (accession numbers: PA11B vat, KR094926; PA15B vat, 
KR094927; PA32B vat, KR094928; PA38B vat, KR094929; PA42B vat, KR094930; PA48B 
vat, KR094931; PA56B vat, KR094932; PA57B vat, KR094933; PA60B vat, KR094934; 
PA66B vat, KR094935). The sequence type of the UPEC urosepsis strains was determined 
using the seven-gene MLST scheme (http://mlst.ucc.ie/mlst/dbs/Ecoli) (Wirth et al., 2006). 
PCR was performed as follows: initial denaturation at 94°C for 5 m; 25 cycles of 
denaturation at 94°C for 30 s, annealing at 50°C for 30 s, extension at 72°C for 30 s followed 
by a final extension at 72°C for 7 m.  
 
3.2.6 Construction of deletion mutants 
  The vat (c0393), vatX (c0392) and hns (c1701) genes were mutated in CFT073 using λ-
Red mediated homologous recombination (Datsenko and Wanner, 2000). Briefly, the 
kanamycin gene from pKD4 or the chloramphenicol gene from pKD3 were amplified using  
PCR primers (lower case: kanR/ camR specific) containing 50-bp flanking regions (upper 
case) homologous to the target genes vat (3353: 5’-
TCGTAATGAACACAGTTCATCTGATCTCCACACACCAAGACTTGATAAGCTcacgtct
tgagcgattgtgtagg-3’ and 3354:  5’-
GAAACCACCACCCCATGATTTTGTTTTACCGCTGTACAGGCCTGCTGACGCgacatgg
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gaattagccatggtcc-3’), vatX (5232: 5’-
TTCACGATACTTCATGTAACACTCAGGTTGAGTAATCTTCgtgtaggctggagctgcttc-3’ 
and 5233:  5’-
AGAATACATTGTAAGAAGATGACTGTTAGTATGTTTTAACAcatatgaatatcctcctta-3’) 
or hns (1583: 5’-
TCGTGCGCAGGCAAGAGAATGTACACTTGAAACGCTGGAAGAAATGCTGGgtgtag
gctggagctgcttc-3’ and 1584: 5’-
TTGATTACAGCTGGAGTACGGCCCTGGCCAGTCCAGGTTTTAGTTTCGCCcatatgaat
atcctccttag-3’). Amplified fragments were transformed into CFT073 (pKD56) expressing of 
the λ-Red recombinase in order to facilitate homologous recombination for inactivation of the 
target gene. Removal of the antibiotic resistance gene cassette was performed using plasmid 
pCP20 as previously described, and enabled the construction of the CFT073vatX hns double 
mutant. 
 
3.2.7 Construction of plasmids   
  A segment of the vat gene corresponding to amino acid residues 63-465 of the 
passenger domain was amplified from CFT073 using primers 1491 (5’-
tacttccaatccaatgcTCCTTACCAGACATACCGCG-3’) and 1494 (5’-
ttatccacttccaatgTTACCCCGCATATTGATCATTGCC-3’) and cloned as a 6 x histidine N-
terminal fusion into the pLicA vector using ligation independent cloning (designated 
pVat
403
). This expression vector (pVat
403
) was later used for recombinant protein purification 
(refer to section 3.2.12) as this region of the Vat passenger domain encompasses the catalytic 
triad motif and is highly conserved. The full-length vat gene (c0393) and the downstream 
gene vatX gene (c0392) were PCR amplified from CFT073 using the following primer pairs; 
vat: 1524 (5’-cgcgCTCGAGataataaggaattactATGAATAAAATATACGCTC-3’) and 1525 
(5’-cgcgcaagcttCAAAGCAATAGTCCCTTTGC-3’); and vatX: 5244 (5’-
cgcgctcgagataataaggaaTCTTCATGAGTTTTCTTTTGCCGTGTGG-3’) and 5245 (5’-
cccggaagcttTCAATTAACATTAAGGTTTGATA-3’). The PCR products were purified and 
cloned into XhoI-HindIII digested pSU2718 to generate the plasmids pVat and pVatX. 
Transcription of the vat and vatX genes in these plasmids was regulated by the lac promoter 
(Martinez et al., 1988).  
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3.2.8 Comparative quantitative reverse transcriptase PCR (qRT-PCR)  
Comparative qRT-PCR was performed essentially as previously described (Simms 
and Mobley, 2008b). Briefly, strains CFT073, CFT073vatX and CFT073vatX (pVatX) were 
grown in LB broth (supplemented with IPTG) until exponential growth phase. The total RNA 
from each strain was extracted using the RNeasy mini kit as per manufacturer’s instructions 
(QIAGEN). Samples were subjected to RNase free DNA digestion and first strand cDNA 
synthesis was performed using SuperscriptIII (Invitrogen Life Technologies) with random 
hexamer (50ng/μL) primers (Invitrogen Life Technologies). Residual RNA was digested by 
RnaseH and samples were re-purified as recommended by the manufacturer (QIAGEN). The 
ViiA 7 instrument and software (v 1.2.1) was used to carry out RT PCR reactions (95°C 10 s; 
95°C 15 s, 60°C 15 s and 72°C 30 s for 40 cycles). Primers specific to the vat gene (5470: 5’-
TACCGTAACCAGCTCATCAACAG-3’ and 5471: 5’- 
CATACCCACCTGTTACCCAATGT-3’) and gapA (control; 820: 5’-
GGTGCGAAGAAAGTGGTTATGAC-3’ and 821: 5’-
GGCCAGCATATTTGTCGAAGTTAG-3’) were used to amplify transcripts with 
SybrGreenI (5 μL) master mix (Applied Biosystems). Each reaction was conducted in 
triplicate and a subsequent melt curve was performed for validation of the results (95°C 15 s, 
60°C 1 m and 95°C for 10 s). Cycle threshold values obtained were normalised to the 
endogenous control and the 2
-∆∆Ct
 method (Livak and Schmittgen, 2001) was applied for the 
comparative analysis. The resulting ratios were statistically analysed using a one-way 
ANOVA. All experiments were performed in triplicate. 
 
3.2.9 5’-RACE and Virtual Footprint analysis 
The transcriptional start site for vat was determined using the 5’ RACE system for 
rapid amplification of cDNA ends (version 2.0 Invitrogen Life Technologies) following the 
manufacture’s specifications. Two gene specific primers (5863: 5’-
ATGCAGATAGTGCCAGAG-3’ and 5864: 5’-CTCTGCGGGTACTCCCTTTAC-3’) were 
used. Putative DNA binding motifs in the vat promoter region were identified using Virtual 
Footprint software (Munch et al., 2005). 
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3.2.10 Electrophoretic mobility shift assay (EMSA) 
EMSA was performed essentially as described previously (Beloin and Dorman, 2003) 
but with minor adaptations. Briefly, four individual fragments (152 bp, 218 bp, 312 bp and 
479 bp) were PCR amplified from the plasmid pBR322 (152 bp: 5’-
CATTGGACCGCTGATCGT-3’ and 5’-CTTCCATTCAGGTCGAGGT-3’; 218 bp: 5’-
AATATTATTGAAGCATTTATCAGGGTTA-3’ and 5’-
ATGATAAGCTGTCAAACATGAGA-3’; 312 bp: 5’-TATCGACTACGCGATCATGG-3’ 
and 5’-TCTCCCTTATGCGACTCCTG-3’; and 479 bp: 5’-GACCGATGCCCTTGAGAG-3’ 
and 5’-GATCGAAGTTAGGCTGGTAAGA-3’). The 218-bp fragment containing the H-NS 
repressed bla gene promoter was included within the assay as a positive control. The 
remaining three fragments do not bind H-NS. The vat gene promoter region (252 bp) 
encompassing all three of the putative H-NS binding sites identified, was also PCR amplified 
(6103: 5’-CCTGAGAAAAAGCAAACAACA-3’ and 6104: 5’-
TTTTAGAGCGTATATTTTATTCAT-3’) from the genomic DNA of the UEPC strain 
CFT073. This 252-bp fragment was added in an equimolar ratio with the control fragments 
(7.5 nM per fragment [~100 ng]). Purified native H-NS protein (a gift from Prof. Richard 
Strugnell) was added to each reaction in increasing concentrations (0 μM, 0.1 μM, 0.5 μM 
and 1.0 μM). Reactions were incubated at room temperature (15 m within H-NS binding 
buffer to allow for protein-DNA complex formation. Samples were examined by high-
resolution agarose gel electrophoresis (3% Lonza Metaphor [50 V at 4°C]), and viewed under 
ultraviolet light after staining with ethidium bromide (0.5μg/ mL). Invitrogen’s 1 Kb plus 
ladder was used as a molecular marker. 
 
3.2.11 Preparation of supernatant proteins 
Bacterial cultures (10 mL) were standardised to an optical density at 600nm equal to 
1.0 (OD600 = 1.0), centrifuged (2057 x g), and the supernatant was collected and filtered (0.22 
µm). Proteins were precipitated by the addition of 10% trichloroacetic acid (TCA) overnight 
at 4°C. Following precipitation, supernatant fractions were concentrated by centrifugation 
(12,100 x g) and washed twice with 80% acetone to remove residual TCA. Proteins were 
resuspended in a final volume of 0.1 mL (100-fold concentration). 
 
 
73 
 
 
3.2.12 Purification of denatured His-tagged Vat protein 
A bacterial culture (200mL) of E. coli BL21 λDE3 expressing the truncated Vat403 
protein encoded on plasmid pVat
403
 was grown in LB. Bacterial cells were pelleted by 
centrifugation (2057 x g) and lysed (7M urea, 0.1 M NaH2PO4, 0.01 M Tris·Cl [pH 8.0]). The 
recombinant Vat
403
 protein was purified under denaturing conditions using QIAGEN’s Ni-
NTA spin column kit. The cleared lysate was passed through a pre-equilibrated column via 
centrifugation (270 x g) to allow for the 6xHis tagged-Vat protein to bind. The column was 
washed (0.1 M NaH2PO4, 0.01 M Tris·Cl ([pH 6.3]) and the bound Vat protein was eluted 
(0.1 M NaH2PO4, 0.01 M Tris·Cl [pH 4.5]) by centrifugation (890 x g). Protein 
concentrations were determined using the bicinchoninic acid protein assay kit as per the 
manufacturer’s instructions (Thermo Scientific Pierce Biotechnology). Purity of the eluted 
protein was validated by sodium-dodecyl-disulfide polyacrylamide gel electrophoresis (SDS-
PAGE) analysis (12% polyacrylamide gel) and Coomassie staining. 
 
3.2.13 Immunoblotting  
The purified His-tagged recombinant Vat protein was used to generate a Vat-specific 
polyclonal antibody following a standard protocol (Institute of Medical and Veterinary 
Science, South Australia). Concentrated supernatant proteins were re-suspended in 50 µL of 
SDS loading buffer (100 mM Tris-HCl, 4% w/v SDS, 20% w/v glycerol, 0.2% w/v 
bromophenol blue, pH 6.8) and a 10 µL sample was boiled for 10 min prior to SDS-PAGE. 
SDS-PAGE and transfer of proteins to a PVDF membrane for western blot analysis was 
performed as previously described (Ulett et al., 2006). Anti-Vat polyclonal antibodies were 
used as the primary antibody, and alkaline phosphatase conjugated anti-rabbit antibodies 
(Sigma Aldrich) were used as the secondary antibody. SIGMAFAST
TM
 BCIP®/NBT (Sigma-
Aldrich) was used as the substrate for detection. 
 
3.2.14 Human plasma samples and measurement of Vat immunogenicity  
Blood plasma was collected from 45 urosepsis patients admitted (collected within four 
days post-admission) to the Princess Alexandra Hospital (Brisbane, Australia) and 42 healthy 
volunteers with no recent history of UTI. An ELISA assay was performed using a Nunc 
MaxiSorp flat-bottom 96 well microtiter plate (Thermo Scientific). Each well was coated 
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within purified recombinant Vat protein (10 µg/ml) in carbonate coating buffer (18 mM 
Na2CO3, 450 mM NaHCO3, pH 9.3 [4
o
C overnight]). Plates were then washed twice with 
0.05% v/v Tween20 PBS (PBST) and blocked with 5% w/v skim milk in PBST (150 µl [90 
min at 37
o
C). Plates were washed four times with PBST and before incubation (90 mins at 
37
o
C) with the plasma samples (5µL [1:10 dilution]). Plates were washed four times with 
PBST to remove unbound antibodies. Peroxidase-conjugated anti-human IgG (1:30,000 
dilution in 5% skim milk) was applied for secondary antibody (incubated at 37
o
C for 90 min). 
Plates were washed four times with PBST before adding 3,3',5,5'-tetramethylbenzidine as a  
substrate for spectrophotometry analysis. Reactions were stopped with 1 M HCl and the 
absorbance for each well was measured at 450 nm using the Spectramax plus
384 
plate reader 
via the SoftMax Pro
®
v5 program. Data obtained was analysed using GraphPrism5 software 
and a one-way ANOVA statistical analysis was performed. Data were grouped according to 
vat gene prevalence based on previous PCR screening of the 45 patient-matched clinical 
isolates (vat+ve [n=31] and vat-ve [n=14]).  
 
3.3 Results 
3.3.1 The vat gene is located in a pathogenicity island at a conserved genomic 
location 
The prevalence of vat was assessed in 77 complete E. coli genomes available on the 
NCBI database (Appendix 3.1). The vat gene was identified in 14 of these strains; these 
included the previously characterised vat-positive UPEC strains CFT073 and 536, as well as 
twelve additional strains from which vat has not previously been characterised (APEC 01, 
NRG 857C, LF82, IHE3034, S88, 83972, PMV-1, clone Di2, clone Di14, ATCC 25922, 
Nissle 1917 and UM146). In all 12 strains, the vat gene was located within a pathogenicity 
island (PAI) flanked by the proA and yagU genes relative to the E. coli K12 MG1655 
chromosome. This genomic location is consistent with the original identification of vat in 
APEC strain Ec222 (Parreira and Gyles, 2003). Closer examination of the genetic context of 
vat revealed that the upstream region (i.e. the yagU end) is highly conserved. In contrast, the 
region downstream of vat (i.e. the proA end) exhibits extensive variation, with a range of 
different DNA segments inserted at various positions of the PAI in strains APEC 01, 83972, 
UM146, 536 and Ec222 (Figure 1A).  
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Figure 3.1: A) BLAST alignment demonstrating the level of nucleotide sequence 
conservation [grey shading] for vat and vatX (red), as well as the other surrounding 
genes (blue). The Vat-PAI (defined by the proA and yagU genes [yellow]) was identified 
in 14 of 77 complete E. coli genomes examined. These sequences were compared to the 
Vat-PAI originally identified in the avian pathogenic E. coli strain Ec222 (top). B) An 
unrooted phylogram representative of the MarR-type regulators characterised within 
E. coli (PapX, FocX, SfaX, MarR/ EmrR, HosA, HpcR/ HpaR and SlyA). Protein 
sequences (330 in total) were obtained from the 77 complete E. coli genomes and aligned 
against VatX from CFT073. 
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3.3.2 Vat is secreted by several genome sequenced UPEC strains 
The secretion of Vat following growth in LB broth at 37
o
C was assessed from a 
selection of the vat-positive UPEC strains described above (i.e. CFT073, IHE3034 and 536). 
As a positive control, the vat gene from CFT073 was amplified by PCR, cloned into the low 
copy number expression vector pSU2718 to generate the plasmid pVat, and transformed into 
E. coli MG1655 to generate the recombinant strain MS4192. Western blot analysis using a 
Vat-specific antibody detected a single band of ~110 kDa that corresponded to the predicted 
size of the secreted passenger domain of Vat in the supernatant of MS4192, but not the vector 
control strain (MS3616) (Figure 2A). The vat gene was also mutated in CFT073 to generate a 
null mutant (strain CFT073vat). SDS-PAGE and western blot analysis of the supernatant 
fraction obtained from CFT073 and CFT073vat using our Vat-specific antibody identified the 
secreted Vat passenger domain from CFT073 but not CFT073vat (Figure 2A). Finally, we 
also detected the Vat passenger domain in the supernatant fraction prepared from strains 
IHE3034 and 536. Taken together, our data demonstrate that Vat is expressed and secreted by 
the genome-sequenced strains CFT073, IHE3034 and 536.  
 
3.3.3 A marR-like gene is located immediately downstream of the vat gene  
We were interested to study the regulation of Vat, and noted a small open reading 
frame located directly downstream of the vat gene in all vat-positive strains (Figure 1). This 
gene, which we have termed vatX, corresponds to c0392 in CFT073 (Welch et al., 2002) and 
ORF#26 in the Vat PAI from Ec222 (Parreira and Gyles, 2003). The VatX protein sequence 
is highly conserved (99% amino acid identity in the 14 vat-positive completely sequenced 
strains described above) and shares 44% amino acid identity with the CFT073 P pilus-
associated transcriptional regulator PapX. Further analysis of VatX revealed it contains a 
MarR PFAM domain (PF01047) and a helix-turn-helix motif characteristic of DNA binding 
proteins. To examine the relationship between VatX and other regulator proteins, we 
generated a dataset comprising previously characterised E. coli MarR type regulators 
(Appendix 3.2) (Delcastillo et al., 1990, Sjostrom et al., 2009, Simms and Mobley, 2008b, 
Lomovskaya et al., 1995, Roper et al., 1993) and performed a multiple sequence alignment to 
generate an unrooted phylogram (Figure 1B). The analysis revealed that VatX clusters in a 
distinct clade of the MarR regulator family, and is most closely related to the PapX, SfaX and 
FocX fimbriae-associated regulators (Paracuellos et al., 2012, Simms and Mobley, 2008b, 
Sjostrom et al., 2009, Dezfulian et al., 2004). 
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3.3.4 Expression of the vat gene is upregulated by VatX 
The proximity, orientation and conserved genetic organization of the vat and vatX 
genes led us to examine if VatX contributes to the regulation of the vat gene. In order to 
study this, we generated a CFT073 vatX mutant (CFT073vatX) and examined the 
transcription of vat in CFT073 and CFT073vatX using comparative qRT-PCR. In addition, 
the vatX gene from CFT073 was PCR amplified and cloned into the pSU2718 expression 
vector (to generate the plasmid pVatX) and used to complement the CFT073vatX mutant. No 
significant difference was observed in the level of vat mRNA transcribed in CFT073 and 
CFT073vatX following growth in LB broth at 37
o
C (Figure 2C). However, the over-
expression of VatX in CFT073vatX(pVatX) resulted in an approximately 3-fold higher level 
of vat mRNA transcript compared to WT CFT073 (Figure 2C). To explore the effect of VatX 
on Vat expression further, we compared the level of Vat secreted into the supernatant fraction 
by CFT073, CFT073vatX and CFT073vatX(pVatX) by western blot analysis (Fig 2B). 
Consistent with our transcriptional data, the over-expression of VatX in CFT073vatX(pVatX) 
resulted in a significantly increased level of Vat in the culture supernatant, while no 
difference in the level of secreted Vat was observed in CFT073 and CFT073vatX. A similar 
increase in secreted Vat was also observed when WT CFT073 was transformed with plasmid 
pVatX (i.e. strain CFT073[pVatX]) (Figure 2B). Taken together, our results demonstrate that 
while deletion of vatX does not alter the level of Vat secretion, its over-expression 
significantly enhances Vat expression. 
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Figure 3.2 A) Immunodetection of the Vat passenger domain 
from supernatant fractions prepared from overnight cultures 
of MG1655(pVat) [lane 1], MG1655(pSU2718) [lane 2], 
CFT073 [lane 3], CFT073vat [lane 4], IHE3034 [lane 5] and 
536 [lane 6]. Lane M, protein molecular weight markers. B) 
Western blot analysing the effect of VatX on Vat expression. 
Supernatant fractions were prepared from overnight cultures 
of MG1655(pVat) [lane 1], MG1655(pSU2718) [lane 2], 
CFT073(pSU2718) [lane 3], CFT073(pVatX) [lane 4], 
CFT073vatX(pSU2718) [lane 5] and CFT073vatX(pVatX) 
[lane 6]. Lane M, protein molecular weight markers. Over-
expression of VatX led to an increase in the amount Vat 
detected in the culture supernatant. C) qRT-PCR analysis of 
vat transcription in CFT073vatX and CFT073vatX(pVatX) 
compared to wild-type CFT073. 
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3.3.5 Transcription of the vat gene is directly repressed by H-NS 
Given the regulatory effect exhibited by VatX on vat transcription, we investigated the 
promoter region of the vat gene to identify putative binding sites for other transcription 
factors. Firstly, the transcriptional start site for vat was determined using 5’ RACE and was 
mapped to a position 80-bp upstream of the Vat ATG start codon. Consensus -35 (5’-
ATCACA-3’) and -10 (5’-ATTAAT-3’) promoter sequence elements, separated by an 18-bp 
spacer region, were identified upstream of this site (Figure 3A). Virtual footprint software 
was used to analyse the vat promoter region for putative regulatory binding sites. From this in 
silico analysis, two putative H-NS nucleation sites were identified on the anti-sense strand 
overlapping the 18-bp spacer region and the 5’ end of the -35 element. A third H-NS 
nucleation site was determined on the direct strand 10-bp downstream of the transcriptional 
start site. 
 
The global transcriptional regulator H-NS is known to bind to curved and A-T rich DNA 
sequences upstream of several defined UPEC virulence genes (Lang et al., 2007), including 
genes encoding for toxins (Yang et al., 2005, Scott et al., 2003, Lithgow et al., 2007, Li et al., 
2008) and autotransporter proteins (Allsopp et al., 2012a, Allsopp et al., 2012b, Totsika et al., 
2012b). To investigate the effect of H-NS on vat transcription, the level of Vat expression 
was compared by western blot analysis of supernatant fractions prepared from WT CFT073, 
CFT073vat, CFT073vatX, CFT073hns and a CFT073vatX hns double mutant (Figure 3B). 
The amount of Vat secreted by CFT073hns and CFT073vatX hns was markedly increased 
compared to WT CFT073. Consistent with previous results, the level of Vat detected in 
supernatant fraction of CFT073vatX was similar to that detected from WT CFT073.  
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Figure 3.3 A) Schematic Scaled depiction of the vat-vatX gene operon in CFT073. The 
position of the promoter and primers used to identify vat-vatX and vatX transcripts is 
indicated. The inset shows the vat gene transcriptional start site (+1), which was mapped 
to 80bp upstream of the ATG start codon (grey arrow). Also indicated are the consensus 
-10 and -35 promoter elements and the three putative H-NS nucleation sites (shown in 
bold). B) Immunodetection of the Vat passenger domain from the supernatant fractions 
of CFT073 (lane 1), CFT073vat (lane 2), CFT073vatX (lane 3), CFT073hns (lane 4) and 
CFT073vatX hns (lane 5). The level of Vat was increased in CFT073hns and 
CFT073vatX hns compared to CFT073. C) EMSA demonstrating the direct interaction 
of H-NS with the vat promoter region. The assay was performed using a 252bp 
fragment encompassing the vat promoter region (indicated by an asterisk), a 218bp 
fragment containing the bla promoter region amplified from pBR322 (positive control: 
indicated by an arrow), and three additional DNA fragments amplified from pBR322 
(negative controls). Native H-NS protein was incubated with the DNA in increasing 
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concentrations: (Lane 1, 0μM H-NS); Lane 2, 0.1μM H-NS); Lane 3, 0.5μM H-NS); 
Lane 4: 1.0μM H-NS); Lane M, molecular weight markers [(200, 300, 500 bp]). D) 
Transcriptional analysis of the vat and vatX genes. Total RNA was extracted during 
exponential growth and converted to cDNA. Shown is the PCR amplification products 
[vat-vatX (1112bp) or vatX (404bp)] amplified from CFT073hns gDNA (vat-vatX PCR 
[Lane 1] and vatX PCR [Lane 2]), CFT073 RNA (vat-vatX PCR [Lane 3] and vatX PCR 
[Lane 4]), CFT073hns RNA (vat-vatX PCR [Lane 5] and vatX PCR [Lane 6]), 
CFT073cDNA (vat-vatX PCR [Lane 7] and vatX PCR [Lane 8]) and CFT073hns cDNA 
(vat-vatX PCR [Lane 9] and vatX PCR [Lane 10]).  
 
3.3.6 H-NS binds to the vat promoter region  
To further investigate the role of H-NS in repressing vat transcription, an EMSA was 
performed using increasing concentrations of native H-NS protein and the 252bp PCR 
amplified region of the vat gene promoter possessing the three potential H-NS binding sites 
(Figure 3C). As a positive control, the bla gene promoter from the cloning vector pBR322 
was also PCR amplified and included in the assay as H-NS is known to bind to this DNA and 
repress bla transcription (Bolivar et al., 1977). Three additional fragments amplified from 
regions of pBR322 known not to bind H-NS were included in the assay as negative controls. 
In our experiment, H-NS bound with strong affinity to the DNA fragment corresponding to 
the vat gene promoter. Indeed, this binding affinity was stronger than that observed for the 
DNA fragment containing the control bla gene fragment. No binding of H-NS was observed 
to the negative control DNA fragments, demonstrating the specificity of H-NS binding in this 
assay.  
 
3.3.7 The vatX gene is co-transcribed with vat 
H-NS regulates the transcription of several UPEC genes by competing for binding to 
their promoter element with a MarR-type regulatory protein; this includes SfaX binding to 
the sfaII fimbrial promoter (Sjostrom et al., 2009), PapX binding to the flhDC flagella master 
regulator promoter (Ko and Park, 2000), and SlyA binding to the type 1 fimbriae fimB 
recombinase promoter (McVicker et al., 2011). The SfaX and PapX regulators are co-
transcribed as part of their respective upstream fimbrial operon (encoding for S and P type 
fimbriae, respectively (Simms and Mobley, 2008b, Sjostrom et al., 2009)). Taking this into 
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consideration, we employed RT-PCR analysis to test for transcription of the vat and vatX 
genes as a single mRNA in CFT073 (Figure 3D). Due to the increased amounts of Vat 
protein secreted by the CFT073hns mutant strain (as shown by Western blot analysis [Figure 
3B]), total RNA was also extracted from this strain for RT PCR analysis. The cDNA 
synthesised from CFT073hns RNA was screened for a vat-vatX nucleic acid fragment using 
internal primers specific for both genes (primers depicted in Figure 3A), while an additional 
set of primers were used to amplify the vatX gene alone for comparison (primers depicted in 
Figure 3A). Genomic DNA and total RNA extracted from both strains were also examined as 
controls. Although a band corresponding to the vatX specific PCR product was present, no 
PCR products corresponding to the vat-vatX fragment size were amplified from WT CFT073 
cDNA. However, bands corresponding to the predicted sizes determined for the vatX and the 
vat-vatX transcripts were amplified from CFT073hns cDNA, indicating that the vat-vatX 
genes are co-transcribed as a single transcript in the absence of H-NS.  
 
3.3.8 Vat is prevalent, highly conserved and is secreted by UPEC urosepsis 
isolates 
The vat gene has previously been shown to be most prevalent in E. coli strains from 
the B2 phylogenetic group, with a similar distribution observed among cystitis, 
pyelonephritis, prostatitis and bloodstream isolates (Parham et al., 2005).  Based on the 
observation that vat is required for UPEC fitness in a mouse model of systemic infection 
(Subashchandrabose et al., 2013), we screened a collection of urosepsis strains for the vat 
gene by PCR. The vat gene was identified in 68% (31/45) of the urosepsis strains. MLST 
analysis revealed strains from ST73, ST12 and ST95 were most predominant in this 
collection (Figure 4B). Furthermore, supernatant fractions produced by these strains were 
examined by Western blotting to analyse the expression and secretion of Vat following 
growth in LB at 37°C. For all strains, a band corresponding to the Vat passenger domain 
hybridised with the Vat-specific polyclonal antibody (Figure 4B). The sequence of the vat 
gene was determined from vat-positive strains representing each ST and found to be highly 
conserved (≥97% amino acid identity [Figure 4B]). Minor sequence variations occurred at six 
locations within the passenger domain of the protein (Figure 4). These residues were located 
within two regions in the Vat passenger domain (Figure 4A), both of which are distal to the 
serine protease catalytic motif based on a structural model built using the Hbp passenger 
domain (Appendix 3.3).  
83 
 
 
Figure 3.4 A) Schematic diagram depicting of a the full length Vat primary protein 
sequence, depicting including the three protein domains typical for SPATES: i) the 
extended signal peptide (SP); ii) the passenger domain comprising the Immunoglobulin 
A1 protease-like domain, which contains the serine protease motif, as well as the 
upstream aspartate (D158) and histidine (H130) residues of the catalytic triad; and iii) 
the translocation domain, which is cleaved at the alpha-helical linker region. Class II 
SPATEs are characterised by the presence of a small additional domain termed Domain 
2 (striped). Two variable regions (VR1 and VR2) located within the passenger domain 
were identified (triangles). B) Alignment of the Vat amino acid sequence in VR1 and 
VR2 from CFT073 and the ten strains representing the diverse STs examined. Residues 
identical to those in Vat from CFT073 are indicated by dots; residues that differed from 
the CFT073 sequence are indicated and highlighted in grey. Vat secretion was 
determined by Western blot analysis of the supernatant fractions from each strain 
following overnight growth in LB broth at 37°C. All strains secreted a ~110KDa protein 
that cross-reacted with the Vat-specific polyclonal antibody (indicated as +). 
 
  
A 
B 
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3.3.9 The presence of vat is significantly associated with increased anti-Vat IgG 
produced during infection 
The high prevalence of vat in the UPEC urosepsis strains examined in this study, in 
combination with its secretion during in vitro growth, prompted us to examine if an 
immunological response against Vat was elicited during infection. To test this, an ELISA 
assay was performed using blood plasma samples collected from the same urosepsis patients 
from which the urosepsis strains were collected (Figure 5). The blood plasma samples were 
examined for the presence of Vat-specific IgG antibodies using purified recombinant Vat 
protein. The urosepsis patients were divided into two groups; those infected with a vat-
positive UPEC strain (n=31) and those infected with a vat-negative UPEC strain (n=14). As 
an additional control, 42 plasma samples collected from age and sex matched healthy 
individuals were also examined for an immunological response against the Vat protein. In 
this assay, we observed a significant difference (P < 0.05) in the anti-Vat IgG plasma titre in 
patients infected with a vat-positive strain compared to a vat-negative strain or healthy 
individuals. Taken together, the data suggests that Vat is a highly conserved immunogenic 
protein that is expressed by many UPEC isolates during infection. 
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Figure 3.5 Immunoreactivity of Vat. Blood plasma was 
collected from 45 urosepsis patients at the time of admittance to 
hospital. Paired UPEC strains were also isolated from the blood 
of each patient, and the presence of the vat gene was 
determined by PCR. Plasma samples were subsequently 
grouped by their association with vat-positive (Vat+) or vat-
negative (Vat-) strains. The presence of IgG-specific antibodies 
was determined by ELISA, and compared to results obtained 
from 425 healthy volunteers with no recent history of UTI 
(Healthy). A significantly higher IgG titre was observed in 
plasma of patients infected with Vat+ strains compared to 
patients infected with Vat- strains and healthy controls. 
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3.4 Discussion 
UPEC strains possess an array of virulence factors that are critical for their ability to 
cause disease in extra-intestinal niches such as the urinary tract and the bloodstream 
(Nielubowicz and Mobley, 2010, Totsika et al., 2012a). Vat is a member of the SPATEs that 
contributes to fitness of E. coli during systemic infection (Subashchandrabose et al., 2013, 
Parreira and Gyles, 2003). In this study, we performed a comprehensive bioinformatic and 
molecular analysis of the vat gene. We defined the transcriptional regulation of vat and 
demonstrated its immunogenicity using plasma samples from urosepsis patients. 
 
The genetic location of the vat gene was examined in all vat-positive completely 
sequenced E. coli strains available on the NCBI database. The vat gene was shown to reside 
within the thrW-PAI, downstream of proA and upstream of yagU relative to the E. coli 
MG1655 chromosome. This is consistent with a previous report that examined the presence 
of vat in UPEC strains CFT073 and 536, as well as the neonatal meningitis strain RS218 
(Parham et al., 2005). The gene content of the vat-containing thrW-PAI was conserved in the 
majority of strains examined, although some differences were noted in strains Ec222, APEC-
01, 83972, UM146 and 536. Overall, our bioinformatic analysis revealed that the vat gene 
(and the co-located vatX regulator gene) are present in a range of different E. coli pathotypes.  
 
Several studies have previously assessed the prevalence of the vat gene in E. coli. A 
study conducted by Parham et al (2005) reported a high prevalence of vat in group B2 
phylogenetic strains of the ECOR collection. A high frequency of the vat gene has also been 
observed in B2 strains associated with cystitis, pyelonephritis and prostatitis (Heimer et al., 
2004, Parham et al., 2005), and vat has been strongly associated with avian pathogenic E. coli 
(APEC) (Spurbeck et al., 2012). Our analysis identified the vat gene in 68% of urosepsis 
isolates (n = 45). We also demonstrated that the sequence of vat is highly conserved within a 
selection of strains representative of each of the ten different sequence types identified within 
the collection. At the amino acid level, minor sequence variations were located within two 
regions (VR1: S
520
-K
529
 and VR2: E
783
-V
823
) of the Vat passenger domain. However, the 
canonical serine protease domain that is important for the catalytic function of SPATEs was 
conserved in all ten of the Vat sequences analysed. Western blotting was also performed to 
examine Vat expression, and revealed that Vat is expressed and secreted by all of the 
urosepsis strains examined when grown at a physiological temperature. Further investigation 
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is required to determine if the minor sequences changes observed in Vat are associated with 
corresponding differences in its cytotoxic properties. 
 
Bioinformatic analysis identified a gene encoding a putative MarR-like transcriptional 
regulator immediately downstream of vat (i.e. vatX). Although mutation of vatX did not result 
in a detectable change in vat transcription or translation, overexpression of VatX via the 
introduction of a plasmid containing the vatX gene (pVatX) was shown to positively regulate 
vat, resulting in a 3-fold increase in vat transcription and a significant increase in the level of 
secreted Vat protein. This data was suggestive of a more complex regulatory control of the 
vat gene. We therefore mapped the promoter of vat, and identified several putative H-NS 
binding sites proximal to this region. H-NS is a histone-like DNA-binding protein that shows 
affinity for A-T rich and bent nucleation sites on DNA (Dorman, 2007). In E. coli, H-NS has 
been shown regulate multiple genes, including genes associated with virulence, pH, 
osmoregulation and temperature sensing (Goransson et al., 1990, Atlung and Ingmer, 1997, 
Amit et al., 2003, Lucchini et al., 2006). Our EMSA data revealed a strong interaction 
between H-NS and a 252-bp region of the vat promoter that contains three putative H-NS 
binding sites. A role for H-NS in vat regulation was subsequently demonstrated through the 
examination of a CFT073hns mutant, which secreted a significantly higher level of Vat 
compared to the parent CFT073 strain. Taken together, these results demonstrate that the 
regulation of vat is coordinated by both VatX and H-NS, and further highlights the role of H-
NS in the regulation of UPEC virulence factors (Allsopp et al., 2012b, Allsopp et al., 2010). 
 
The MarR family of transcriptional regulators control the expression of multiple 
different genes, including virulence factors, often in response to environmental stress 
(reviewed in Wilkinson and Grove, 2006, Ellison and Miller, 2006). Bioinformatic analysis 
of MarR-type regulators from 77 completely sequenced E. coli genomes revealed a high level 
of amino acid sequence conservation within each clade, but significant variation between 
MarR regulators from different clades. VatX clustered as a separate clade and is most closely 
related to PapX. Interestingly, the proteins encoding for other fimbrial associated MarR-type 
regulators were also found within the PapX clade (Appendix 3.2). Despite their association 
with different fimbriae, these regulatory proteins are highly conserved (≥97% identity at the 
amino acid level). Some strains such as E. coli 536, 83972 and Nissle 1917 possess three or 
more chromosomal copies of papX (Appendix 3.2). PapX regulates UPEC motility by 
repressing transcription of the flhDC master regulator genes (Simms and Mobley, 2008b). We 
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investigated the potential for VatX to repress flagella-mediated motility of CFT073. 
However, no significant difference in motility was observed between WT CFT073, 
CFT073vatX and the complemented CFT073vatX (pVatX) mutant strains after growth at 
28°C and 37°C (Appendix 3.4). The FliC major flagellin subunit was also produced at a 
similar level in all three strains as determined by immunoblotting (Appendix 3.4). Taken 
together, our data has identified VatX as a new member of the MarR type family that 
regulates vat in concert with H-NS. Further work is now required to map the direct binding of 
VatX to the vat gene promoter, and to examine the competitive interplay between VatX and 
H-NS in the regulation of vat transcription.   
 
In a recent study using high-throughput transposon mutagenesis screening 
(Subashchandrabose et al., 2013), the vat gene was shown to contribute to survival of the 
UPEC strain CFT073 within the bloodstream of mice. This, together with the observation that 
many urosepsis strains secrete Vat, prompted us to examine the immunoreactivity of Vat in 
urosepsis patients. We detected a significant increase in Vat-specific IgG titre in the plasma 
of urosepsis patients infected with vat-positive UPEC strains compared to plasma from 
patients infected with vat-negative strains and healthy controls. A proportion of these patients 
presented significant anti-Vat IgG antibody titres. Higher levels of circulating IgG present 
during infection indicate an anamnestic immune response in these patients, as opposed to 
primary exposure. However, this is consistent with the notion that Vat is expressed during 
infection of the bloodstream and elicits a strong immune response in some patients. Further 
work is now required to understand the role of Vat during human infection and its 
cytotoxicity profile. 
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4.0 Chapter 4: The Periplasmic Chaperone Skp contributes to Expression and Secretion 
of Uropathogenic Escherichia coli Autotransporter Proteins. 
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4.1 Introduction 
UPEC are the primary cause for all UTIs and comprise a range of virulence factors 
known to cause disease. UPEC possess several virulence factors that are secreted by the type 
V secretion pathway conserved throughout Gram-negative bacteria. AT proteins are 
classified into five different subtypes, type Va-e. These AT subtypes are categorised based on 
domain organisation and subsequent protein expression to the cell surface. Type Va 
translocation pathway comprise the largest and most diverse subset of AT proteins, termed 
the “classical” AT proteins (Wells et al., 2010, Celik et al., 2012). Type Va precursor proteins 
consist of three conserved domains: i) a leader signal peptide, ii) a functional passenger 
domain and iii) a C-terminal β-barrel domain. The passenger domain is linked together with 
the C-terminal β-barrel domain via an α-helical linker region. Type Va AT proteins are 
further classified as AIDA-I type proteins or SPATE proteins. AIDA-I type AT proteins 
encode for adhesive properties while SPATE proteins possess chymotrypsin-like cytotoxic or 
immunomodulating properties. Virulence-associated ADIA-I type AT proteins characterised 
from UPEC include the self-associating adhesion Ag43, UpaB, UpaB and UpaH (Allsopp et 
al., 2012b, Ulett et al., 2007b, Allsopp et al., 2010). SPATE proteins secreted by UPEC 
include Vat, Pic and Sat (Heimer et al., 2004, Parham et al., 2004, Guyer et al., 2000). 
 
Classical AT proteins that form homotrimers on the cell surface are termed trimeric 
(type Vc) AT proteins. The prototypical YadA adhesin produced by enteropathogenic 
Yersinia species is the most well-characterised trimeric AT protein to date. Trimeric AT 
proteins characterised from E. coli include the UPEC-associated adhesin UpaG (Valle et al., 
2008b), and the subset of E. coli immunoglobulin binding proteins, EibA, -C, -D, -E (Sandt 
and Hill, 2000), EibF (Sandt and Hill, 2001) and EibG (Lu et al., 2006). Both UpaG and 
EibD confer adhesive properties including auto-aggregation of bacterial cells, biofilm 
formation and adherence to host cells/ proteins (Valle et al., 2008b, Totsika et al., 2012b, Leo 
et al., 2011). The passenger domain of trimeric AT proteins contains three distinct regions, 
the N-terminal head domain, the neck region and the stalk domain. All three regions 
contribute to the characteristic “lollipop” structure consisting of a globular head attached to a 
coil-coiled stalk. The coil-coiled stalk is anchored to the C-terminal 12-stranded β-barrel 
structure embedded within the OM. The shorter β-domains of trimeric AT proteins contribute 
four of the 12-β sheets required to form the 12-stranded anti-parallel β-barrel structure 
characteristic of type V secretion proteins.  
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AT translocation was originally thought to involve threading of an unfolded passenger 
domain through the central channel of the β-barrel structure, formed by the C-terminal 
domain of the AT protein. This “hairpin” model for AT secretion was originally proposed in 
1987 (Pohlner et al.) based on the characterisation of the IgAI protease of Neisseria 
gonorrhoeae. However, partial folding of certain AT proteins was later discovered to occur 
pre-translocation, thereby challenging the idea of threading due to the innately narrow pore 
size (~10Å wide) of the β-barrel structure (Skillman et al., 2005, Jong et al., 2007c). In 2009, 
three independent studies discovered direct interactions between two SPATE proteins (EspP 
and Hbp) and the periplasmic PPIase chaperone SurA (Sauri et al., 2009, Ieva and Bernstein, 
2009a, Ruiz-Perez et al., 2009), the cavity-chaperone Skp (Ruiz-Perez et al., 2009, Ieva and 
Bernstein, 2009a) and the serine protease chaperone DegP. EspP secretion was also shown to 
be dramatically impaired in E. coli mutants lacking the degP gene, and to a lesser extent 
mutants lacking the skp and surA genes (Ruiz-Perez et al., 2009). Unprocessed forms of Hbp 
and secretion incompetent Hbp derivatives were also found to accumulate in the periplasm of 
surA and degP mutants, respectively (Jong et al., 2007c, Sauri et al., 2009). A follow on 
study conducted by Ruiz-Perez and colleagues (2010) also reported a direct interaction 
between the periplasmic chaperone FkpA and the unfolded passenger domain of EspP. Thus 
the “auto” nomenclature of these proteins was redefined. 
 
SurA is a key periplasmic chaperone involved in the transportation and expression of 
OMPs. Skp and DegP are thought to function in parallel with SurA, as deletion of the surA 
gene in combination with either the skp or degP gene results in synthetic lethality (Rizzitello 
et al., 2001). SurA is also known to bind to the POTRA domain of BamA, and is thought to 
deliver nascent OMPs to the BAM complex for final translocation across the OM (Sklar et 
al., 2007b). Components of the BAM complex (BamA, BamB and BamD) were also 
identified to directly interact with EspP (WT and translocation intermediates) and Hbp 
(translocation intermediate) (Ruiz-Perez et al., 2009, Sauri et al., 2009, Ieva and Bernstein, 
2009a, Ieva et al., 2011). The Bam complex is a heterologous pentameric protein complex 
(BamA-E) involved in OM biogenesis. BamA constitutes an integral OMP that comprises the 
essential complex core. The BamB-E proteins are accessory lipoproteins that contribute 
towards the overall efficiency of the BAM complex.  
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In 2012, Selkrig and colleagues identified an additional transenvelope protein 
complex belonging to the Omp85/ TpsB protein superfamily. This protein complex was 
termed the translocation and assembly module (TAM) and is encoded by the tamAB 
(originally ytfMN) two-gene operon. The TAM was thought to function analogously to the 
BAM complex, however unlike the BAM complex is not essential for viability. Mutation of 
the tamAB genes impacts on cell-surface expression of the AT proteins Ag43, EhaA and the 
plasmid encoded C. rodentium putative AT, p1112 (Selkrig et al., 2012). The BAM complex 
has also been shown to contribute to the translocation of Ag43 and EspP (Norell et al., 2014). 
 
Although the “autonomous” autotransport view originally proposed by Meyer and 
colleagues (Jose et al., 1995, Klauser et al., 1993) has been refined over the past decade, the 
complex interplay between periplasmic proteins and the diverse array of AT proteins remains 
to be elucidated. In this study, we investigated the role of the periplasmic chaperones Skp, 
DegP, DegQ, FkpA, PpiA and PpiD, as well as the TAM complex, in the AT expression. 
Three specific AT proteins (Ag43, Vat and EibD) were analysed as representatives of the 
classical AIDA-I type AT proteins (Ag43), SPATE AT proteins (Vat) and trimeric AT 
proteins (EibD). Out of the six periplasmic chaperones analysed, the small cavity chaperone 
Skp was found to contribute to expression of Ag43, EibD and to a lesser extent Vat. In 
addition, deletion of the tamAB operon impeded EibD-mediated biofilm formation in an 
MG1655 background. 
 
4.2 Materials and Methods 
4.2.1 Bacterial strains and growth conditions 
Unless otherwise stated, all bacterial strains were routinely grown aerobically 
(250rpm) at 37°C in LB broth. The K-12 strain MG1655 (Blattner et al., 1997) and the UPEC 
strain CFT073 (Mobley et al., 1990) were used. The MG1655tamAB (ytfMN [b4220-b4221]) 
(Selkrig et al., 2012) and CFT073tamAB (ytfMN [c5318-c5319]) mutants were constructed 
using λ Red-mediated homologous recombination; in both cases tamAB was replaced with a 
kanamycin resistance gene cassette. The depletion strain CFT073RExTET::ytfMN (Cam
R, 
30µg/mL) was constructed by Dr Makrina Totsika. In this strain, the tamAB genes were 
placed under the direct control of the AHT-inducible RExTET promoter (Da Re et al., 2007).  
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4.2.2 Genetic Manipulation 
Genes encoding for periplasmic chaperones that were targeted (skp [b1078], degP 
[b0161], degQ [b3234], fkpA [b3347], ppiA [b3363], and ppiD [b0441]) for null mutation are 
listed in table 4.1. All of the chaperone mutants were made via λ Red-mediated homologous 
recombination as previously described (Datsenko and Wanner, 2000). Briefly, primers (Table 
4.1) used to PCR amplify the kanamycin resistance gene cassette (Kan
R
 [sourced from pKD4 
(Datsenko and Wanner, 2000)], were designed with additional 50bp flanking sequences. 
These sequences correspond to homologous regions flanking each target gene. The amplified 
Kan
R
 cassette (with flanking 50bp) was then transformed into competent cells expressing the 
λ-Red recombinase (pKD46 (Datsenko and Wanner, 2000)). Target genes were replaced with 
the Kan
R
 cassette; transformants were selected and screened by PCR using a combination of 
external (Table 4.1) and internal kan gene specific primers (F: 5’-
CAGTCATAGCCGAATAGCCT-3’ and R: 5’-CCTGCCATCACGAGATTTCG-3’). All 
mutants were confirmed by sequencing the site of the kan gene insertion. The MG1655 
skp::kan
 
and degP: kan mutants (MG1655skp and MG1655degP) were used as a source of 
template DNA for the construction of analogous mutants in CFT073 (skp [c0215] and degP 
[c0197]). All deletion and screening primers used in this project are listed in Table 4.1. 
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Table 4.1: List of primers used to construct E. coli MG1655 and CFT073 mutants. 
Knockout Primers  
Strain Target 
Gene 
Direction Primer Sequence 
MG1655 skp  F 5'-
CAGCCTGTTCCAGCAGGTAGCGCAGAAAACCGGTGTTTCTAA
CACGCTGGAgtgtaggctggagctgcttc-3' 
R 5'-
AAGCAACGGCGTTTGCATCAACAACCAGATCGATATCCTGGC
TGTTGGCAcatatgaatatcctcctta -3' 
degP F 5'-
TGAGACTTCTTCAGCAACGACAGCCCAGCAGATGCCAAGCCT
TGCACCGAgtgtaggctggagctgcttc-3' 
R 5'-
TTCGCGCCAATAATCACATCACCTTTCTTCAGGCCGATCTGCG
CAGCCGGcatatgaatatcctcctta-3' 
degQ F 5'-
CCCAGTCTGGCTCCAATGCTGGAAAAAGTGCTTCCGGCAGTG
GTGAGCGTgtgtaggctggagctgcttc-3' 
R 5'-
TTTAGCTGACCATCGCTCAACGTTGCACCTTCCAGCGCTGGCG
TGATCATcatatgaatatcctcctta-3' 
fkpA F 5'-
CGGAACACCCGCTTTGCCGTAAGCCAGTTCTGGTGGAATAAC
CAGTTTGAgtgtaggctggagctgcttc-3' 
R 5'-
AAGAACAAGAAAAACTGGGCATCAAACTGGATAAAGATCAG
CTGATCGCTcatatgaatatcctcctta-3' 
ppiA F 5'-
CCTTTCACCGCGTCATTCCTGGCTTTATGATTCAGGGCGGCGG
TTTCACCGgtgtaggctggagctgcttc-3' 
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R 5'-
CTTATCGGCAACGTCCATGCCTTTCACCACTTTACCAAATACC
GCGTAACcatatgaatatcctcctta-3' 
ppiD F 5'-
ACTCCGAGCTGGCAGCGAACGAAGGCTATATGAAAACCCTGC
GTCAACAGgtgtaggctggagctgcttc-3' 
R 5'-
GCATATCGGTCGCCATACCGTAGCTCGGTTTGTCTTTCGCTGG
CAGTGGCcatatgaatatcctcctta-3' 
CFT073 skp  F 5'-gtttaggcggcaaagagatg-3' 
R 5'-cgacgttatgtgcaatctgg-3' 
degP F 5'-gcttgaattgcagggctatc-3' 
R 5'-gcagaccagttcgccatatttac-3' 
Screening Primers 
Strain Target 
Gene 
Direction Primer Sequence 
MG1655 skp  F 5'-ttagctgcaggtctcggtttag-3' 
R 5'-cagtacgtcggcagtgatgtc-3' 
CFT073 F 5'-gtttaggcggcaaagagatg-3' 
R 5'-cgacgttatgtgcaatctgg-3' 
MG1655 degP F 5'-actgagtgcactggctctgag-3' 
R 5'-gcattaacaggtagatggtg-3' 
CFT073 F 5'-cgaatgcagcgatcttctta-3' 
R 5'-gttgcgcccattcagtaagtg-3' 
MG1655 degQ F 5'-cccagctgttgagtgcattag-3' 
R 5'-ttcattgccgcgtacaatttg-3' 
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fkpA F 5'-gctggtttcacatccagcag-3' 
R 5'-tgcatgcaccaatcacttttg-3' 
ppiA F 5'-gctgctgttttcgctctttc-3' 
R 5'-tttgacggcacattctggtac-3' 
ppiD F 5'-cggctgcaaacagtctcgtg-3' 
R 5'-atccagcgccagcagaaccac-3' 
 
4.2.3 Plasmid construction 
The gene encoding for the periplasmic chaperone skp was PCR amplified from 
MG1655 and ligated into the expression vector pSU2718. The skp gene was amplified using 
primers F: 5'- cgcgCTCGAGataataaggaaTTATTGTGAAAAAGTGGTTATTAGCTGCA-3' 
and R: 5'-CCCGGaagcttTTATTTAACCTGTTTCAGTACG-3', digested with XhoI-HindIII, 
ligated into similarly digested pSU2718 and  transformed into E. coli DH5α. The correct 
transformant was selected on LB agar supplemented with 30µg/mL chloramphenicol and 
confirmed by PCR and sequencing.   
 
4.2.4 Growth curve analysis 
Bacterial growth was analysed in rich (LB broth) or defined (M9-glucose) minimal 
media. Cultures were inoculated at an initial OD600nm= 0.05, and grown in flat bottom 
polystyrene 96-well microtiter plates (200µL/ well) covered with a Breathe-Easy
®
 permeable 
membrane (Diversified Biotech). Optical density readings were measured every 15 minutes 
for a total of 12 hours using the FLUOstar OPTIMA microplate spectrophotometer with the 
corresponding MARS Data Analysis Software (BMG LABTECH). ANOVA and Dunnett 
post-test statistical analyses were performed 
(https://mdphan.shinyapps.io/GrowthCurvesAnalysis/ [OmniLog® PM software]) to examine 
for significant differences between growth curve parameters.  
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4.2.5 Concentration of supernatant fractions 
Supernatant fractions were prepared from standardised late exponential phase cultures 
(10ml; OD600nm = 0.8–1.0). Cells were pelleted by centrifugation (6000 x g), and the 
supernatant fraction was removed and filtered through a 0.22 μm filter. Supernatant proteins 
were precipitated overnight at 4ºC with the addition of TCA (10% w/ v). Proteins were 
harvested by centrifugation, washed twice with 80% acetone and reconstituted in 100µL SDS 
loading buffer (1x) for subsequent SDS-PAGE analysis.   
 
4.2.6 Ag43 Heat Release Assay 
Release of Ag43 from the cell surface was conducted as previously described (Ulett et 
al., 2007b). Briefly, cells harvested from standardised subcultures and were washed once with 
saline solution (0.9% NaCl), followed by resuspension in 0.75mM Tris buffer (1mL). Ag43 
expressing cells were subjected to brief heat treatment (60ºC for 3 minutes) to disrupt the 
non-covalent bonds linking the passenger domain of Ag43 to the β-barrel structure. The 
supernatant was removed, centrifuged (14, 000 x g), and proteins (including the Ag43 
passenger domain) were precipitated overnight at 4ºC with 10% (w/v) TCA. Precipitated 
proteins were harvested via centrifugation, washed twice with 80% acetone and resuspended 
in 100µL of SDS loading buffer (1x) for subsequent SDS-PAGE analysis. Where required, 
whole cell lysates were also prepared from standardised OD600nm = 1.0 cultures.  
 
4.2.7 Immunoblotting   
Whole cell lysates and concentrated supernatant proteins were subjected to SDS-
PAGE and western blot analysis as previously described (Sambrook, 2001). Samples were 
boiled for 5-10 min prior to electrophoresis, which was performed at 150V for 1.5 h. Samples 
were run alongside Novex Sharp or Page Ruler Pre-stained protein ladders for comparison. 
Upon separation of proteins, samples were either stained with Coomassie Blue or transferred 
to PVDF membrane for immunoblot analysis. Transferred proteins were incubated with 
blotto solution prior to incubation with protein-specific primary antibodies. Antibodies used 
in this project included polyclonal anti-Ag43α (Ulett et al., 2007b) and polyclonal anti-Vatα 
(Chapter 3). The EibD polyclonal antibody was raised against an N-terminal portion of the 
protein (amino acids T
144
-N
343
) (Suku, 2010). Antibodies were absorbed against 
corresponding mutant strains to reduce non-specific cross-reactivity. Binding of primary 
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antibodies (1:1, 000 dilution for anti-Ag43α and anti-Vatα; 1: 2,000 dilution for anti-EibDα) 
was detected using alkaline phosphatase conjugated anti-rabbit IgG goat antibodies. Bands 
were developed with the addition of NBT/ BCIP substrate solution. 
 
4.2.8 Auto-aggregation assay  
MG1655, the isogenic mutant MG1655skp and the MG1655agn43 mutants were 
transformed with the Ag43-expression vector, pCO2 (referred to in this document as pAg43) 
and the corresponding vector control plasmid pBADMycHisA (Kjærgaard et al., 2002). 
Expression of the agn43 gene from pAg43 is controlled by the L-arabinose (0.2% [w/ v]) 
inducible araBAD promoter. Ag43-mediated auto-aggregation assays were performed as 
previously described (Kjaergaard et al., 2000). Briefly, MG1655 strains harbouring the 
pAg43 plasmid (or pBADMycHisA) were grown to an OD600nm ≈ 0.3, induced with L-
arabinose (0.2% final concentration [w/ v]), and grown overnight. Standardised (OD600nm = 
3.0) cultures (10mL) were transferred to 10mL Falcon tubes for auto-aggregation analysis. 
Absorbance readings (OD600nm) were measured every 20 mins by extracting 100µL from the 
top of each culture and aggregation was calculated as a percentage of the initial absorbance 
reading (T = 0). All experiments were performed as at least three independent replicates. 
 
4.2.9 Microtiter biofilm assays 
Microtiter biofilm assays were performed as previously described (Schembri and 
Klemm, 2001). Cells were grown in M9 minimal media at 28°C or 37°C. Where required, 
induction of AT protein expression was performed using L-arabinose (0.2% [w/ v]. The 
pEibD plasmid was described previously (Suku, 2010). Absorbance readings (OD595nm) were 
measured for each well using the Spectramax plus
384
 plate reader via the SoftMax Pro
®
v5 
program. Statistical analysis was performed using one-way ANOVA analysis.  
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4.3 Results 
4.3.1 Construction of E. coli K-12 MG1655 periplasmic chaperone mutants  
Several genes encoding periplasmic chaperones were examined for their role in AT 
protein translocation in the E. coli K-12 strain MG1655 (Table 4.2). The selected chaperones 
included Skp, DegP, DegQ, FkpA, PpiA and PpiD (Table 4.2). All mutants were constructed 
by λ Red-mediated homologous recombination and confirmed by PCR and sequencing. 
Based on the abundance of data published for the contribution of SurA to the expression of 
OMPs (namely OmpA, OmpF, and LamB) (reviewed in Behrens-Kneip, 2010), in 
combination with the experimental difficulties posed by deleting the surA gene (Tormo et al., 
1990, Lazar et al., 1998, Rouviere and Gross, 1996, Missiakas et al., 1996), SurA was not 
considered for further investigation.  
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Table 4.2: List of target genes encoding for periplasmic 
chaperones that were mutated in MG1655. 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2 Growth characteristics of MG1655 periplasmic chaperone mutant strains 
Periplasmic chaperones are highly conserved within bacteria as they are often an 
essential component in biogenesis and maintenance of the OM. Among the periplasmic 
chaperones selected for analysis in this study, growth defects have previously been reported 
for degP (Sawa et al., 2011, Schwechheimer and Kuehn, 2013) and degQ (Sawa et al., 2011) 
mutants (i.e. in the K-12 strain MC4100 following growth in LB broth at 37°C). Therefore, 
the periplasmic chaperone mutants constructed in MG1655 in this study were similarly 
analysed for growth in rich and defined minimal medium.  
  
Gene (Synonym) Chaperone Function Locus Tag 
skp (hlpA, ompH) Cavity chaperone b0178 
degP (htrA) 
Serine protease with dual chaperone 
properties 
b0161 
degQ (hhoA) 
Serine protease with dual chaperone 
properties 
b3234 
fkpA  
Parvulin PPIase with dual chaperone 
properties 
b3347 
ppiA (rotA) Cyclophilin-like PPIase b3363 
ppiD (ybaU) PPIase independent chaperone activity b0441 
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4.3.2.1 Mutation of the periplasmic chaperone genes skp, degP and degQ 
affect the growth of MG1655 in rich media  
Growth of the MG1655skp, MG1655degP, MG1655degQ, MG1655fkpA, 
MG1655ppiA and MG1655ppiD mutants was compared to wild-type MG1655 (Figure 4.1). 
All experiments were performed in LB broth at 37
o
C. This data represents the average of 
three independent experiments ± SEM and were statistically compared (ANOVA and 
Dunnett post-test). Based on the calculated area under the curve for each strain, the overall 
growth for the MG1655skp, MG1655degP or MG1655degQ mutants was significantly 
reduced (P < 0.05). The MG1655skp mutant exhibited the greatest growth defect (Figure 
4.1).  
 
 
Figure 4.1 Growth analysis of MG1655 and the isogenic MG1655 periplasmic 
chaperone mutant strains in LB broth at 37°C. The MG1655skp, MG1655degP and 
MG1655degQ mutant strains exhibited significantly reduced growth (P < 0.005).  
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4.3.2.2 Mutation of the periplasmic chaperone genes skp and ppiD affect the 
growth of MG1655 in minimal media 
Growth of the MG1655skp, MG1655degP, MG1655degQ, MG1655fkpA, 
MG1655ppiA and MG1655ppiD mutants was also examined in M9 minimal media (Figure 
4.2). This data represents the average of three independent experiments ± SEM and were 
statistically compared (ANOVA and Dunnett post-test). As observed in LB broth, the overall 
growth (area under the curve) of MG1655skp was significantly reduced (P < 0.05). However, 
the growth rate for this mutant strain was comparable to that of the WT strain during 
exponential phase. In contrast, no significant defect in growth was observed for the other 
mutants. An interesting observation was that the MG1655ppiD mutant exhibited significantly 
enhanced exponential growth compared to the WT MG1655 (P < 0.05). However, this 
phenotype was not examined further. 
 
 
  
Figure 4.2 Growth analysis of MG1655 and the isogenic MG1655 periplasmic 
chaperone mutant strains in M9 minimal media at 37°C. The MG1655skp mutant strain 
failed to reach a final optical density comparable to the WT (P < 0.005). In contrast, the 
MG1655ppiD strain exhibited enhanced exponential growth (P < 0.005).  
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4.3.3 The role of periplasmic chaperones in secretion of AIDA-I Type AT Protein 
Ag43 
Ag43 is phase variable AIDA-I type AT protein characterised by the ability to bind to 
independent Ag43 molecules expressed on neighbouring cells (Heras et al., 2014). This 
Ag43-mediated cell-to-cell interaction promotes biofilm formation and contributes to long-
term persistence of UPEC within urinary tract of mice (Ulett et al., 2007b, Luthje and 
Brauner, 2010). Overexpression of Ag43 also causes auto-aggregation of bacterial cells 
suspended within solution (Diderichsen, 1980). This process causes sedimentation of cells 
(Figure 4.3 B and C), resulting in reduced absorbance in the media over time. This 
phenomenon provides a simple yet efficient way to measure the function of Ag43 expressed 
on the cell surface. Thus, Ag43 was chosen as a representative AT protein to determine the 
role of periplasmic chaperones in the expression of an AIDA-I type AT protein.  
 
4.3.3.1 MG1655skp exhibits impaired Ag43-mediated cell-cell aggregation 
Chromosomal expression of agn43 is phase variable with an ON-to-OFF switch 
frequency of 2.2 x 10
-3
 per cell, per generation (Henderson et al., 1997). To avoid the effect 
of this phenomenon, the pAg43 expression vector was transformed into each of the MG1655 
periplasmic chaperone mutants. This vector contains the agn43 gene under the control of the 
arabinose-inducible pBAD promoter. As such, variances in expression due to chromosomal 
phase-variation would be avoided. To demonstrate consistent Ag43 expression, the 
MG1655agn43(pBAD) and the complemented MG1655agn43(pAg43) mutant strains were 
included in the assay for comparison. All cultures were standardised to the same optical 
density before commencing the assay. From the six different chaperone mutants analysed, 
MG1655skp harbouring pAg43 exhibited impaired auto-aggregation (Figure 4.3).  
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Figure 4.3 A) Auto-aggregation assay assessing Ag43 expression by MG1655 and 
derivative strains. Surface expression of Ag43 causes cell aggregation and settling out of 
solution (B and C [T = 120 mins]). This phenomenon is measured by the decrease in 
absorbance (OD600nm) over time (% of initial absorbance [T = 0]). To overcome the 
phase variability associated with the agn43 gene, strains were transformed with the 
pAg43 expression vector. MG1655skp (pAg43) exhibited an impaired auto-aggregative 
phenotype and did not form a visible sediment (D) at the bottom of the tube (T = 120 
mins). Shown is the data from a single experiment, which is representative of three 
independent experiments. 
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4.3.3.2 An MG1655skp mutant expressing Ag43 does not form a biofilm  
Several studies have shown that Ag43 contributes to E. coli biofilm formation during 
growth in minimal media (Danese et al., 2000b, Klemm et al., 2004). The inability of 
MG1655skp (pAg43) to auto-aggregate suggests impaired expression of Ag43 on the cell 
surface. Thus, a microtiter biofilm assay was performed to examine biofilm formation. The 
experiments were performed at 28
o
C and 37
o
C to account for temperature-dependent 
differences. Ag43-mediated biofilm formation was observed for both the WT MG1655 
(pAg43) strain and the MG1655skp (pAg43) mutant when grown at a physiological 
temperature (37°C). However, the MG1655skp mutant failed to produce a biofilm when 
grown at 28°C.  
 
 
 
 
Figure 4.4 Ag43-mediated biofilm formation produced by MG1655 
and the isogenic MG1655skp mutant following growth in M9 minimal 
media at 28°C and 37°C, respectively. Ag43 expression was induced 
from the pAg43 expression vector by the addition of L-arabinose. The 
MG1655skp mutant exhibited impaired biofilm formation during 
growth at 28
o
C (***P < 0.001).  
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4.3.3.3 Ag43 is located on the cell surface in an MG1655skp mutant 
Upon translocation across the cell surface, Ag43 is auto-catalytically cleaved, leaving 
the passenger domain non-covalently bound to the β-barrel domain in the OM. Brief 
exposure of cells to higher temperatures (i.e. 60°C) can overcome this anchoring interaction, 
thus releasing the Ag43 into the supernatant. As such, the amount of Ag43 released form the 
cell surface of MG1655skp (pAg43) and into the supernatant was subsequently analysed 
using immunoblotting analysis. The WT strain MG1655 (pAg43) and the complemented 
MG1655agn43 (pAg43) strain were included in the assay for comparison. All samples were 
prepared form bacterial cultures grown in LB broth at physiological temperature. The amount 
Ag43 produced by expression from the chromosomally-encoded agn43 gene alone was not 
detectable in both WT MG1655 (pBAD) and MG1655skp (pBAD), further justifying the 
need to use pAg43 in this experiment (Figure 4.5 A). No significant difference was observed 
between the level of Ag43 released from the cell surface of WT MG1655 (pAg43) and the 
complemented MG1655agn43 (pAg43) strain. The amount of the Ag43 released into the 
supernatant from the MG1655skp (pAg43) was also similar, and possibly increased based on 
the intensity of the hybridising band (Figure 4.5 B). This result, in combination with previous 
results regarding biofilm formation and auto-aggregation, suggests Ag43 is expressed on the 
cell surface of MG1655skp (pAg43) but in a non-functional conformation. 
 
Complementation of MG1655skp (pAg43) with a plasmid containing the skp gene 
was attempted. The skp gene was PCR amplified from MG1655 (b0178) and inserted into the 
multiple cloning site (via the endonucleases XhoI and HindIII) of pSU2718. However, 
MG1655skp (pAg43, pSkp) exhibited severe growth defects when grown in the presence of 
antibiotics to maintain both plasmids. A lower copy number Ag43 expression vector 
(pBR322::Ag43 (Kjærgaard et al., 2002)) was also used, but the same growth defect was 
observed (Appendix 4.1). Therefore, the phenotypes of impaired Ag43-mediated auto-
aggregation and biofilm formation in MG1655skp (pAg43) could not be complemented by 
the addition of a plasmid containing the skp gene.   
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Figure 4.5 Western blot analysis detecting the Ag43 passenger 
domain (55KDa) in A) cellular and B) supernatant fractions 
prepared from MG1655, MG1655agn43 and MG1655skp 
pAg43-containing and vector control strains. Release of the 
Ag43 passenger domain into the supernatant was mediated by 
brief heat treatment at 60
o
C. An increase in Ag43 release was 
observed in the supernatant fraction of MG1655skp (pAg43) 
compared to MG1655 (pAg43) and MG1655agn43 (pAg43). 
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4.3.4 The role of periplasmic chaperones in expression of the SPATE protein Vat 
The previous results suggest a role for the periplasmic chaperone Skp in the 
translocation and expression of the AIDA-I type AT protein Ag43. However, previous 
publications that initially highlighted the involvement of periplasmic chaperones in AT 
translocation were based on the expression of the SPATE proteins EspP and Hbp (Table 4.2). 
SurA has been reported to bind to both Hbp and EspP (Sauri et al., 2009, Vertommen et al., 
2009, Ieva and Bernstein, 2009a), while both Skp and FkpA have also been shown to bind to 
EspP (Ieva and Bernstein, 2009a, Ruiz-Perez et al., 2010). Evidence also suggests secretion-
incompetent intermediate forms of the SPATE protein Hbp are degraded by DegP in 
periplasm (Jong et al., 2007a, Jong et al., 2010). The oligomeric structures formed by DegP 
(Jiang et al., 2008), as well as DegQ (Malet et al., 2012), are thought to provide cavity like 
chaperone properties. As Vat shares 78% protein identify with Hbp, Vat protein expression 
was anticipated to involve PPIase activity (FkpA, PpiA), SurA-like (PPIase independent) 
chaperone activity of PpiD, or additional chaperone activity produced by the DegP/DegQ 
oligomeric structures. Therefore, Vat was selected as a representative SPATE protein to assay 
for similar interactions in the E. coli MG1655 periplasmic chaperone mutants described 
above. 
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4.3.4.1 Vat secretion is not affected by mutation of periplasmic chaperone 
genes in MG1655 
To test the hypothesized role for periplasmic chaperones in Vat secretion, the pVat 
clone (previously constructed in Chapter 3.0) was transformed into each of the MG1655 
periplasmic chaperone mutant strains. This plasmid contains the CFT073 vat gene cloned into 
the expression vector pSU2178. WT MG1655 harbouring pVat or the empty vector control 
(pSU2178) were included as controls. All strains were grown aerobically under physiological 
conditions in LB broth supplemented with Cam 30 µg/ mL and 1mM IPTG for plasmid 
maintenance and induction of vat transcription, respectively. Supernatant fractions were then 
prepared and assessed for Vat via immunoblotting analysis (Figure 4.6). The level of Vat 
detected in supernatant fractions prepared from each of the mutants was comparable to that of 
the WT strain.  
 
 
Figure 4.6 Immunodetection of Vat (110KDa passenger domain) in the 
supernatant fractions prepared from MG1655 and the isogenic periplasmic 
chaperone mutants MG1655skp, MG1655degP, MG1655degQ, MG1655fkpA, 
MG1655ppiA and MG1655ppiD. Vat was overexpressed from the pVat 
plasmid vector. 
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4.3.4.2 Mutation of skp in CFT073 leads to impaired Vat secretion 
Although secretion of Vat into the supernatant was maintained within the subset of 
MG1655 periplasmic chaperones mutants, vector-driven expression of Vat may override 
sensitivity of the assay. As such, the skp gene was mutated in the UPEC strain CFT073. 
CFT073 expresses Vat during growth in LB broth at physiological temperature (Heimer et 
al., 2004; refer to Chapter 3). The degP gene was also mutated in CFT073 as a control. 
CFT073skp and CFT073degP supernatant fractions were subsequently examined for 
evidence of Vat secretion by western blot analysis (Figure 4.7). While the Vat passenger 
domain (Vatα) was detected in the supernatant fraction of WT CFT073 and CFT073degP, no 
Vatα was detected in the supernatant fraction of CFT073skp.  
 
Figure 4.7 Immunodetection of the Vat 
passenger domain in supernatant fractions 
prepared from CFT073 and the isogenic 
CFT073skp and CFT073degP mutants. 
CFT073vat was included as a negative control. 
Deletion of the skp gene resulted in impaired 
Vat secretion compared to the WT strain. 
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4.3.5 The role of periplasmic chaperones in the translocation of the trimeric AT 
protein EibD 
Periplasmic chaperones are thought to maintain AT proteins in a folding competent 
state during translocation across the protein dense bacterial periplasm. Expression of trimeric 
AT proteins on the cell surface involves the added complexity of quaternary structure 
formation. As such, additional factors may be required for the translocation of trimeric AT 
proteins across the OM. Based on the data described above, we hypothesized that Skp may 
contribute to this process. Indeed, an in vitro study recently demonstrated direct protein 
interactions between Skp and the Yersinia trimeric AT adhesion YadA (Ulrich et al., 2014). 
Ulrich and colleagues (2014) also demonstrated that Skp is required for optimal YadA 
surface expression. Here, the E. coli immunoglobulin binding protein EibD was selected as a 
representative trimeric AT protein to further investigate the role of Skp and other periplasmic 
chaperones in the type V secretion pathway.   
 
 
4.3.5.1 Expression of EibD in MG1655skp results in impaired biofilm 
formation  
 
The set of MG1655 periplasmic chaperone mutant strains described above were 
transformed with a plasmid containing EibD (pEibD). Plasmid pEibD contains the eibD gene 
amplified from the ECOR strain ECOR9 cloned into the high copy number plasmid 
pBADMycHisA. Expression of EibD in each of the MG1655 mutant strains was induced with 
the addition of 0.2% (w/v) L-arabinose. Strains were grown in LB broth at 28
o
C for 24 h 
under shaking conditions. Strains MS3339 [MG1655(pEibD)] and MS1715 
[MG1655(pBAD)] were used as positive and negative controls, respectively. Each strain was 
assessed for biofilm formation with and without induction of pEibD expression (± 0.2% L-
arabinose). Among the periplasmic chaperone mutants tested, only MG1655skp (pEibD) was 
impaired in EibD mediated biofilm formation (Figure 4.8). Interestingly, the expression of 
EibD in MG1655degP, MG1655fkpA and MG1655ppiA resulted in significantly enhanced 
biofilm formation compared to MG1655 (pEibD). MG1655degQ (pEibD) and MG1655ppiD 
(pEibD) produced biofilms comparable to the MS3339 positive control (Figure 4.8).  
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Figure 4.8 EibD-mediated biofilm formation produced by the MG1655 
periplasmic chaperone mutant strains. Strains MS3339 (pEibD) and MS1715 
(pBAD) were included as a positive and negative control, respectively. 
Vector-driven EibD expression was induced by L-arabinose. The MG1655skp 
mutant was impaired (P ≤ 0.001) in biofilm formation compared to MS3339 
(EibD). In contrast, deletion of the degP (P ≤ 0.001), fkpA (P ≤ 0.01) and ppiA 
(P ≤ 0.05) genes resulted in enhanced biofilm production. UI: uninduced; I: 
induced. 
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4.3.5.2 Cellular fractions prepared from MG1655skp contained less 
monomeric EibD, in comparison to the positive control strain MS3339 
The reduced biofilm formation exhibited by the MG1655skp (pEibD) strain suggests 
reduced expression of the EibD protein on the cell surface. Unlike Vat and Ag43, the EibD 
protein remains anchored to the OM and thus there is no simple assay to monitor cell-surface 
expression of EibD. However, to compare overall EibD expression, whole cell lysates were 
prepared from cultures of MG1655 (pEibD) and MG1655skp (pEibD) and subjected to 
immunoblotting analysis using an EibD specific polyclonal antibody. Interestingly, less 
monomeric EibD was detected in MG1655skp compared to MS3339 (Figure 4.9). Several 
EibD-specific cross-reacting bands were observed in all EibD-positive strains, suggesting the 
protein is partially degraded in the periplasm when over-expressed. An additional Coomassie 
stained gel was also run alongside the Western blot analysis to demonstrate equal protein 
loading (Appendix 4.2). The presence of these degradation products in WT MG1655 suggests 
this may be due to over-expression rather than the requirement of a specific periplasmic 
chaperone.  
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Figure 4.9 Immunoblot detection of EibD (54KDa; monomeric form) in the set of 
MG1655 periplasmic chaperone mutant strains.  Strains MS3339 (pEibD) and MS1715 
(pBAD) were included as a positive and negative control, respectively. Vector-driven 
EibD expression was induced by L-arabinose. The MG1655skp strain produced less 
EibD compared to the positive control MS3339. 
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4.3.6 The role of the TAM complex in the secretion of Vat 
In addition to the periplasmic chaperones SurA, Skp, DegP and FkpA, the BAM 
complex has also been shown to bind to and assist in AT protein translocation. In fact, based 
on the observed interaction between SurA and the POTRA domain of BamA, the periplasmic 
chaperone SurA is thought to deliver AT proteins to the BAM complex for the final step in 
translocation across the OM (Sklar et al., 2007b). The BAM complex has also been 
implicated in the translocation of the trimeric AT protein YadA. Indeed, depletion of BamA 
resulted in decreased YadA expression on the cell surface (Lehr et al., 2010), and a BamA 
binding motif was identified within the YadA C-terminal domain (Ackermann et al., 2008). 
The recently identified TAM complex was found to aid in expression of the self-associating 
AT proteins Ag43 and EhaA (Selkrig et al., 2012). The TAM complex consists of a 
transenvelope two-protein complex and is thought to function homologously to the BAM. 
This hypothesis was recently supported by Norell and colleagues (2014), who simulated 
BAM-mediated insertion of Ag43 into the membrane of BamA-E enriched proteoliposomes. 
Work in this study aimed to further investigate the role of the TAM complex in the 
translocation of the SPATE protein Vat 
 
 
4.3.6.1 The TAM complex is not required for Vat secretion into the 
supernatant  
Components of the BAM complex have previously been shown to interact with the 
SPATE proteins Hbp, EspP and Pet (Sauri et al., 2009, Ieva and Bernstein, 2009b, 
Vertommen et al., 2009, Rossiter et al., 2011). Additionally, depletion of bamA (yaeT) 
resulted in significantly reduced IgA1 secretion by N. meningitidis (Voulhoux et al., 2003), 
and significantly reduced IcsA (Jain and Goldberg, 2007) and SepA (Jain and Goldberg, 
2007) secretion by S. flexneri. Hence, we tested the role of the TAM in the secretion of Vat 
using previously constructed tamAB mutants in MG1655 (MG1655tamAB) and CFT073 
(CFT073tamAB). For these experiments, Vat expression in the MG1655 strains was provided 
by the plasmid pVat, while Vat expression in the CFT073 strains was provided by the 
chromosomal copy of the vat gene. Overall, there was no difference in the secretion of Vat in 
the presence and absence of the TAM in MG1655 (Figure 4.11 A) and CFT073 (Figure 4.11 
B).  
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In contrast to BamA, disruption of the tamAB operon is not lethal in E. coli (Selkrig et 
al., 2012). However, deletion of the tamAB genes may result in pleiotropic effects. 
Additionally, as the TAM has been suggested to act as a functional homologue of the BAM 
complex, redundancy may exist between the two complexes with respect to Vat translocation. 
Indeed both complexes have previously been shown to assist in Ag43 surface expression 
(Selkrig et al., 2012, Norell et al., 2014). Hence, a strain containing a tightly controlled and 
tuneable promoter (CFT073RExTET::tamAB) was used to further examine if the TAM 
contributes to Vat translocation. The CFT073RExTET::tamAB strain was constructed by a 
fellow lab member and contains the RExTET promoter directly in front of the tamAB genes, 
for which transcription was induced by the addition of AHT (Appendix 4.3). The amount of 
Vat secreted by the CFT073RExTET::tamAB strain was subsequently analysed in relation to 
increasing tamAB expression (Figure 4.11 B). Overall, the secretion of Vat by 
CFT073RExTET::tamAB was similar to WT CFT073, regardless of the level of tamAB 
expression. Taken together, these results suggest that Vat does not require the TAM complex 
for translocation across the OM. 
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Figure 4.10 A) Immunoblot detection of the Vat passenger domain (Vatα: 
110KDa) in concentrated supernatant fractions prepared from (A) MG1655 
and (B) CFT073 derivative strains. In (B), Vat secretion was examined in the  
CFT073RExTET::tamAB strain, which produced increased TamAB in the 
presence of AHT (0, 0.01 and 0.05 µg/mL). No difference in Vat secretion was 
observed in the presence or absence of the TAM in both MG1655 and CFT073.  
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4.4 Discussion 
UPEC ATs are associated with virulence and enhanced colonisation of the bladder. 
Despite the vast array of functions associated with AT proteins, the translocation of these 
proteins appears to be conserved among UPEC and other Gram-negative pathogens. The 
periplasmic chaperones SurA, Skp, DegP and FkpA are known to bind to AT proteins and 
assist in their translocation (Ruiz-Perez et al., 2009, Sauri et al., 2009, Ieva and Bernstein, 
2009a, Ruiz-Perez et al., 2010). Mutation of the skp and degP genes, respectively, resulted in 
attenuated virulence of the UPEC strain CFT073 (Redford and Welch, 2006). Both mutants 
were outcompeted by the WT parent strain at 24 hours post-infection in a mouse UTI model. 
As such, it was hypothesised this attenuated virulence is due to a lack of virulence-associated 
AT proteins expressed on the cell surface. In this project, the periplasmic chaperones Skp, 
DegP, DegQ, FkpA, PpiA and PpiD were investigated for their role in AT expression and 
translocation across the OM. The AT proteins analysed in this project included Ag43, Vat 
and EibD. These AT proteins were chosen as representatives for the AIDA-I type, SPATE 
and trimeric AT proteins, respectively.  
 
The SPATE Hbp was the first AT shown to be degraded by DegP, as the protein was 
found to accumulate in strains of E. coli lacking the degP gene (Jong et al., 2007b). In 2009, 
Sauri and colleagues later demonstrated co-purification of Hbp with SurA and two BAM 
component proteins (BamA and BamB). Deletion of the surA gene or depletion of the BAM 
complex (i.e. bamA) resulted in accumulation of Hbp within the cell. As Hbp shares 78% 
homology to Vat, a series of mutants containing deletions in skp, degP, degQ, fkpA, ppiA and 
ppiD were constructed and used to test the role of these periplasmic proteins in Vat 
translocation across the cell surface. The mutants were constructed in MG1655 (which 
enabled examination of Vat expression from the plasmid pVat) and CFT073 (which enabled 
examination of Vat expression from a chromosomally-located vat gene). In the MG1655 
mutants, no difference in Vat secretion was observed (Figure 4.6), possibly reflecting the 
overexpression of Vat from plasmid pVat. In CFT073, however, a reduction in Vat secretion 
was observed in the skp mutant. Further analysis is now required to confirm a direct 
interaction between Vat and Skp. As the TAM complex is thought to act as a BAM functional 
homologue, the TAM was also tested for its possible role in Vat secretion. However, neither 
deletion nor depletion of the TAM complex affected Vat secretion by either MG1655 (Figure 
4.11A) or CFT073 (Figure 4.11B).  
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To test if specific periplasmic chaperones were involved in the translocation of Ag43, 
the set of MG1655 periplasmic chaperone mutants were assessed for Ag43 expression using 
the pAG43 expression plasmid. Among the mutants examined, MG1655skp exhibited 
impaired Ag43 expression as indicated by reduced auto-aggregation and biofilm formation 
(Figure 4.3 and Figure 4.4). The impaired biofilm formation observed for the MG1655skp 
gene was not reproducible at a physiological temperature (Figure 4.3). This may be due to the 
expression of larger adhesins such as type 1 fimrbiae (Hasman et al., 1999), which can 
physically interfere with the close contact interactions required for Ag43 self-association. 
 
The impaired auto-aggregative phenotype in combination with the reduced biofilm 
produced by the MG1655skp (pAg43) suggested impaired Ag43 expression on the cell 
surface. Thus, immunoblotting analysis was employed to detect the amount of Ag43 released 
following mild heat treatment. In these assays, the amount of Ag43 released into the 
supernatant from MG1655skp (pAg43) was slightly increased compared to WT MG1655 
(Figure 4.5 [B]). This result indicates that in the absence of Skp, Ag43 reaches the cell 
surface in a non-functional conformation. In contrast to supernatant fractions, cellular levels 
of Ag43 were comparable to that of the control strains (Figure 4.5 [A]), indicating similar 
expression levels between strains. It is possible that the cavity-chaperone activity of Skp 
sequesters Ag43 within the periplasm, thereby slowing down Ag43 translocation and 
turnover. Skp has previously been shown to inhibit secretion of the OMPs PagP (nine-fold 
difference) (McMorran et al., 2013) and OmpA (seven-fold difference) under neutral 
conditions (Patel et al., 2009). In the absence of Skp, Ag43 folding may be uninhibited, but 
also unassisted. Faster folding would lead to higher quantities of Ag43 on the cell surface but 
would also leave Ag43 prone to forming non-functional yet cleavable intermediates.  
 
Although standardised cultures (OD600nm = 3.0) were used, the growth defect observed 
for MG1655skp may have been exacerbated by over-expressing Ag43. Indeed, the impaired 
phenotype observed for expression of Ag43 by MG1655skp could not be complemented 
using a dual plasmid system. In an attempt to optimise expression levels, a lower copy 
number Ag43 expression vector was used (based on pBR322, 10-20 copies per cell). 
However, this did not alleviate the growth defect of MG1655skp (pAg43, pSkp) in the 
presence of antibiotic selection for maintenance of both plasmids (Appendix 4.1). Similar 
difficulties associated with the complementation of skp mutants have reported previously in 
CFT073 (Redford and Welch, 2006).  
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The growth defect observed for the MG1655skp mutant was more severe when 
cultured in LB media as compared to minimal media (Figure 4.1 and 4.2). The skp gene is 
transcribed as part of an operon including the lpxD-fabZ-lpxA genes. The transcriptional start 
site for the skp-lpxD-fabZ-lpxA operon is located 27bp upstream of the skp gene 
(Dartigalongue et al., 2001). In N. meningitidis, mutation of skp resulted in a corresponding 
growth defect (which could not be complemented) as well as decreased levels of lpxD (~30-
fold) and fabZ (~9-fold). The polar effects were significantly offset (i.e. no growth defect and 
only a 5-fold difference in lpdX transcription) by inserting the antibiotic cassette in the 5' end 
of the gene. A second promoter is also located upstream of the lpxD gene (Dartigalongue et 
al., 2001). As such, lpxD-fabZ-lpxA are also transcribed independently of skp. It should be 
noted that in frame deletion of skp did not affect growth and resulted in a 2-fold increase in 
LPS production in the E. coli K-12 strain MC4100 (Schafer et al., 1999). Nonetheless LpxD 
and LpxA are important enzymes involved in lipid A synthesis, while FabZ is involved fatty 
acid biosynthesis. Decreased LPS in the OM may reduce cell wall integrity in MG1655skp. A 
decrease in phospholipid density may enable more Ag43 protein to insert into the OM, as 
observed by Western blot analysis (Figure 4.5). However, a weakened outer membrane may 
also leave Ag43 susceptible to misfolding upon translocation into the OM. This may explain 
the reduced aggregation and biofilm formation properties of the MG1655skp (pAg43) strain.  
 
EibD-mediated biofilm formation was also impeded when EibD was overexpressed in 
MG1655skp (Figure 4.8). In the future, this experiment should be repeated using an agn43 
knockout background similar to that of the positive control strain MS3339 (MG1655agn43 
[pEibD]). The level of EibD within the cellular fractions was also analysed using 
immunodetection. In contrast to Ag43, however, EibD remains anchored to the cell surface 
and cannot be readily detached. Interestingly, the amount of the EibD detected in 
MG1655skp was reduced compared to the positive control MS3339 (Figure 4.9). Future 
experiments could compare the level of EibD expression on the cell surface of MG1655 and 
MG1655skp using immunofluorescence microscopy. 
 
The prototypical trimeric AT protein YadA has previously been shown to interact 
with Skp (Ulrich et al., 2014). Ulrich and colleagues (2014) also demonstrated YadA can 
become integrated into the mitochondrial membrane surface of yeast cells. In the same study, 
co-expression of Skp (cloned from E. coli) was also shown to enhance the expression of 
YadA (Ulrich et al., 2014). YadA expression has also previously been shown to require 
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BamA of the BAM complex (Lehr et al., 2010). The process of trimer formation, including 
the anchoring together of three independent passenger domains, is likely to require additional 
assistance from the BAM for translocation and insertion into the OM. The shorter β-barrel 
domains of trimeric AT proteins contribute 4 β-strands of the overall 12-stranded β-barrel 
structure formed within the OM (Meng et al., 2006a). In addition, the tip of each monomer 
oligomerises together to form a globular head (Leo et al., 2011).  
 
Given that part of the transenvelope TAM complex comprises the integral OMP 
protein TamA, the TAM participate in EibD translocation into the OM. Trimeric AT proteins 
may also require periplasmic chaperones such as Skp for passage through the periplasm in 
order to keep both the globular head and β-barrel domains from prematurely oligomerising. 
Indeed, the β-barrel domain of the EibA protein has been shown to oligomerise with the 
passenger domain of YadA to form a fully functional YadA chimeric-trimeric protein 
(Ackermann et al., 2008). The low-specificity exhibited by these hybrid trimers suggests the 
need for chaperone intervention during transit across the periplasmic space. Future 
experiments utilising the immunoglobulin binding properties of EibD (Sandt and Hill, 2000, 
Leo and Goldman, 2009b, Sauri et al., 2009) are required to detect the amount of functional 
EibD present on the cell surface of the MG1655tamAB strain. In contrast to the previous 
reports regarding the role of the BAM in the translocation of the SPATE proteins Hbp, EspP 
and Pet (Rossiter et al., 2011, Leyton et al., 2011, Ieva and Bernstein, 2009a, Ruiz-Perez et 
al., 2009, Sauri et al., 2009), secretion of Vat was analysed in the absence of the TAM 
complex. The amount of Vat produced both by MG1655tamAB (pVat) and CFT073tamAB 
was comparable to that of the isogenic parent strains [Figure 4.11]). Given the hypothesised 
functional homology between the TAM and the BAM, Vat secretion into the supernatant was 
also analysed within a CFT073tamAB depletion strain. However, different expression levels 
of the TAM complex did not affect the amount of Vat secreted into the supernatant by 
CFT073 [Figure 4.11].   
 
Taken together, this work has demonstrated an important role for Skp in the 
translocation and secretion of AT proteins. Similar to SurA, the importance of Skp in AT 
secretion as well as OMP biogenesis is reflected in the experimental limitations posed by 
mutating this important gene, which forms part of the sigma E regulon stress response 
pathway. Similar to skp, both degP and fkpA are also upregulated upon activation of the 
RpoE pathway (Dartigalongue et al., 2001). However, simultaneous detection of each 
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periplasmic chaperone analysed was beyond the scope of this study. Future experiments 
could use a conditional skp mutant to avoid the pleiotropic effects caused by diminished cell 
wall integrity. Additionally, the direct interaction between AT proteins and periplasmic 
chaperones such as Skp could be examined using methods such as the yeast-two hybrid 
system, SPR analysis or cross-linking and pull down assays. These techniques may avoid 
overlapping redundancy that exists between periplasmic chaperones and the β-barrel 
translocation machinery of the OM.  
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5.0 Discussion and Conclusions  
 
UPEC are the major cause of UTI, a disease of significant impact to global human 
health. The rapid rise in the incidence of antibiotic resistant UPEC has increased the severity 
of this problem, highlighting the urgent need to develop alternative treatment and prevention 
measures. In addition, a greater understanding of UPEC virulence and pathogenesis is 
required. AT proteins are important UPEC virulence factors and encode a range of functions 
including adherence, biofilm formation, iron acquisition, toxicity, host cell invasion and 
evasion of the immune system. This study examined the UPEC SPATE protein Vat, as well 
as the role of periplasmic chaperones in AT translocation and secretion.  
 
The characterisation of Vat involved a combination of bioinformatic and molecular 
analyses. The vat gene was shown to be highly prevalent among UPEC urosepsis isolates. A 
novel regulator of vat, termed vatX in this study, was identified and characterised. The vat-
vatX genes were shown to be co-transcribed and repressed by H-NS, and the binding of H-NS 
to the vat promoter region was demonstrated. Finally, Vat-specific antibodies were detected 
in plasma samples from urosepsis patients infected by vat-containing UPEC strains, 
demonstrating Vat is expressed during human infection. Vat is known to be upregulated 
during infection of the lower urinary tract of mice and contributes to the virulence of CFT073 
during a sepsis infection (Heimer et al., 2004, Subashchandrabose et al., 2013). Taken 
together, these findings now pave the way for future studies to comprehensively understand 
the contribution of Vat to UPEC pathogenesis. A recent study demonstrated that Vat can 
cleave a range of host cell O-linked glycoproteins present on human leukocytes (Ayala-Lujan 
et al., 2014). This suggests that Vat may help UPEC to combat the host immune system 
during infection.  
 
In the Vat IgG analysis from human plasma samples, some level of Vat recognition 
was also observed in the negative control groups (Figure 3.5). This cross-reactivity may have 
been due to previous infection, suggesting immunogenic properties for Vat. However, further 
analysis is required to assess immunogenicity of the native form of the entire Vat passenger 
protein. Based on the data from both the urosepsis patients and control groups, it is also 
possible that Vat may represent a viable UPEC vaccine target. Several UPEC vaccine 
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candidates have been trialled over the past decade included live-attenuated vaccines, 
immunisation with whole-cell/ cellular fractions and antigen based subunit vaccines. 
Virulence factors targeted in these trials have included capsule polysaccharides (Kumar et al., 
2005, Straube et al., 1986), O-antigen (Uehling and Wolf, 1969, Russo et al., 2007, Billips et 
al., 2009, Russo et al., 2009), α-haemolysin (O'Hanley et al., 1991, Moriel et al., 2010, Smith 
et al., 2015), CNF-1 (Smith et al., 2015), iron acquisition receptors (Russo et al., 2003, 
Wieser et al., 2010, Wieser et al., 2012, Durant et al., 2007, Alteri et al., 2009) and fimbrial 
adhesins (Langermann et al., 1997, Langermann et al., 2000, Goluszko et al., 2005, Roberts 
et al., 2004). Despite these extensive efforts, there is still no effective vaccine against UPEC. 
Several AT proteins are already used as vaccine antigens, including pertactin from B. 
pertussis (an important constituent of the current acellular pertussis vaccine) (reviewed in 
Poolman and Hallander, 2007) and the trimeric AT NadA (a component of the recently 
licensed vaccine against Neisseria meningitidis serotype B (Bexsero) (Serruto et al., 2012, 
Giuliani et al., 2006). It is possible that Vat could be investigated as an integral antigen in a 
multicomponent UPEC vaccine. However, this awaits further study. 
 
In this project, the periplasmic chaperone Skp was shown to contribute to secretion of 
Vat and Ag43 mediated cell aggregation. Weak evidence was also provided to suggest Skp 
may contribute to EibD translocation. Skp exists as a small trimeric “jellyfish” type protein 
and is known to sequester unfolded OMPs in a cavity-chaperone like manner. The 
contribution of Skp to the translocation of Ag43, Vat and EibD suggests it plays a general 
role in AT protein secretion.  
 
Skp is also known to bind to the negative glycolipid LPS (De Cock et al., 1999b). 
Indeed, Skp mediated expression of the OMP OmpA requires LPS in complex with Skp 
(Bulieris et al., 2004). McMorran and colleagues (2013) demonstrated the Skp-mediated 
folding rates of the OMP PagP to double in the presence of LPS under neutral conditions. 
However, Skp alone did not influence folding rates of PagP in solution. In fact, Skp was 
found to impede folding of both PagP and OmpA under neutral conditions (McMorran et al., 
2013, Patel et al., 2009). In contrast, Skp-mediated folding of PagP and OmpA increased 
under negatively charged conditions (i.e. 80:20 [1,2-dilauroyl-sn-glycero-3-phosphocholine: 
1,2-dilauroyl-sn-glycero-3-phospho-(1'-rac-glycerol)]). Despite this, the presence of LPS was 
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found to slow down folding of both OMPs regardless of the membrane composition. This 
suggests crucial interactions between Skp and the lipid membrane are important for outer 
membrane biogenesis. LPS is known to spontaneously insert into lipid membranes from 
aqueous solutions (Alam and Yamazaki, 2011). Protein interactions between LPS and Skp are 
thought to slow OMP folding during migration across the periplasm, allowing enough time 
for the protein to fold and/ or to interact with additional chaperones. It is likely that the 
interaction between Skp and LPS also contributes to AT protein translocation. 
 
Delivery of LPS to the OM involves the Lpt pathway. Perhaps Skp/LPS-mediated 
delivery of AT proteins is shunted to the OM using the Lpt bridge. Similar to ATs, 
integration of LPS into the OM requires assistance from membrane bound β-barrel 
machinery. The integral OM protein complex used in the Lpt pathway comprises the β-barrel 
protein LptD and the accessory lipoprotein LptE. The structural topology of LptD is similar, 
albeit much larger (26-β strands), to that of BamA (Dong et al., 2014). Indeed, the lateral gate 
(Noinaj et al., 2014, Noinaj et al., 2013a) conformational change simulated for BamA was 
also suggested for LptD (Dong et al., 2014). The BAM exists as a BamAB and BamACDE 
protein complex (Sklar et al., 2007a, Malinverni et al., 2006, Hagan et al., 2010, Jansen et al., 
2015a). However, LptE differs from BamB in structure, size (BamB: 40KDa, LptE: 20KDa), 
and location in relation to the central protein component. While BamB is known to interact 
with the periplasmic domains of BamA, LptE is situated within the central channel of LptD 
(Dong et al., 2014). In fact, the overall structure of LptE resembles a similar topology to that 
of the lipoprotein of BamE (Kim et al., 2011b). Based on these structural similarities, it is 
possible that LptD may interact with AT proteins in the OM, however, this remains to be 
demonstrated. 
 
The primary OMP protein BamA has been extensively studied in OMP biogenesis. 
The accessory roles played by the BAM lipoproteins BamB-E, however, remain unclear. 
Gessmann and colleagues (2014) demonstrated BamA catalyses folding of OMPs into 
liposome membranes in the absence of BamBCDE. BamD is the only lipoprotein known to 
be essential for a functional BAM complex (Wu et al., 2005, Onufryk et al., 2005, Malinverni 
et al., 2006). BamE and BamC are thought to stabilise the interaction between BamA and 
BamD, and to modulate the functional activity of BamA and BamD, respectively (Kim et al., 
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2011a, Rigel et al., 2012). BamB is known to form a propeller like structure within the 
periplasm and is linked together with BamA via the third POTRA domain (Jansen et al., 
2015a, Dong et al., 2012b). The junction between the second and third POTRA domains of 
BamA is flexible, creating a hinge like structure (Noinaj et al., 2013a, Gatzeva-Topalova et 
al., 2010, Gatzeva-Topalova et al., 2008). It is thought nascent polypeptides are threaded 
through the central pore of BamB and are delivered to BamA directly via the lever-like 
motion of BamA POTRA domains.  
 
In addition to the periplasmic chaperone Skp, both BamA and BamB have also been 
identified to directly interact with EspP (Ruiz-Perez et al., 2009, Ieva and Bernstein, 2009a). 
These interactions were observed to occur with the β-barrel domain of EspP. In contrast, both 
SurA and FkpA interact with the unfolded passenger domain of EspP (Ruiz-Perez et al., 
2010, Ruiz-Perez et al., 2009). Ieva and colleagues (Ieva et al., 2011) also showed that Skp 
interacts with EspP early in the translocation process, while SurA binds to EspP at a later 
stage. A cross-linking pull down assay has also shown that Pet interacts directly with both 
BamA and BamD (Leyton et al., 2011). Depletion of either BAM component impeded 
secretion of Pet into the supernatant (Rossiter et al., 2011). It is possible that Skp targets AT 
proteins to the BamAB sub-complex, while the PPIase activity of SurA and FkpA assist in 
folding. 
 
All five BAM proteins were recently shown to contribute to the translocation of both 
Ag43 and EspP into the membrane of proteoliposomes (Norell et al., 2014, Roman-
Hernandez et al., 2014). Furthermore, the TAM also aids in the translocation of Ag43 in E. 
coli (Selkrig et al., 2012). In contrast to the BAM complex, however, the TAM spans the 
entire periplasm, encompassing both the inner and outer membrane. The TAM may shuttle 
newly synthesised AT proteins directly from the SEC translocon to the cell surface. Selkrig 
and colleagues (2015) recently compared the structural topology conserved between BamA 
and TamA by using Rate4Site and Cluster Analysis of Sequences software. Although the 
third POTRA domain of TamA (the POTRA interacting with the β-barrel structure) exhibits 
similarity to BamA, the PORTA1 and PORTA2 domains of TamA are much less conserved 
in comparison to BamA. PORTA1 and PORTA2 of TamA are elongated in structure and are 
much more rigid. Recent magnetic contrast neutron reflectrometry analysis demonstrated the 
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three POTRA domains of TamA undergo conformational changes triggered by Ag43 (Shen et 
al., 2014). Interestingly the presence of TamA alone was sufficient for Ag43 membrane 
insertion, suggesting TamB may provide the resistance required to modulate the lever-like 
arm of TamA. 
 
The exit pore and lateral gate identified in BamA is also conserved in the β-barrel 
structure of TamA (Selkrig et al., 2015). Secretion of AT proteins is now thought to occur 
laterally through this exit pore. The short β-strands associated with this exit pore are thought 
to provide additional space to allow for the passenger domain to fold uninhibited. In addition, 
the weak electrostatic interactions that exist between the first and last β-strand have been 
suggested to dissociate during AT translocation. The exposed β-strands of TamA are then 
thought to transiently interact with β-barrel domain of the translocating AT. Indeed, Selkrig 
and colleagues (2015) demonstrated this region of TamA was found to be the most highly 
conserved face of TamA. The conserved structural topology and the overlapping substrate 
proteins targeted by BAM/TAM suggest redundancy between these β-barrel assembly 
complexes. It is possible the BAM and TAM complexes both contribute to Vat secretion, thus 
explaining why mutation of the TAM did produce a clear phenotype. Future work would 
need to determine a direct interaction between the TAM and AT proteins such as Vat.   
 
Overall, the results obtained from this project suggest Skp is an important component 
of AT protein translocation in E. coli. Further analysis is now required to confirm a direct 
interaction between Skp and representative AIDA-I, SPATE and trimeric AT proteins. In the 
context of Vat, further work is required to understand its contribution to virulence. Overall, a 
greater understanding of how AT proteins contribute to UPEC pathogenesis will inform 
future efforts aimed at the development of new methods to treat and prevent UTIs.  
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7.0 Appendix  
 
7.1 Appendix 3.1 
 
Appendix 3.1: List of the 77 sequenced E. coli genomes obtained from the NCBI 
website. These strains include a selection of environmental, non-pathogenic (NP) and 
pathogenic strains of E. coli. Based on the host, host symptoms and location of infection; 
pathogenic strains of E. coli can be further classified into various pathotypes. Included 
in this table are the E. coli pathotypes: enteropathogenic E. coli (EPEC), enterotoxigenic 
E. coli (ETEC), adherent-invasive E. coli (AIEC), enterohaemorrhagic E. coli (EHEC), 
enteroaggregative haemorrhagic E. coli (EAHEC), Shiga toxin-producing E. coli 
(STEC), neonatal meningitis E. coli (NMEC), uropathogenic E. coli (UPEC) as well as 
UPEC strains with the sequence type 131 (ST131), and avian pathogenic E. coli (APEC). 
Strain Pathotype 
Source of Isolate 
(Associated Disease) Reference 
42 EAEC Human (Diarrhoea) 
(Chaudhuri et al., 
2010) 
536 UPEC 
Human (Acute 
Pyelonephritis) 
(Hochhut et al., 
2006) 
11128 EHEC Human (Diarrhoea) (Ogura et al., 2009) 
11368 EHEC Human (Diarrhoea) (Ogura et al., 2009) 
12009 EHEC 
Human (Haemorrhagic 
Diarrhoea) (Ogura et al., 2009) 
55989 EAEC  Human (Diarrhoea)  - 
83972 UPEC 
Human (Asymptomatic 
Bacteriuria) 
(Zdziarski et al., 
2010) 
2009EL-2050 EAHEC 
Human (Haemorrhagic 
Diarrhoea Outbreak) 
(Ahmed et al., 
2012) 
2009EL-2071 EAHEC 
Human (Haemorrhagic 
Diarrhoea Outbreak) 
(Ahmed et al., 
2012) 
2011C-3493 EAHEC 
Human (Haemorrhagic 
Diarrhoea Outbreak) 
(Ahmed et al., 
2012) 
APEC O1 APEC Turkey (Colibacillosis) 
(Johnson et al., 
2006) 
APEC O78 APEC Turkey (Colibacillosis) 
(Mangiamele et al., 
2013) 
ATCC 25922 NP Human 
(Minogue et al., 
2014) 
ATCC 8739 NP Human - 
B7A ETEC Human (Diarrhoea) -  
BL21(DE3) NP  - (Jeong et al., 2009) 
BL21-
Gold(DE3)pLysS AG NP  -  - 
BW25113 NP - 
(Grenier et al., 
2014) 
BW2952 NP  -  
(Ferenci et al., 
2009)  
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C321.deltaA NP  -  (Lajoie et al., 2013) 
CB9615 EPEC Human (Diarrhoea) (Zhou et al., 2010) 
CE10 NMEC  
Human (Neonatal 
Meningitis)  (Lu et al., 2011) 
CFT073 UPEC  
Human (Acute 
Pyelonephritis) 
(Welch et al., 
2002)  
clone D i14 UPEC Human 
(Reeves et al., 
2011) 
clone D i2 UPEC  Canine 
(Reeves et al., 
2011) 
DH1 NP -  
(Suzuki et al., 
2011)  
DH10B NP  -  
(Durfee et al., 
2008)  
E2348/69 EPEC  Human (Diarrhoea) (Iguchi et al., 2009) 
E24377A ETEC  -  (Rasko et al., 2008) 
EC4115 EHEC Human  
(Eppinger et al., 
2011) 
EC958 
UPEC 
(ST131)  Human (UTI)  (Forde et al., 2014) 
ED1a NP  Human  -  
EDL933 EHEC  
Ground Beef 
(Haemorrhagic Diarrhoea 
Outbreak) (Latif et al., 2014)  
H10407 ETEC Human (Diarrhoea)  
(Crossman et al., 
2010)  
HMS174 NP  - 
(Mairhofer et al., 
2014) 
HS NP  Human  
(Rasko et al., 
2008)  
IAI1 NP  Human  - 
IAI39 UPEC  Human (Pyelonephritis)  
(Touchon et al., 
2009)  
IHE3034 NMEC  
Human (Neonatal 
Meningitis)   
(Moriel et al., 
2010)  
JJ1886 
UPEC 
(ST131)  Human (Urosepsis)  
(Andersen et al., 
2013) 
KLY  - -  
(Fridman et al., 
2014)  
KO11FL NP -  
(Turner et al., 
2012)  
LF82 AIEC  Human (Crohn’s Disease)  
(Miquel et al., 
2010) 
LY180 NP -  
(Geddes et al., 
2014) 
MC4100 NP -  
(Laehnemann et al., 
2014)  
MDS42 NP  -  -  
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MG1655 NP  -  
(Hayashi et al., 
2006)  
NA114 
UPEC 
(ST131)  Human (Prostatitis)  
(Avasthi et al., 
2011) 
Nissle 1917 NP  Human  
(Reister et al., 
2014)  
NRG 857C AIEC  Human (Crohn’s Disease)   (Nash et al., 2010)  
P12b -  -  (Liu et al., 2012) 
PMV-1 ExPEC -  
(Peris-Bondia et 
al., 2013) 
REL606 NP  -  (Jeong et al., 2009)  
RM12579 EPEC  Human  (Kyle et al., 2012)  
RM12581 STEC  
Lettuce (Colitis/ Haemolytic 
Uremic Syndrome 
Outbreak) 
(Cooper et al., 
2014b)  
RM12761 STEC 
Ice-cream (Colitis/ 
Haemolytic Uremic 
Syndrome Outbreak) 
(Cooper et al., 
2014b)  
RM13514 STEC  
Human (Colitis/ Haemolytic 
Uremic Syndrome 
Outbreak)  
(Cooper et al., 
2014a)  
RM13516 STEC  
Human (Colitis/ Haemolytic 
Uremic Syndrome 
Outbreak)  
(Cooper et al., 
2014a) 
RV308 NP  -  
(Krempl et al., 
2014) 
S88 NMEC  
Human (Neonatal 
Meningitis)   
(Touchon et al., 
2009) 
Sakai  EHEC 
Human (Haemorrhagic 
Diarrhoea Outbreak) 
(Hayashi et al., 
2001) 
SE11 NP  Human  
(Oshima et al., 
2008)  
SE15 NP  Human  (Toh et al., 2010)  
SMS-3-5 Environmental 
Shipyard Creek, United 
States of America (Fricke et al., 2008) 
SS17 EHEC  
Bovine (“Super-shedder”: 
animal reservoir of the E. 
coli isolate)   (Cote et al., 2015) 
ST2747 UPEC  Human (UTI)  
(Xavier et al., 
2014) 
ST540 UPEC  Human (UTI)  
(Xavier et al., 
2014)  
TW14359 EHEC  
Human (Colitis/ Haemolytic 
Uremic Syndrome 
Outbreak) 
(Kulasekara et al., 
2009)  
TW14588 EHEC  
Lettuce (Colitis/ Haemolytic 
Uremic Syndrome 
Outbreak) - 
UM146 AIEC  Human (Crohn’s Disease)  (Krause et al., 
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2011)  
UMN026 UPEC  Human (Acute Cystitis)  
(Touchon et al., 
2009) 
UMNF18 ETEC  
Porcine (Post-weaning 
Diarrhoea) 
(Shepard et al., 
2012) 
UMNK88 ETEC  
Porcine (Post-weaning 
Diarrhoea) 
(Shepard et al., 
2012) 
UTI89 UPEC  Human (Acute Cystitis)  (Chen et al., 2006)  
W Environmental 
Soil near a cemetery, United 
States of America  
(Archer et al., 
2011) 
W3110 NP  -  
(Hayashi et al., 
2006)  
Xuzhou21 EHEC 
Human (Haemolytic Uremic 
Syndrome Outbreak) (Xiong et al., 2012) 
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7.2 Appendix 3.2: 
 
Appendix 3.2: List of MarR-type transcriptional regulators. Amino acid sequences 
corresponding to each of the accession numbers were used to BLAST against the set of 
77 complete E. coli genomes, extracted and aligned for phylogenetic analysis. Query 
sequences representative for each clade encode for MarR-type regulators previously 
characterised in E. coli (underlined).  The overall protein conservation was recorded for 
each clade (MarR; MprA/ EmrR; HosA; HpcR/ HpaR; SlyA; SfaX/ FocX/ PapX and 
VatX). 
Protein (Amino Acid 
Conservation %) 
Strain Locus Tag 
NCBI Accession 
Number 
MarR (98%) 
42 EC042_1663 YP_006095973  
536 ECP_1513 YP_669421 
11128 ECO111_1927 YP_003234370  
11368 ECO26_2132 YP_003229135 
12009 ECO103_1661 YP_003221612 
55989 EC55989_1665 YP_002402734 
83972 ECABU_c17560 YP_006105837 
2009EL-2050 O3M_12785 YP_006770201 
2009EL-2071 O3O_12810 YP_006784326  
2011C-3493 O3K_12825 YP_006779255 
APEC O1 APECO1_648 YP_852663 
APEC O78 APECO78_11400 YP_007381453 
ATCC 25922 DR76_3328 AIL17225 
ATCC 8739 EcolC_2128 YP_001725095   
B7A L960_0780 AIF60603  
BL21(DE3) B21_01500 YP_002999307 
BL21-
Gold(DE3)pLysS 
AG 
ECBD_2110 YP_003036334 
BW25113 BW25113_1530 AIN31972 
BW2952 BWG_1349 YP_002926546 
C321.deltaA N840_1557 AGX33623  
CB9615 G2583_1895 YP_003499451  
CE10 CE10_1759 YP_006143839  
CFT073 c1952 NP_753847 
clone D i14 i14_1774 YP_006153887  
clone D i2 i02_1774 YP_006148968  
DH1 EcDH1_2116 YP_006092060 
DH10B ECDH10B_1661 YP_001730517 
E2348/69 E2348C_1650 YP_002329173   
E24377A EcE24377A_1732 YP_001462815 
EC4115 ECH74115_2144 YP_002270528   
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EC958 EC958_1785 CDN82065 
ED1a ECED1_1658 YP_002397632 
EDL933 Z2171 NP_287622 
H10407 ETEC_1600 YP_006115173  
HMS174 ECHMS174_01524 CDY58123 
HS EcHS_A1612 YP_001458320 
IAI1 ECIAI1_1543 YP_002386976 
IAI39 ECIAI39_1826 YP_002407806.1 
IHE3034 ECOK1_1678 YP_006100868   
JJ1886 P423_08395 YP_008721712 
KLY HQ24_07555 AIF36821 
KO11FL EKO11_2286 YP_005277960 
LF82 LF82_1278 YP_002556403 
MC4100 BN896_1349 CDJ71930  
MDS42 ECMDS42_1241 YP_007556891 
MG1655 b1530 NP_416047 [1] 
NA114 ECNA114_1613 YP_006138712  
Nissle 1917 ECOLIN_08425 AID78603  
NRG 857C NRG857_07550 YP_006119868 
P12b P12B_c1547 YP_006168578 
PMV-1 ECOPMV1_01656 YP_008571515 
REL606 ECB_01489 YP_003044692 
RM12579 ECO55CA74_09295 YP_006159000 
RM12581 ECRM12581_9150 AHY70360   
RM12761 ECRM12761_9315 AHY64900 
RM13514 ECRM13514_1860 AHG08539 
RM13516 ECRM13516_1896 AHG14564 
RV308 ECRV308_01512 WP_000843414 
S88 ECS88_1606 YP_002391345 
Sakai ECs2137 NP_310164 
SE11 ECSE_1620 YP_002292895  
SE15 ECSF_1427 YP_003349417 
SMS-3-5 EcSMS35_1640 YP_001743694  
SS17 SS17_2034 AIF93612 
ST2747 CF60_14830 AHM52860  
ST540 CF61_15200 AHM39172  
TW14359 ECSP_2015 YP_003077912 
TW14588 ESCCO14588_3698 EEC25946 
UM146 UM146_09370 YP_006110769 
UMN026 ECUMN_1798 YP_002412533 
UMNF18 UMNF18_1995 AEJ56580 
UMNK88 UMNK88_1951 YP_006133709  
UTI89 UTI89_C1749 YP_540758 
W WFL_08125 YP_006173073 
W3110 Y75_p1505 YP_489793 
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Xuzhou21 CDCO157_1977 YP_006312845 
MprA/ EmrR (99%) 
42 EC042_2881 YP_006097181 
536 ECP_2649 YP_670539 
11128 ECO111_3407 YP_003235764  
11368 ECO26_3752 YP_003230685  
12009 ECO103_3224 YP_003223109  
55989 EC55989_2951 YP_002403947 
83972 ECABU_c29500 YP_006106966  
2009EL-2050 O3M_06180 YP_006768902  
2009EL-2071 O3O_19510 YP_006783009 
2011C-3493 O3K_06135 YP_006777939  
APEC O1 APECO1_3838 YP_853870 
APEC O78 APECO78_17005 YP_007382566 
ATCC 25922 DR76_1950 AIL16751 
ATCC 8739 EcolC_1023 YP_001724019   
B7A L960_4336c AIF64159    
BL21(DE3) B21_02504 YP_003000277  
BL21-
Gold(DE3)pLysS 
AG 
ECBD_1036 YP_003035287 
BW25113 BW25113_2684 AIN33064 
BW2952 BWG_2425 YP_002927622   
C321.deltaA N840_2735 AGX34700 
CB9615 G2583_3331 YP_003500834  
CE10 CE10_3105 YP_006145132  
CFT073 c3237 NP_755119 
clone D i14 i14_2967 YP_006155056 
clone D i2 i02_2967 YP_006150137 
DH1 EcDH1_1000 YP_006090971.1 
DH10B NC_010473 NC_010473.1 
E2348/69 E2348C_2948 YP_002330435  
E24377A EcE24377A_2967 YP_001463996 
EC4115 ECH74115_3928 YP_002272150  
EC958 EC958_2949 WP_000378443 
ED1a ECED1_3138 CAR09155 
EDL933 Z3985 NP_289235   
ETEC H10407 ETEC_2880 YP_006116428  
HMS174 ECHMS174_02691 CDY60816 
HS EcHS_A2820 YP_001459453  
IAI1 ECIAI1_2779 YP_002388144 
IAI39 ECIAI39_2873 YP_002408807 
IHE3034 ECOK1_3052 YP_006102181  
JJ1886 P423_14690 YP_008722939 
KLY HQ24_13360 AIF37918 
KO11FL EKO11_1088 YP_005276787 
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LF82 LF82_1385 YP_002557517 
LY180 LY180_13590 YP_008565794   
MC4100 BN896_2425 CDJ74139    
MDS42 ECMDS42_2188 YP_007557786  
MG1655 b2684 NP_417169[2] 
NA114 ECNA114_2716 YP_006139825  
Nissle 1917 ECOLIN_14460 AID79723 
NRG 857C NRG857_13145 YP_006120979    
P12B P12B_c2791 YP_006169800  
PMV-1 ECOPMV1_02937 WP_000378442 
REL606 ECB_02539 YP_003045728 
RM12579 ECO55CA74_15870 YP_006160297 
RM12581 ECRM12581_17375 AHY72005   
RM12761 ECRM12761_16590 AHY66355 
RM13514 ECRM13514_3525 AHG10189  
RM13516 ECRM13516_3391 AHG16031   
RV308 ECRV308_02685 CDZ21484 
S88 ECS88_2949 YP_002392588  
Sakai ECs3546 NP_311573 
SE11 ECSE_2937 YP_002294212 
SE15 ECSF_2480 YP_003350470  
SMS-3-5 EcSMS35_2806 YP_001744835 
SS17 SS17_3664 AIF95202 
ST2747 CF60_22325 AHM53965  
ST540 CF61_07690 AHM38078 
TW14359 ECSP_3631 YP_003079467   
TW14588 ESCCO14588_5235 EEC28112 
UM146 UM146_03165 YP_006109561 
UMN026 ECUMN_3009 YP_002413702 
UMNF18 UMNF18_3482 AEJ57996 
UMNK88 UMNK88_3353 YP_006135063    
UTI89 UTI89_C3044 YP_542031 
W WFL_14075 YP_006174258 
W3110 Y75_p2627 YP_490898 
Xuzhou21 CDCO157_3307 YP_006314174   
HosA (95%)  
42 EC042_2934 YP_006097232 
11128 ECO111_3464 YP_003235821 
11368 ECO26_3809 YP_003230742 
12009 ECO103_3282 YP_003223165 
55989 EC55989_3011 YP_002404005 
2009EL-2050 O3M_05875 YP_006768841 
2009EL-2071 O3O_19815 YP_006782948 
2011C-3493 O3K_05830 YP_006777878 
B7A L960_4272c AIF64095 
CB9615 G2583_3388 YP_003500885 
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CE10 CE10_3165 YP_006145187 
E2348/69 E2348C_3010 YP_002330492[3] 
E24377A EcE24377A_3041 YP_001464063 
EC4115 ECH74115_3991 YP_002272203 
EDL933 Z4048 NP_289289 
IAI1 ECIAI1_2839 YP_002388201 
IAI39 ECIAI39_2928 YP_002408860 
KO11FL EKO11_1029 YP_005276728 
LY180 LY180_13920 YP_008565855 
RM12579 ECO55CA74_16130 YP_006160348 
RM12581 ECRM12581_17680 AHY72066 
RM12761 ECRM12761_16890 AHY66415 
RM13514 ECRM13514_3591 AHG10250 
RM13516 ECRM13516_3457 AHG16091 
Sakai ECs3594 NP_311621 
SE11 ECSE_2992 YP_002294267 
SMS-3-5 EcSMS35_2865 YP_001744889 
SS17 SS17_3721 AIF95254 
ST2747 CF60_22700 AHM54015 
TW14359 ECSP_3688 YP_003079517 
TW14588 ESCCO14588_5300 EEC28053.1 
W WFL_14385 YP_006174317 
Xuzhou21 CDCO157_3354 YP_006314221 
HpcR/ HpaR (99%) 
11128 ECO111_5215 YP_003237481 
11368 ECO26_5558 YP_003232418 
12009 ECO103_5137 YP_003224950 
APEC O78 APECO78_02925 YP_007379768 
ATCC 8739 EcolC_3701 YP_001726639 
BL21(DE3) B21_04197 YP_003001910 
BL21-
Gold(DE3)pLysS 
AG 
ECBD_3665 YP_003037845 
HS EcHS_A4585 YP_001461119 
IAI1 ECIAI1_4576 YP_002389804 
KO11FL EKO11_3959 YP_005279593 
LY180 LY180_22845 YP_008567570 
REL606 ECB_04231 YP_003047392 
RM12581 ECRM12581_27575 AHY74046 
RM12761 ECRM12761_25945 AHY68227 
RM13514 ECRM13514_5610 AHG12227 
RM13516 ECRM13516_5323 AHG17905 
SE11 ECSE_4630 YP_002295905 
ST2747 CF60_03635 AHM46742 
ST540 CF61_27285 AHM40910 
UMN026 ECUMN_4976 YP_002415553    
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UMNF18 UMNF18_5425 AEJ59851 
W WFL_22965 YP_006176015[4] 
SlyA (99%) 
42 EC042_1812 YP_006096123  
536 ECP_1588 YP_669494 
11128 ECO111_2112 YP_003234536  
11368 ECO26_2371 YP_003229358  
12009 ECO103_1783 YP_003221726 
55989 EC55989_1810 YP_002402872 
83972 ECABU_c18950 YP_006105971 
2009EL-2050 O3M_11985 YP_006770042 
2009EL-2071 O3O_13615 YP_006784166 
2011C-3493 O3K_12020 YP_006779095 
APEC O1 APECO1_725 YP_852741  
APEC O78 APECO78_12030 YP_007381579 
ATCC 25922 DR76_3196 AIL16989 
ATCC 8739 EcolC_1987 YP_001724960 
B7A L960_0933c AIF60756 
BL21(DE3) B21_01602 YP_002999404 
BL21-
Gold(DE3)pLysS 
AG 
ECBD_2001 YP_003036230 
BW25113 BW25113_1642 AIN32081 
BW2952 BWG_1457 YP_002926654 
C321.deltaA N840_1675 AGX33729 
CB9615 G2583_2037 YP_003499592  
CE10 CE10_1915 YP_006143990 
CFT073 c2034 NP_753929 
clone D i14 i14_1856 YP_006153969 
clone D i2 i02_1856 YP_006149050 
DH1 EcDH1_1998 YP_006091944 
DH10B ECDH10B_1776 YP_001730626 
E2348/69 E2348C_1729 YP_002329250 
E24377A EcE24377A_1852 YP_001462933  
EC4115 ECH74115_2354 YP_002270712 
EC958 EC958_1865 CDN82146 
ED1a ECED1_1843 B7MVC0 
EDL933 Z2657 NP_288078 
H10407 ETEC_1677 YP_006115249  
HMS174 ECHMS174_01624 CDY58357 
HS EcHS_A1718 YP_001458422 
IAI1 ECIAI1_1694 YP_002387123 
IAI39 ECIAI39_1413 YP_002407418 
IHE3034 ECOK1_1760 YP_006100948 
JJ1886 P423_08785 YP_008721788 
KLY HQ24_08120 AIF36929 
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KO11FL EKO11_2132 YP_005277811 
LF82 LF82_2138 YP_002556535 
LY180 LY180_08565 YP_008564820 
MC4100 BN896_1457 CDJ72038 
MDS42 ECMDS42_1313 YP_007556963 
MG1655 b1642 NP_416159[5] 
NA114 ECNA114_1690 YP_006138792 
Nissle 1917 ECOLIN_08850 AID78686  
NRG 857C NRG857_08230 YP_006120004 
P12b P12B_c1439 YP_006168472 
PMV-1 ECOPMV1_01737 YP_008571595 
REL606 ECB_01612 YP_003044812  
RM12579 ECO55CA74_10010 YP_006159143 
RM12581 ECRM12581_10535 AHY70637  
RM12761 ECRM12761_10015 AHY65040 
RM13514 ECRM13514_2135 AHG08816 
RM13516 ECRM13516_2037 AHG14704 
RV308 ECRV308_01630 CDZ20477 
S88 ECS88_1690 YP_002391426 
Sakai ECs2351 NP_310378 
SE11 ECSE_1765 YP_002293040 
SE15 ECSF_1505 YP_003349495 
SMS-3-5 EcSMS35_1557 YP_001743612 
SS17 SS17_2229 AIF93802 
ST2747 CF60_15380 AHM52946 
ST540 CF61_14490 AHM39072 
TW14359 ECSP_2207 YP_003078096 
TW14588 ESCCO14588_3846 EEC26577 
UM146 UM146_08940 YP_006110687 
UMN026 ECUMN_1933 YP_002412662 
UMNF18 UMNF18_2080 AEJ56665 
UMNK88 UMNK88_2102 YP_006133857 
UTI89 UTI89_C1833 YP_540842 
W WFL_08865 YP_006173220 
W3110 Y75_p1619 YP_489906  
Xuzhou21 CDCO157_2185 YP_006313050 
 SfaX, FocX and PapX 
(91%) 
536 ECP_4531 YP_672368 
536 ECP_0301  YP_668235 
536 ECP_3776 YP_671648 
83972 ECABU_c12050  YP_006105302 
83972 ECABU_c48440 NC_017631  
83972 ECABU_c32610 YP_006107260 
APEC O1 APECO1_2260 YP_859801 
ATCC 25922 DR76_3927 AIL16282 
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ATCC 25922 DR76_1633 AIL18605 
CE10 CE10_3421 YP_006145434 
CFT073 c1247 NP_753161 
CFT073 c3582  NP_755457 [6,7] 
clone D i14 i14_1141 YP_006153267.1 
clone D i14 i14_3278 YP_006155363   
clone D i2' i02_1141 YP_006148348.1 
clone D i2' i02_3278 YP_006150444 
EC958 EC958_3259 CDN83597 
IAI39 ECIAI39_3395 YP_002409314 
IHE3034 ECOK1_1106 YP_006100314 
JJ1886 P423_16300 YP_008723248  
Nissle 1917 ECOLIN_05595 AID78088 
Nissle 1917 ECOLIN_25870 AID81790 
Nissle 1917 ECOLIN_24555 AID81585 
Nissle 1917 ECOLIN_16015 AID80010 
PMV-1 ECOPMV1_01077 YP_008570963 
S88 ECS88_4713 YP_002394203 
UM146 UM146_12320 YP_006111345  
UM146 UM146_21640 YP_006113168  
UTI89 UTI89_C1117 YP_540132 
UTI89 UTI89_C4886 YP_543820  
VatX (91%) 
536 ECP_0344 YP_668277 
83972 ECABU_c03660 YP_006104501  
APEC O1 APECO1_1713 YP_851471 
ATCC 25922 DR76_4662 AIL15615 
CFT073 c0392 
NP_752329[This 
Study] 
clone D i14 i14_0371 YP_006152509   
clone D i2 i02_0371 YP_006147590  
IHE3034 ECOK1_0269 YP_006099514  
LF82 LF82_042 YP_002555227 
Nissle 1917 ECOLIN_01795 AID77387 
NRG 857C NRG857_01330 YP_006118630 
PMV-1 ECOPMV1_00277 YP_008570212    
S88 NC_011742 NC_011742  
UM146 UM146_15935 YP_006112058 
UTI89 UTI89_C0297 YP_539329 
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7.3 Appendix 3.3: 
 
Appendix 3.3: Vat catalytic triad and VIR1/2 regions mapped using 
the crystal structure of haemoglobin protease (Hbp) passenger 
domain (3AK5). Hbp is the most related SPATE to Vat, sharing 79% 
amino acid identity. Mapping reveals that VIR1/2 are not directly 
associated with the globular catalytic triad. 
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7.4 Appendix 3.4: 
 
 
Appendix 3.4: A) VatX was assayed for a role in motility in UPEC CFT073. A) The WT 
strain, the isogenic vatX mutant and complemented vatX (pVatX) mutant strains were 
inoculated onto LB agar (0.25% [w/ v]) and grown at 28°C. B) The distance travelled 
was measured every 60 mins and the rate of motility (cm/ h) was calculated. The 
experiment was conducted in triplicate (i.e. three independent plates: 1, 2, 3) and the 
non-motile CFT073fliC mutant was used a negative control. C) The level of the major 
flagellar protein FliC was examined by western blot analysis using a FliC-specific 
antibody. Whole cell lysates were prepared and examined from CFT073 WT and 
derivative strains as indicated.  
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7.5 Appendix 4.1: 
 
 
Appendix 4.1 Growth of MG1655skp (pSU2718+pBR322), MG1655skp 
(pSU2718+pAg43), MG1655skp (pSkp + pBR322), MG1655skp (pSkp + pAg43) in 
LB broth containing ampicillin and chloramphenicol. 
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7.6 Appendix 4.2:  
 
Appendix 4.2: A) SDS-PAGE analysis of the MG1655 chaperone 
mutants (skp, degP, degQ, fkpA, ppiA and ppiD) expressing the 
trimeric AT protein EibD. B) The MG1655tamAB (pEibD) mutant 
was similarly analysed. Gels were stained with Coomassie Blue. 
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7.7 Appendix 4.3: 
 
Appendix 4.3: Western blot demonstrating increasing levels 
of the TamAB proteins in CFT073 following induction with 
anhydrotetracycline hydrochloride (AHT [0, 0.01, 0.1 and 
1μM/mL]). The tamAB genes were placed under the control 
of the inducible RExTET promoter.  
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ABSTRACT 29 
 30 
The vacuolating autotransporter (AT) toxin (Vat) contributes to Uropathogenic Escherichia coli 31 
(UPEC) fitness during systemic infection. Here we characterised Vat and investigated its 32 
regulation in UPEC. We assessed the prevalence of vat in a collection of 45 UPEC urosepsis 33 
strains and showed that it was present in 31 (68%) of the isolates. The isolates containing the vat 34 
gene corresponded to three major E. coli sequence types (ST12, 73 and 95) and these strains 35 
secreted the Vat protein. Further analysis of the vat genomic locus identified a conserved gene 36 
located directly downstream of vat that encodes a putative MarR-like transcriptional regulator, 37 
which we termed vatX. The vat-vatX genes were present in the UPEC reference strain CFT073 38 
and RT-PCR revealed both genes are co-transcribed. Over-expression of vatX in CFT073 led to a 39 
3-fold increase in vat gene transcription. The vat promoter region contained three putative 40 
nucleation sites for the global transcriptional regulator H-NS; thus the hns gene was mutated in 41 
CFT073 (to generate CFT073hns). Western blot analysis using a Vat-specific antibody revealed 42 
a significant increase in Vat expression in CFT073hns compared to wild-type CFT073. Direct H-43 
NS binding to the vat promoter region was demonstrated using purified H-NS in combination 44 
with electrophoresis mobility shift assays. Finally, Vat-specific antibodies were detected in 45 
plasma samples from urosepsis patients infected by vat-containing UPEC strains, demonstrating 46 
Vat is expressed during infection. Overall, this study has demonstrated that Vat is a highly 47 
prevalent and tightly regulated immunogenic SPATE secreted by UPEC during infection.  48 
 49 
IMPORTANCE  50 
 51 
Uropathogenic Escherichia coli (UPEC) are the major cause of hospital and community acquired 52 
urinary tract infections. The Vacuolating autotransporter toxin (Vat) is a cytotoxin known to 53 
contribute to UPEC fitness during murine sepsis infection. In this study, Vat was found to be 54 
highly conserved and prevalent among a collection of urosepsis clinical isolates, and expressed at 55 
human core body temperature. Regulation of vat was demonstrated to be directly repressed by 56 
the global transcriptional regulator H-NS and upregulated by the downstream gene vatX (a new 57 
MarR-type transcriptional regulator). Additionally, increased Vat-specific IgG titres were 58 
detected in plasma from corresponding urosepsis patients infected with vat-positive isolates. 59 
Hence, Vat is a highly conserved and tightly regulated urosepsis-associated virulence factor.60 
INTRODUCTION 61 
 62 
Urinary tract infections (UTIs) are one of the most common human infections, and affect 40-63 
50% of women and approximately 12% of men globally (1). UTIs are ascending infections and 64 
can involve infection of the bladder (cystitis), kidneys (pyelonephritis) or dissemination into the 65 
bloodstream (urosepsis). Uropathogenic Escherichia coli (UPEC) are the primary etiological 66 
agent of UTI and cause 70-90 % of all such infections (2). UPEC can survive in the urinary tract 67 
and cause disease due to a diverse range of virulence factors including fimbriae (3-6), 68 
autotransporter (AT) proteins (7-10), surface polysaccharides such as the O-antigen and capsule 69 
(11-13), iron acquisition systems (14-16) and toxins (17-21). 70 
 71 
AT proteins constitute a large family of proteins from Gram-negative bacteria that are 72 
translocated by a dedicated type V secretion system (reviewed in 22, 23-26). AT translocation 73 
also requires accessory proteins including the β-barrel assembly module (BAM) and the 74 
translocation and assembly module (TAM) (27-30). AT proteins consist of three major domains: 75 
(i) a signal peptide that targets the protein to the secretory apparatus for inner membrane 76 
translocation; (ii) a passenger domain that comprises the functional domain of the protein; and 77 
(iii) a translocator domain that inserts into the outer membrane (reviewed in 22, 23, 25, 31-33) . 78 
One major subgroup of AT proteins is the serine protease AT proteins of Enterobacteriaceae 79 
(SPATEs). SPATEs are characterised by the presence of an immunoglobulin A1-like protease 80 
domain (PF02395) within the passenger domain that contains the conserved serine protease motif 81 
GDSGS (34, 35). The first serine within this motif comprises the catalytic triad in conjunction 82 
with upstream conserved histidine and aspartate residues. SPATEs can be phylogenetically 83 
grouped into two classes (reviewed in 34, 36, 37). Class I SPATEs represent the major group of 84 
these proteins and exhibit cytotoxic activity (37-43). Class II SPATEs recognise a more diverse 85 
range of substrates including mucins (reviewed in 34, 36, 37) and immunomodulatory host 86 
proteins (44).  87 
 88 
The vacuolating AT toxin (Vat) of E. coli is a class II SPATE (34, 36, 45) that exhibits 89 
cytotoxicity to chicken embryonic fibroblast cells and contributes to avian cellulitis infection 90 
(46). The vat gene was originally identified within a pathogenicity island (Vat-PAI) from the 91 
avian pathogenic E. coli (APEC) strain Ec222 (46). The Vat-PAI is integrated into the Ec222 92 
chromosome at the thrW-tRNA site between the proA and yagU genes (45, 46). The Vat-PAI 93 
from Ec222 consists of 33 open reading frames (ORFs), with the vat gene residing at ORF#27. 94 
Only five additional ORFs in this PAI were reported to share homology with other previously 95 
known protein sequences. This includes the ORF located downstream of vat (ORF#26), which 96 
shares 44% amino acid identity to the P pilus associated transcriptional regulatory protein PapX 97 
from UPEC strain CFT073 (46). PapX belongs to the family of multiple antibiotic resistance 98 
(MarR) regulators of Enterobacteriaceae and contributes to flagella regulation by binding to the 99 
promoter region of the flhDC master regulator genes (47-49). In UPEC, the vat gene is 100 
associated with virulence and contributes to survival during murine systemic infection (50). 101 
 102 
The full-length Vat protein is ~140 kDa and is processed during translocation to release a 111.8 103 
kDa passenger domain into the extracellular milieu. Vat shares 78% identity to the APEC 104 
associated Temperature-sensitive hemagglutinin (Tsh), which is almost identical (99% amino 105 
acid identity) to the SPATE Haemoglobin binding protein (Hbp) (51, 52). Hbp has been analysed 106 
extensively in the E. coli intra-abdominal clinical strain EB1, and its crystal structure has been 107 
solved (53, 54). Tsh/Hbp possess dual proteolytic and adhesive properties (55-57). Unlike 108 
Tsh/Hbp, Vat is unable to digest casein at 37°C (45, 46).   109 
 110 
Despite these functional differences, the high protein sequence identity shared between Tsh/Hbp 111 
and Vat has led to confusion in the annotation of vat genes within E. coli genomes available on 112 
the NCBI database. For example, the CFT073 vat gene (c0393) has been annotated as hbp (58), 113 
and even referred to as tsh due to its temperature-dependent regulation (59). In addition, the vat 114 
gene from UPEC strain 536 is annotated as sepA, which encodes the Shigella extracellular 115 
protein A (45).  116 
 117 
In this study, we have examined the sequence conservation of vat genes from available E. coli 118 
genomes and compared its genomic location, with the aim to correct existing annotation errors 119 
and vat nomenclature. We also examined the role of the putative MarR regulator identified 120 
downstream of the vat gene as well as the histone-like nucleoid protein H-NS in regulation of the 121 
vat gene. Finally, we examined the prevalence, expression and secretion of Vat in a collection of 122 
UPEC urosepsis isolates, and investigated its immunogenicity by examining plasma from 123 
urosepsis patients.  124 
 125 
MATERIALS AND METHODS 126 
 127 
Ethics statement. This study was performed in accordance with the ethical standards of The 128 
University of Queensland, Princess Alexandra Hospital, Gold Coast Hospital, Queensland 129 
Health, Griffith University and the Helsinki Declaration. The study was approved, and the need 130 
for informed consent was waived by the institutional review boards of the Princess Alexandra 131 
Hospital (2008/264), Queensland Health and Griffith University (MSC/18/10/HREC). 132 
 133 
Bacterial strains and growth conditions. E. coli strains CFT073 (60), IHE3034 (61), 536 (62), 134 
MG1655 (63) and BL21 (64), as well as the E. coli reference (ECOR) collection (65), have been 135 
described previously. The 45 urosepsis UPEC strains were isolated from the blood of patients 136 
presenting with urosepsis at the Princess Alexandra Hospital (Brisbane, Australia). A matching 137 
urine sample was also cultured from each patient; in all cases the blood and urine isolates were 138 
identical as determined by virulence gene profiling. Unless otherwise stated, strains used in this 139 
study were routinely grown at 37°C on solid or in liquid Lysogeny broth (LB) supplemented 140 
with antibiotics: kanamycin (kan [100μg/mL]), ampicillin (amp [100μg/mL]) or chloramphenicol 141 
(cam [30μg/mL]). Supplementation of growth media with L-arabinose (0.2% [w/v]) or isopropyl 142 
β-D-1-thiogalactopyranoside (IPTG [1mM]) was used to induce plasmid-mediated gene 143 
expression. 144 
 145 
Bioinformatic analysis. The presence of the vat gene was determined in 77 complete E. coli 146 
genomes (listed in Table S1) available from the National Centre for Biotechnology Information 147 
(NCBI) database by BLAST analysis using the vat gene (c0393) from the CFT073 genome 148 
(Genbank accession no.: AE014075.1 (58)) as a search tool. The cut-off was set at >85% amino 149 
acid identity of the encoded protein sequence. The genomic location surrounding the vat gene in 150 
each of the vat-positive strains was investigated in Artemis (66). All vat genes identified were 151 
located on a PAI defined by the proA and yagU genes. The nucleotide sequence of each vat-152 
associated PAI was compared in EasyFig (67).  153 
A comparative protein analysis of the MarR family of transcriptional regulators (Table S2) was 154 
performed to analyse their relative phylogenetic relationship to VatX. The MarR dataset was 155 
compiled using an iterative approach that involved BLAST analysis against the 77 complete 156 
NCBI E. coli genomes listed in Table S1. Representative protein sequences, underlined in Table 157 
S2, were chosen for each MarR type regulator based on previous characterisation in the 158 
literature. These sequences included MarR from MG1655 (b1530), MprA(EmrR) from MG1655 159 
(b2684), HosA from E2348/69 (E2348C_3010), HpcR/ HpaR from strain W (WFL_22965), 160 
SlyA from MG1655 (b1642) and PapX from CFT073 (c3582). Each of the representative 161 
sequences were used to BLAST against the 77 complete E. coli genomes and 330 homologous 162 
protein sequences were identified (E<0.001). The evolutionary relationship between VatX and 163 
other representative MarR regulators, as well as the protein sequences listed in Table S2,  was 164 
inferred using ClustalΩ (68, 69) and visualised through FigTree (70).  165 
 166 
DNA manipulation and genetic techniques. DNA techniques were performed as previously 167 
described (71). Isolation of plasmid DNA was performed using the QIAprep spin column 168 
miniprep kit (QIAGEN). Polymerase chain reactions (PCR) were performed using the specified 169 
primers which were sourced from Integrated DNA Technologies (Singapore). PCR products 170 
were amplified using Taq DNA polymerase according to the manufacturer’s instructions (New 171 
England Biolabs). Sequencing reactions were performed using the BigDye Terminator v3.1 cycle 172 
DNA sequencing kit as per the manufacturer's specifications (Applied Biosystems) and analysed 173 
by the Australian Equine Genome Research Centre. Cloning reactions involving restriction 174 
endonucleases were performed as per the manufacturer’s instructions (New England Biolabs).  175 
 176 
Multi locus sequence typing (MLST) and PCR screening. Prevalence of the vat gene was 177 
assessed by PCR using primers 2020 (5’-GTATATGGGGGGCAACATAC-3’) and 2021 (5’-178 
GTGTCAGAACGGAATTGTCG-3’), which were designed based on the sequence of the vat 179 
gene from CFT073 (c0393). The vat gene sequence from ten of the 31 vat-positive UPEC 180 
urosepsis strains was determined and deposited on the NCBI database (accession numbers: 181 
PA11B vat, KR094926; PA15B vat, KR094927; PA32B vat, KR094928; PA38B vat, 182 
KR094929; PA42B vat, KR094930; PA48B vat, KR094931; PA56B vat, KR094932; PA57B 183 
vat, KR094933; PA60B vat, KR094934; PA66B vat, KR094935). The sequence type of the 184 
UPEC urosepsis strains was determined using the seven-gene MLST scheme 185 
(http://mlst.ucc.ie/mlst/dbs/Ecoli) (72). PCR was performed as follows: initial denaturation at 186 
94°C for 5 m; 25 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 30 s, extension at 187 
72°C for 30 s followed by a final extension at 72°C for 7 m.  188 
 189 
Construction of deletion mutants. The vat (c0393), vatX (c0392) and hns (c1701) genes were 190 
mutated in CFT073 using λ-Red mediated homologous recombination (73). Briefly, the 191 
kanamycin gene from pKD4 or the chloramphenicol gene from pKD3 were amplified using PCR 192 
primers containing 50-bp flanking regions homologous to the target genes vat (3353: 5’-193 
TCGTAATGAACACAGTTCATCTGATCTCCACACACCAAGACTTGATAAGCTcacgtcttga194 
gcgattgtgtagg-3’ and 3354:  5’-195 
GAAACCACCACCCCATGATTTTGTTTTACCGCTGTACAGGCCTGCTGACGCgacatgggaa196 
ttagccatggtcc-3’), vatX (5232: 5’-197 
TTCACGATACTTCATGTAACACTCAGGTTGAGTAATCTTCgtgtaggctggagctgcttc-3’ and 198 
5233:  5’-199 
AGAATACATTGTAAGAAGATGACTGTTAGTATGTTTTAACAcatatgaatatcctcctta-3’) or 200 
hns (1583: 5’-201 
TCGTGCGCAGGCAAGAGAATGTACACTTGAAACGCTGGAAGAAATGCTGGgtgtaggctg202 
gagctgcttc-3’ and 1584: 5’-203 
TTGATTACAGCTGGAGTACGGCCCTGGCCAGTCCAGGTTTTAGTTTCGCCcatatgaatatcc204 
tccttag-3’). Amplified fragments were transformed into CFT073(pKD56) expressing of the λ-205 
Red recombinase in order to facilitate homologous recombination for inactivation deletion of the 206 
target gene. Removal of the antibiotic resistance gene cassette was performed using plasmid 207 
pCP20 as previously described, and enabled the construction of the CFT073vatX hns double 208 
mutant. 209 
 210 
Construction of plasmids. A segment of the vat gene corresponding to amino acid residues 63-211 
465 of the passenger domain was amplified from CFT073 using primers 1491 (5’-212 
tacttccaatccaatgcTCCTTACCAGACATACCGCG-3’) and 1494 (5’-213 
ttatccacttccaatgTTACCCCGCATATTGATCATTGCC-3’) and cloned as a 6 x histidine N-214 
terminal fusion into the pLicA vector using ligation independent cloning (designated pVat403). 215 
The full-length vat gene (c0393) and the downstream gene vatX gene (c0392) were PCR 216 
amplified from CFT073 using the following primer pairs; vat: 1524 (5’-217 
cgcgCTCGAGataataaggaattactATGAATAAAATATACGCTC-3’) and 1525 (5’-218 
cgcgcaagcttCAAAGCAATAGTCCCTTTGC-3’); and vatX: 5244 (5’-219 
cgcgctcgagataataaggaaTCTTCATGAGTTTTCTTTTGCCGTGTGG-3’) and 5245 (5’-220 
cccggaagcttTCAATTAACATTAAGGTTTGATA-3’). The PCR products were purified and 221 
cloned into XhoI-HindIII digested pSU2718 to generate the plasmids pVat and pVatX. 222 
Transcription of the vat and vatX genes in these plasmids was regulated by the lac promoter (74).  223 
 224 
Comparative quantitative reverse transcriptase PCR (qRT-PCR). Comparative qRT-PCR 225 
was performed essentially as previously described (47). Briefly, strains CFT073, CFT073vatX 226 
and CFT073vatX (pVatX) were grown in LB broth (supplemented with IPTG) until exponential 227 
growth phase. The total RNA from each strain was extracted using the RNeasy mini kit as per 228 
manufacturer’s instructions (QIAGEN). Samples were subjected to RNase free DNA digestion 229 
and first strand cDNA synthesis was performed using SuperscriptIII (Invitrogen Life 230 
Technologies) with random hexamer (50ng/μL) primers (Invitrogen Life Technologies). 231 
Residual RNA was digested by RNaseH and samples were re-purified as recommended by the 232 
manufacturer (QIAGEN). The ViiA 7 instrument and software (v 1.2.1) was used to carry out RT 233 
PCR reactions (95°C 10 s; 95°C 15 s, 60°C 15 s and 72°C 30 s for 40 cycles). Primers specific to 234 
the vat gene (5470: 5’-TACCGTAACCAGCTCATCAACAG-3’ and 5471: 5’- 235 
CATACCCACCTGTTACCCAATGT-3’) and gapA (control; 820: 5’-236 
GGTGCGAAGAAAGTGGTTATGAC-3’ and 821: 5’-GGCCAGCATATTTGTCGAAGTTAG-237 
3’) were used to amplify transcripts with SybrGreenI (5 μL) master mix (Applied Biosystems). 238 
Each reaction was performed in triplicate and a subsequent melt curve was generated for 239 
validation of the results (95°C 15 s, 60°C 1 m and 95°C for 10 s). Cycle threshold values 240 
obtained were normalised to the endogenous control and the 2-∆∆Ct method (75) was applied for 241 
the comparative analysis. The resulting ratios were statistically analysed using a one-way 242 
ANOVA. All experiments were performed in triplicate. 243 
 244 
5' RACE and Virtual Footprint analysis. The transcriptional start site for vat was determined 245 
using the 5' RACE system for rapid amplification of cDNA ends (version 2.0, Invitrogen Life 246 
Technologies) following the manufacture’s specifications. Two gene specific primers (5863: 5’-247 
ATGCAGATAGTGCCAGAG-3’ and 5864: 5’-CTCTGCGGGTACTCCCTTTAC-3’) were 248 
used. Putative DNA binding motifs in the vat promoter region were identified using Virtual 249 
Footprint software (76). 250 
 251 
Electrophoretic mobility shift assay (EMSA). EMSA was performed essentially as described 252 
previously (77) but with minor adaptations. Briefly, four individual fragments (152 bp, 218 bp, 253 
312 bp and 479 bp) were PCR amplified from the plasmid pBR322 (152 bp: 5’-254 
CATTGGACCGCTGATCGT-3’ and 5’-CTTCCATTCAGGTCGAGGT-3’; 218 bp: 5’-255 
AATATTATTGAAGCATTTATCAGGGTTA-3’ and 5’-256 
ATGATAAGCTGTCAAACATGAGA-3’; 312 bp: 5’-TATCGACTACGCGATCATGG-3’ and 257 
5’-TCTCCCTTATGCGACTCCTG-3’; and 479 bp: 5’-GACCGATGCCCTTGAGAG-3’ and 5’-258 
GATCGAAGTTAGGCTGGTAAGA-3’). The 218-bp fragment containing the H-NS repressed 259 
bla gene promoter was included in the assay as a positive control, while the remaining three 260 
fragments do not bind H-NS. The vat gene promoter region (252 bp) encompassing all three of 261 
the putative H-NS binding sites identified, was also PCR amplified (6103: 5’-262 
CCTGAGAAAAAGCAAACAACA-3’ and 6104: 5’-TTTTAGAGCGTATATTTTATTCAT-3’) 263 
from the genomic DNA of CFT073. This 252-bp fragment was added in an equimolar ratio with 264 
the control fragments (7.5 nM per fragment [~100 ng]). Purified native H-NS protein was added 265 
to each reaction in increasing concentrations (0 μM, 0.1 μM, 0.5 μM and 1.0 μM). Reactions 266 
were incubated at room temperature (15 m in H-NS binding buffer to allow for protein-DNA 267 
complex formation. Samples were examined by high-resolution agarose gel electrophoresis (3% 268 
Lonza Metaphor [50 V at 4°C]), and viewed under ultraviolet light after staining with ethidium 269 
bromide (0.5μg/ mL). Invitrogen’s 1 kbp+ ladder was used as a molecular marker. 270 
 271 
Preparation of supernatant proteins. Bacterial cultures (10 mL) were standardised to an 272 
optical density at 600nm equal to 1.0 (OD600 = 1.0), centrifuged (2057 x g), and the supernatant 273 
was collected and filtered (0.22 µm). Proteins were precipitated by the addition of 10% 274 
trichloroacetic acid (TCA) overnight at 4°C. Following precipitation, supernatant fractions were 275 
concentrated by centrifugation (12,100 x g) and washed twice with 80% acetone to remove 276 
residual TCA. Proteins were resuspended in a final volume of 0.1 mL (100-fold concentration). 277 
 278 
Purification of denatured His-tagged Vat protein. A bacterial culture (200mL) of E. coli 279 
BL21 λDE3 expressing the truncated Vat403 protein encoded on plasmid pVat403 was grown in 280 
LB. Bacterial cells were pelleted by centrifugation (2057 x g) and lysed (7M urea, 0.1 M 281 
NaH2PO4, 0.01 M Tris·Cl [pH 8.0]). The recombinant Vat403 protein was purified under 282 
denaturing conditions using QIAGEN’s Ni-NTA spin column kit. The cleared lysate was passed 283 
through a pre-equilibrated column via centrifugation (270 x g) to allow for the 6xHis tagged-Vat 284 
protein to bind. The column was washed (0.1 M NaH2PO4, 0.01 M Tris·Cl ([pH 6.3]) and the 285 
bound Vat protein was eluted (0.1 M NaH2PO4, 0.01 M Tris·Cl [pH 4.5]) by centrifugation (890 286 
x g). Protein concentrations were determined using the bicinchoninic acid protein assay kit as per 287 
the manufacturer’s instructions (Thermo Scientific Pierce Biotechnology). Purity of the eluted 288 
protein was validated by sodium-dodecyl-disulfide polyacrylamide gel electrophoresis (SDS-289 
PAGE) analysis (12% polyacrylamide gel) and Coomassie staining. 290 
 291 
Immunoblotting. The purified His-tagged recombinant Vat protein was used to generate a Vat-292 
specific polyclonal antibody following a standard protocol (Institute of Medical and Veterinary 293 
Science, South Australia). Concentrated supernatant proteins were re-suspended in 50 µL of SDS 294 
loading buffer (100 mM Tris-HCl, 4% w/v SDS, 20% w/v glycerol, 0.2% w/v bromophenol blue, 295 
pH 6.8) and a 10 µL sample was boiled for 10 min prior to SDS-PAGE. SDS-PAGE and transfer 296 
of proteins to a PVDF membrane for western blot analysis was performed as previously 297 
described (78). Anti-Vat polyclonal antibodies were used as the primary antibody, and alkaline 298 
phosphatase conjugated anti-rabbit antibodies (Sigma Aldrich) were used as the secondary 299 
antibody. SIGMAFASTTM BCIP®/NBT (Sigma-Aldrich) was used as the substrate for detection. 300 
 301 
Human plasma samples and measurement of Vat immunogenicity. Blood plasma (collected 302 
within 4 days post-admission) and matching clinical isolates were obtained from 45 urosepsis 303 
patients admitted to the Princess Alexandra Hospital (Brisbane, Australia).  The clinical strains 304 
isolated from each urosepsis patient were grouped as Vat positive (Vat+) and Vat-negative (Vat-) 305 
according to the prevalence of the vat gene, as determined by PCR screening using vat specific 306 
primers. A negative control group of plasma samples was independently obtained from 42 307 
healthy volunteers with no recent history of UTI. The ELISA assay was performed using Nunc 308 
MaxiSorp flat-bottom 96 well microtiter plates (Thermo Scientific). Each well was coated with 309 
recombinant Vat protein (10 µg/ml) using carbonate coating buffer (18 mM Na2CO3, 450 mM 310 
NaHCO3, pH 9.3 [4°C, overnight]). Plates were washed twice with 0.05% v/v Tween20 PBS 311 
(PBST) and blocked with 5% w/v skim milk in PBST (150 µl) for 90 min at 37°C. Each well 312 
was then washed four times with PBST prior to incubation (90 min at 37°C) with individual 313 
plasma samples (1:10 dilution). Unbound antibodies were removed by washing with PBST. 314 
Peroxidase-conjugated anti-human IgG (1:30,000 dilution in 5% skim milk) was applied as a 315 
secondary antibody for detection (incubated at 37°C for 90 min). Plates were washed four times 316 
with PBST and bound anti-human IgG was detected using 3,3',5,5'-tetramethylbenzidine as a 317 
substrate. Reactions were stopped with 1 M HCl. The absorbance of each well was measured at 318 
450 nm using the Spectramax plus384 plate reader via the SoftMax Pro®v5 program. Data 319 
obtained was analysed using GraphPrism5 software and a one-way ANOVA statistical analysis 320 
was performed. 321 
 322 
RESULTS 323 
 324 
The vat gene is located on a pathogenicity island at a conserved genomic location. The 325 
prevalence of vat was assessed in 77 complete E. coli genomes available on the NCBI database 326 
(Table S1). The vat gene was identified in 14 of these strains; these included the previously 327 
characterised vat-positive UPEC strains CFT073 and 536, as well as twelve additional strains 328 
from which vat has not previously been characterised (APEC O1, NRG 857C, LF82, IHE3034, 329 
S88, 83972, PMV-1, clone D i2, clone D i14, ATCC 25922, Nissle 1917 and UM146). In all 12 330 
strains, the vat gene was part of a pathogenicity island (PAI) flanked by the proA and yagU 331 
genes relative to the E. coli K12 MG1655 chromosome. This genomic location is consistent with 332 
the original identification of vat in APEC strain Ec222 (46). Closer examination of the genomic 333 
context of vat revealed that the upstream region (i.e. the yagU end) is highly conserved. In 334 
contrast, the region downstream of vat (i.e. the proA end) exhibits extensive variation, with a 335 
range of different DNA segments inserted at various positions of the PAI in strains APEC 01, 336 
83972, UM146, 536 and Ec222 (Fig. 1A).  337 
 338 
Vat is secreted by several genome sequenced UPEC strains. The secretion of Vat following 339 
growth in LB broth at 37°C was assessed from a selection of the vat-positive UPEC strains 340 
described above (i.e. CFT073, IHE3034 and 536). As a positive control, the vat gene from 341 
CFT073 was amplified by PCR, cloned into the low copy number expression vector pSU2718 to 342 
generate the plasmid pVat, and transformed into E. coli MG1655 to generate the recombinant 343 
strain MG1655(pVat). Western blot analysis using a Vat-specific antibody detected a single band 344 
of ~110 kDa that corresponded to the predicted size of the secreted passenger domain of Vat in 345 
the supernatant of MG1655(pVat), but not the vector control strain MG1655(pSU2718) (Fig. 346 
1B). The vat gene was also mutated in CFT073 to generate null mutant strain CFT073vat. SDS-347 
PAGE and western blot analysis of the supernatant fraction obtained from CFT073 and 348 
CFT073vat using our Vat-specific antibody identified the secreted Vat passenger domain from 349 
CFT073 but not CFT073vat (Fig. 1B). Finally, we also detected bands corresponding to the Vat 350 
passenger domain in the supernatant fraction prepared from strains IHE3034 and 536. Taken 351 
together, our data demonstrate that Vat is expressed and secreted by the genome-sequenced 352 
strains CFT073, IHE3034 and 536.  353 
 354 
A marR-like gene is located immediately downstream of the vat gene. We were interested to 355 
study the regulation of Vat, and noted a small open reading frame located directly downstream of 356 
the vat gene in all vat-positive strains (Fig. 1A). This gene, which we have termed vatX, 357 
corresponds to c0392 in CFT073 (58) and ORF#26 in the Vat PAI from Ec222 (46). The VatX 358 
protein sequence is highly conserved (99% amino acid identity in the 14 vat-positive completely 359 
sequenced strains described above) and shares 44% amino acid identity with the CFT073 P pilus-360 
associated transcriptional regulator PapX. Further analysis of VatX revealed it contains a MarR 361 
PFAM domain (PF01047) and a helix-turn-helix motif characteristic of DNA binding proteins. 362 
To examine the relationship between VatX and other regulator proteins, we generated a dataset 363 
comprising previously characterised E. coli MarR type regulators (Table S2) (47, 79-82). A 364 
multiple sequence alignment using representative regulator protein sequences (Fig. 2) as well as 365 
a more detailed phylogenetic analysis of all MarR-like sequences identified in the 77 complete E. 366 
coli genomes described above (Fig S1) revealed that VatX forms a distinct clade within the 367 
MarR regulator family, and is most closely related to the PapX, SfaX and FocX fimbriae-368 
associated regulators (47, 80, 83, 84). 369 
 370 
Expression of the vat gene is upregulated by VatX. The proximity, orientation and conserved 371 
genetic organization of the vat and vatX genes led us to examine if VatX contributes to the 372 
regulation of the vat gene. In order to study this, we generated a CFT073 vatX mutant 373 
(CFT073vatX) and examined the transcription of vat in CFT073 and CFT073vatX using 374 
comparative qRT-PCR. In addition, the vatX gene from CFT073 was PCR amplified and cloned 375 
into the pSU2718 expression vector (to generate the plasmid pVatX) and used to complement the 376 
CFT073vatX mutant. No significant difference was observed in the level of vat mRNA 377 
transcribed in CFT073 and CFT073vatX following growth in LB broth at 37°C (Fig. 3A). 378 
However, the over-expression of VatX in CFT073vatX (pVatX) resulted in an approximately 3-379 
fold higher level of vat mRNA transcript compared to WT CFT073 (Fig. 3A). To explore the 380 
effect of VatX on Vat expression further, we compared the level of Vat secreted into the 381 
supernatant fraction by CFT073, CFT073vatX and CFT073vatX(pVatX) by western blot analysis 382 
(Fig 3B). Consistent with our transcriptional data, the over-expression of VatX in 383 
CFT073vatX(pVatX) resulted in a significantly increased level of Vat in the culture supernatant, 384 
while no difference in the level of secreted Vat was observed in CFT073 and CFT073vatX. A 385 
similar increase in secreted Vat was also observed when WT CFT073 was transformed with 386 
plasmid pVatX (i.e. strain CFT073[pVatX]) (Fig. 3B). Taken together, our results demonstrate 387 
that while deletion of vatX does not alter the level of Vat secretion, its over-expression 388 
significantly enhances Vat expression. 389 
 390 
Transcription of the vat gene is directly repressed by H-NS. Given the regulatory effect 391 
exhibited by VatX on vat transcription, we investigated the promoter region of the vat gene to 392 
identify putative binding sites for other transcription factors. The transcriptional start site for vat 393 
was determined using 5' RACE and was mapped to a position 80-bp upstream of the Vat ATG 394 
start codon. Consensus -35 (5’-ATCACA-3’) and -10 (5’-ATTAAT-3’) promoter sequence 395 
elements, separated by an 18-bp spacer region, were identified upstream of this site (Fig. 4A). 396 
Virtual footprint software was used to analyse the vat promoter region for putative regulatory 397 
binding sites. From this in silico analysis, two putative H-NS nucleation sites were identified on 398 
the anti-sense strand overlapping the 18-bp spacer region and the 5’ end of the -35 element. A 399 
third H-NS nucleation site was determined on the direct strand 10-bp downstream of the 400 
transcriptional start site. 401 
 402 
The global transcriptional regulator H-NS is known to bind to curved and A-T rich DNA 403 
sequences upstream of several defined UPEC virulence genes (85), including genes encoding for 404 
toxins (86-89) and autotransporter proteins (8, 10, 90). To investigate the effect of H-NS on vat 405 
transcription, the level of Vat expression was compared by western blot analysis of supernatant 406 
fractions prepared from WT CFT073, CFT073vat, CFT073vatX, CFT073hns and a CFT073vatX 407 
hns double mutant (Fig. 4B). The amount of Vat secreted by CFT073hns and CFT073vatX hns 408 
was markedly increased compared to WT CFT073. Consistent with previous results, the level of 409 
Vat detected in supernatant fraction of CFT073vatX was similar to that detected from WT 410 
CFT073.  411 
 412 
H-NS binds to the vat promoter region. To further investigate the role of H-NS in repression of 413 
vat transcription, an EMSA was performed using increasing concentrations of native H-NS 414 
protein and the 252bp PCR amplified region of the vat gene promoter possessing the three 415 
potential H-NS binding sites (Fig 4C). As a positive control, the bla gene promoter from the 416 
cloning vector pBR322 was also PCR amplified and included in the assay; H-NS is known to 417 
bind to this DNA fragment (91). Three additional fragments amplified from regions of pBR322 418 
known not to bind H-NS were included in the assay as negative controls. In our experiment, H-419 
NS bound with strong affinity to the DNA fragment corresponding to the vat gene promoter. 420 
Indeed, this binding affinity was stronger than that observed for the DNA fragment containing 421 
the control bla gene promoter. No binding of H-NS was observed to the negative control DNA 422 
fragments, demonstrating the specificity of H-NS binding in this assay.  423 
 424 
The vatX gene is co-transcribed with vat. H-NS regulates the transcription of several UPEC 425 
genes by competing for binding to their promoter element with a MarR-type regulatory protein; 426 
this includes SfaX binding to the sfaII fimbrial promoter (80), PapX binding to the flhDC flagella 427 
master regulator promoter (92), and SlyA binding to the type 1 fimbriae fimB recombinase 428 
promoter (93). The SfaX and PapX regulators are co-transcribed as part of their respective 429 
upstream fimbrial operon (encoding S and P type fimbriae, respectively (47, 80)). Taking this 430 
into consideration, we employed RT-PCR analysis to test for transcription of the vat and vatX 431 
genes as a single mRNA in CFT073. Due to the increased amount of Vat protein secreted by the 432 
CFT073hns mutant strain (as shown by Western blot analysis), total RNA was extracted from 433 
this strain, converted to cDNA and screened for a vat-vatX nucleic acid fragment using internal 434 
primers specific for both genes by RT-PCR (Fig. 4D). For comparison, an additional set of 435 
primers were used to amplify the vatX gene alone. Bands corresponding to the predicted sizes 436 
determined for the vatX and the vat-vatX transcripts were amplified from CFT073hns cDNA. 437 
Thus, while we cannot rule out the presence of an independent promoter upstream of vatX, our 438 
results demonstrate that the vat-vatX genes are co-transcribed in the absence of H-NS.  439 
 440 
Vat is prevalent, highly conserved and is secreted by UPEC urosepsis isolates. The vat gene 441 
has previously been shown to be most prevalent in E. coli strains from the B2 phylogenetic 442 
group, with a similar distribution observed among cystitis, pyelonephritis, prostatitis and 443 
bloodstream isolates (45). Based on the observation that vat is required for UPEC fitness in a 444 
mouse model of systemic infection (50), we screened a collection of urosepsis strains for the vat 445 
gene by PCR. The vat gene was identified in 68% (31/45) of the urosepsis strains. MLST 446 
analysis revealed strains from ST73, ST12 and ST95 were most predominant in this collection 447 
(Fig. 5). Furthermore, supernatant fractions produced by these strains were examined by Western 448 
blotting to analyse the expression and secretion of Vat following growth in LB at 37°C. For all 449 
strains, a band corresponding to the Vat passenger domain hybridised with the Vat-specific 450 
polyclonal antibody. The sequence of the vat gene was determined from vat-positive strains 451 
representing each ST and found to be highly conserved (≥97% amino acid identity [Fig. 5]). 452 
Minor sequence variations occurred at six locations within the passenger domain of the protein. 453 
These residues were located within two regions in the Vat passenger domain (Fig. 5), both of 454 
which are distal to the serine protease catalytic motif based on a structural model built using the 455 
Hbp passenger domain (Fig. S2).  456 
 457 
The presence of vat is associated with increased anti-Vat IgG produced during infection. 458 
The high prevalence of vat in the UPEC urosepsis strains examined in this study, in combination 459 
with its secretion during in vitro growth, prompted us to examine if an immunological response 460 
against Vat was elicited during infection. To test this, an ELISA assay was performed using 461 
blood plasma samples collected from the same urosepsis patients from which the urosepsis 462 
strains were collected (Fig. 6). The blood plasma samples were examined for the presence of 463 
Vat-specific IgG antibodies using purified recombinant Vat protein. The urosepsis patients were 464 
divided into two groups; those infected with a vat-positive UPEC strain (n=31) and those 465 
infected with a vat-negative UPEC strain (n=14). As an additional control, 42 plasma samples 466 
collected from age and sex matched healthy individuals were also examined for an 467 
immunological response against the Vat protein. In this assay, we observed a significant 468 
difference (P < 0.05) in the anti-Vat IgG plasma titre in patients infected with a vat-positive 469 
strain compared to a vat-negative strain or healthy individuals. Taken together, these data 470 
suggest that Vat is a highly conserved immunogenic protein that is expressed by many UPEC 471 
isolates during infection.   472 
 473 
DISCUSSION  474 
 475 
UPEC strains possess an array of virulence factors that are critical for their ability to cause 476 
disease in extra-intestinal niches such as the urinary tract and the bloodstream (94, 95). Vat is a 477 
member of the SPATEs that contributes to fitness of E. coli during systemic infection (46, 50). In 478 
this study, we performed a comprehensive bioinformatic and molecular analysis of the vat gene. 479 
We defined the transcriptional regulation of vat and demonstrated its immunogenicity using 480 
plasma samples from urosepsis patients. 481 
 482 
The genomic location of the vat gene was examined in all vat-positive completely sequenced E. 483 
coli strains available on the NCBI database. The vat gene was shown to reside within the thrW-484 
PAI, downstream of proA and upstream of yagU relative to the E. coli MG1655 chromosome. 485 
This is consistent with a previous report that examined the presence of vat in UPEC strains 486 
CFT073 and 536, as well as the neonatal meningitis strain RS218 (45). The gene content of the 487 
vat-containing thrW-PAI was conserved in the majority of strains examined, although some 488 
differences were noted in strains Ec222, APEC-O1, 83972, UM146 and 536. Overall, our 489 
bioinformatic analysis revealed that the vat gene (and the co-located vatX regulator gene) is 490 
present in a range of different E. coli pathoypes.  491 
 492 
Several studies have previously assessed the prevalence of the vat gene in E. coli. A study 493 
conducted by Parham et al (45) reported a high prevalence of vat in group B2 phylogenetic 494 
strains of the ECOR collection. A high frequency of the vat gene has also been observed in B2 495 
strains associated with cystitis, pyelonephritis and prostatitis (45, 59), and vat has been strongly 496 
associated with avian pathogenic E. coli (APEC) (96). Our analysis identified the vat gene in 497 
68% of urosepsis isolates (n = 45). We also demonstrated that the sequence of vat is highly 498 
conserved within a selection of strains representative of each of the ten different sequence types 499 
identified in our collection. At the amino acid level, minor sequence variations were located 500 
within two regions (VR1: S520-K529 and VR2: E783-V823) of the Vat passenger domain. However, 501 
the canonical serine protease domain that is important for the catalytic function of SPATEs was 502 
conserved in all ten of the Vat sequences analysed. Western blotting was also performed to 503 
examine Vat expression, and revealed that Vat is expressed and secreted by all of the urosepsis 504 
strains examined when grown at human core body temperature. Further investigation is required 505 
to determine whether the minor sequence changes observed in Vat are associated with 506 
corresponding differences in its cytotoxic properties. 507 
 508 
Bioinformatic analysis identified a gene encoding a putative MarR-like transcriptional regulator 509 
immediately downstream of vat (i.e. vatX). Although mutation of vatX did not result in a 510 
detectable change in vat transcription or translation, overexpression of VatX via the introduction 511 
of a plasmid containing the vatX gene (pVatX) was shown to positively regulate vat, resulting in 512 
a 3-fold increase in vat transcription and a significant increase in the level of secreted Vat 513 
protein. This data was suggestive of a more complex regulatory control of the vat gene. We 514 
therefore mapped the promoter of vat, and identified several putative H-NS binding sites 515 
proximal to this region. H-NS is a histone-like DNA-binding protein that shows affinity for A-T 516 
rich and bent nucleation sites on DNA (97). In E. coli, H-NS has been shown to regulate multiple 517 
genes, including genes associated with virulence, pH, osmoregulation and temperature sensing 518 
(98-101). Our EMSA data revealed a strong interaction between H-NS and a 252-bp region of 519 
the vat promoter that contains three putative H-NS binding sites. A role for H-NS in vat 520 
regulation was subsequently demonstrated through the examination of a CFT073hns mutant, 521 
which secreted a significantly higher level of Vat compared to the parent CFT073 strain. Taken 522 
together, these results demonstrate that the regulation of vat is coordinated by both VatX and H-523 
NS, and further highlights the role of H-NS in the regulation of UPEC virulence factors (8, 9). 524 
 525 
The MarR family of transcriptional regulators control the expression of multiple different genes, 526 
including virulence factors, often in response to environmental stress (reviewed in 102, 103). 527 
Bioinformatic analysis of MarR-type regulators from 77 completely sequenced E. coli genomes 528 
revealed a high level of amino acid sequence conservation for proteins in each clade, but 529 
significant variation between MarR regulators from different clades. VatX clustered as a separate 530 
clade and is most closely related to PapX. Interestingly, the proteins encoding for other fimbrial 531 
associated MarR-type regulators were also found within the PapX clade (Fig S1). Despite their 532 
association with different fimbriae, these regulatory proteins are highly conserved (≥97% amino 533 
acid identity). Some strains such as E. coli 536, 83972 and Nissle 1917 possess three or more 534 
chromosomal copies of papX (Table S2). PapX regulates UPEC motility by repressing 535 
transcription of the flhDC master regulator genes (47). We investigated the potential for VatX to 536 
repress flagella-mediated motility of CFT073. However, no significant difference in motility was 537 
observed between WT CFT073, CFT073vatX and the complemented CFT073vatX (pVatX) 538 
mutant strains after growth at 28°C and 37°C (data not shown). The FliC major flagellin subunit 539 
was also produced at a similar level in all three strains as determined by immunoblotting (data 540 
not shown). Taken together, our data has identified VatX as a new member of the MarR type 541 
family that appears to regulate vat in concert with H-NS. Further work is now required to map 542 
the direct binding of VatX to the vat gene promoter, and to examine the competitive interplay 543 
between VatX and H-NS in the regulation of vat transcription.   544 
 545 
In a recent study using high-throughput transposon mutagenesis screening (50), the vat gene was 546 
shown to contribute to survival of the UPEC strain CFT073 in the bloodstream of mice. This, 547 
together with the observation that many urosepsis strains secrete Vat, prompted us to examine 548 
the immunoreactivity of Vat in urosepsis patients. We detected a significant increase in Vat-549 
specific IgG titre in the plasma of urosepsis patients infected with vat-positive UPEC strains 550 
compared to plasma from patients infected with vat-negative strains and healthy controls. 551 
Although we cannot rule out that the responses we detected may in part be due to previous or 552 
ongoing infection that culminated in sepsis, overall the data is consistent with the notion that Vat 553 
is expressed during infection and elicits a strong immune response in some patients. Further 554 
work is now required to understand the role of Vat during human infection and its cytotoxicity 555 
profile.  556 
 557 
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FIGURE LEGENDS 869 
 870 
FIG. 1. (A) BLAST alignment demonstrating the level of nucleotide sequence conservation 871 
(grey shading) for vat and vatX (labelled red), as well as the other surrounding genes (labelled 872 
blue). The Vat-PAI (defined by the proA and yagU genes [labelled yellow]) was identified in 14 873 
of 77 complete E. coli genomes examined. These sequences were compared to the Vat-PAI 874 
originally identified in the avian pathogenic E. coli strain Ec222 (top). (B) Immunodetection of 875 
the Vat passenger domain (Vatα) from supernatant fractions prepared from overnight cultures of 876 
the well-characterised UPEC strains CFT073, IHE3034 and 536. Vat expression by MG1655 877 
(pVat) is shown as a positive control, while MG1655(pSU2718) and CFT073vat were included 878 
as a negative controls.  879 
 880 
FIG. 2. Phylogram demonstrating the relationship between representative E. coli MarR-type 881 
regulator proteins. The scale represents the number of amino acid substitutions per site over 194 882 
positions. 883 
 884 
FIG. 3. (A) qRT-PCR analysis of vat transcription in CFT073vatX and CFT073vatX(pVatX) 885 
compared to wild-type CFT073. The transcription of vat was significantly increased in 886 
CFT073vatX(pVatX) compared to CFT073 (**P<0.01). (B) Western blot analysing the effect of 887 
VatX on Vat expression. Supernatant fractions were prepared from overnight cultures of 888 
MG1655(pVat), MG1655(pSU2718), CFT073(pSU2718), CFT073(pVatX), 889 
CFT073vatX(pSU2718) and CFT073vatX(pVatX). Over-expression of VatX led to an increase in 890 
the amount Vat detected in the culture supernatant.  891 
 892 
FIG. 4. (A) Schematic of the vat-vatX gene operon in CFT073. The position of the promoter and 893 
primers used to identify vat-vatX and vatX transcripts is indicated. The inset shows the vat gene 894 
transcriptional start site (+1), which was mapped to 80bp upstream of the ATG start codon (grey 895 
arrow). Also indicated are the consensus -10 and -35 promoter elements and the three putative H-896 
NS nucleation sites (shown in bold). (B) Immunodetection of the Vat passenger domain from the 897 
supernatant fractions of CFT073 , CFT073vat, CFT073vatX, CFT073hns  and CFT073vatX hns. 898 
The level of Vat was increased in CFT073hns and CFT073vatX hns compared to CFT073. (C) 899 
EMSA demonstrating the direct interaction of H-NS with the vat promoter region. The assay was 900 
performed using a 252bp fragment encompassing the vat promoter region (indicated by an 901 
asterisk), a 218bp fragment containing the bla promoter region amplified from pBR322 (positive 902 
control: indicated by an arrow), and three additional DNA fragments amplified from pBR322 903 
(negative controls: 152bp, 312bp and 479bp). Native H-NS protein was incubated with the DNA 904 
in increasing concentrations (0μM H-NS, 0.1μM H-NS, 0.5μM H-NS and 1.0μM H-NS). (D) 905 
Transcriptional analysis of the vat and vatX genes. Total RNA was extracted during exponential 906 
growth of CFT073hns and converted to cDNA. Shown are the PCR products [vat-vatX (1112bp) 907 
or vatX (404bp)] amplified from CFT073hns gDNA (positive control), total RNA (negative 908 
control) and cDNA.  909 
 910 
FIG. 5. (A) Diagram depicting the full length Vat primary protein sequence, including three 911 
protein domains typical for SPATES: i) the extended signal peptide (SP); ii) the passenger 912 
domain comprising the Immunoglobulin A1 protease-like domain, which contains the serine 913 
protease motif, as well as the upstream aspartate (D158) and histidine (H130) residues of the 914 
catalytic triad; and iii) the translocation domain, which is cleaved at the alpha-helical linker 915 
region. Class II SPATEs are characterised by the presence of a small additional domain termed 916 
Domain 2 (striped). Two variable regions (VR1 and VR2) located within the passenger domain 917 
were identified (triangles). (B) Alignment of the Vat amino acid sequence in VR1 and VR2 from 918 
CFT073 and the ten strains representing the diverse STs examined. Residues identical to those in 919 
Vat from CFT073 are indicated by dots; residues that differed from the CFT073 sequence are 920 
indicated and highlighted in grey. Vat secretion was determined by Western blot analysis of the 921 
supernatant fractions from each strain following overnight growth in LB broth at 37°C. All 922 
strains secreted a ~110kDa protein that cross-reacted with the Vat-specific polyclonal antibody 923 
(indicated as +). 924 
 925 
FIG. 6. Immunoreactivity of Vat. Blood plasma was collected from 45 urosepsis patients at the 926 
time of admittance to hospital. Paired UPEC strains were also isolated from the blood of each 927 
patient, and the presence of the vat gene was determined by PCR. Plasma samples were 928 
subsequently grouped by their association with vat-positive (Vat+) or vat-negative (Vat-) strains. 929 
The presence of IgG-specific antibodies was determined by ELISA, and compared to results 930 
obtained from 42 healthy volunteers with no recent history of UTI (Healthy). A significantly 931 
higher IgG titre was observed in plasma of patients infected with Vat+ strains compared to 932 
patients infected with Vat- strains and healthy controls. 933 
 934 
 935 
